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ABSTRACT
INTEGRATING MEAL AND EXERCISE INTO PERSONALIZED GLUCOREGULATION
MODELS: METABOLIC DYNAMICS AND DIABETIC ATHLETES
Sofie W. Schunk, B.S.
Marquette University, 2015
Diabetes affects nearly 26 million Americans, according to the American
Diabetes Association, with as many as three million Americans who have Type 1
Diabetes (ADA, 2015). Type 1 Diabetes (T1D) is autoimmune and characterized by
little to no insulin production whereas Type 2 Diabetes (T2D) concerns insulin
resistance and inability to use produced insulin. Factors contributing to current
diabetes management and regulation include exercise type, daily movement
activities, and distinct tissue compartment metabolism, each challenging to model in
a robust and comprehensive manner. Past models are highly limited in regard to
exercise and varying glucose fluctuations dependent on type, intensity, and
duration. Modeling could greatly enhance factors that contribute to diabetes
management—currently, T1D is managed with a pump and/or injections, informed
by constant blood glucose monitoring.
This thesis addresses knowledge gaps in the management and etiology of
diabetes through development of a novel dynamic mathematical model informing
controller design and implementation (artificial pancreas, continuous glucose
monitors, and pumps). Diet and meal content on the basis of varying glycemic index
and on the effects of activity and exercise, with lifestyle habit implications are a
main focus. Emphasis is placed on model personalization with a T1D athlete
example. The following model and case study implement specific aims:

10th order model designed in Matlab with 4 interrelated sub-models to
integrate meal diversity, exercise activities, and personalized body composition.
o 3-State Glucose Compartmental Model
o 2-State Control Mechanisms: Insulin and Glucagon
o 2-State Digestion Model
o 2-State Exogenous Insulin Control
o Skeletal Muscle Model with Mitochondrial State
o Nonlinear relations including Hill Functions

A 2 Phase Case Study, IRB approved for a Type 1 athletic 23-year-old
female to evaluate and develop the model.
Results illustrate effects of meal type (slow vs. fast glycemic index) and
exercise/activity based glucose-glycogen consumption on blood plasma glucose
predictions and hormonal control action for both non-diabetic and diabetic model
versions. Current challenges are addressed with model personalization, providing
input flexibility for body mass, muscle ratio, stress, and types of diabetes (T1D, T2D)
informing artificial pancreas design and possible sports performance applications.
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GLOSSARY
AP, Artificial Pancreas
AT, Anaerobic Threshold
BG, Blood Glucose
bpm, Beats Per Minute
CGM, Continuous Glucose Monitor
CHO, Carbohydrate
Cgm, Glucagon Control Parameter, Muscle Tissue Gain, scaled to pg/dl (Cgb in code)
Cgnm, Glucagon Control Parameter, Non-Muscle Tissue Gain, scaled to pg/dl (Cga)
Cinm, Insulin Control Parameter, Non-Muscle Tissue Gain (Cia in code)
Cim, Insulin Control Parameter, Muscle Tissue Gain (Cib in code)
ECF, Extracellular Fluid
FFA, Free Fatty Acid
GI, Glycemic Index
GLC, Glucagon
GLUT2, Non-Muscle Glucose Transporter
GLUT4, Muscle Glucose Transporter
Gefff, Non-Linear Hill Controller for Rate of xd entering xg (Gabs in code)
Geffs, Non-Linear Hill Controller for Rate of xds entering xd path (Gslow in code)
Gexer, Blood Glucose Loss with Muscle Demand Gradient (Gmgrad in code)
Gex-Total, Total Aerobic Exercise Glucose Consumption (kcal/hr)
Gmetm, Basal Metabolic Elimination Rate to Muscle Tissue, Scaled by wm (g/hr)
Gmetnm, Basal Metabolic Elimination Rate to Non-Muscle Tissue, Scaled by wnm (g/hr)
HR, Heart Rate (bpm), inputted as u5
kgreft, Reference Threshold for BG for Non-Muscle Flux Direction (mg/dl)
IMTG, Intramuscular Triglyceride
kfast, Meal GI Parameter (Scale of 0-100)
ks-ds, Half-Way Value for Hill Control, Slow Digestive Pathway (Rising)
rattype1i, Ratio of T1D (Decimal Percent, Remaining Insulin Production)
rattype1g, Ratio of T1D (Decimal Percent, Remaining Glucagon Production)
RER, Respiratory Exchange Ratio
T1D, Type 1 Diabetes
T2D, Type 2 Diabetes
u1fast, Input Representing Fast Absorbing Carbohydrate Path, in kcal/hr
u1slow, Input Representing Slow Absorbing Carbohydrate Path, in kcal/hr
u2, Input Representing Insulin Injection
u3, Input Representing Aerobic Exercise (same as uexer), in kcal/hr
u4, Input Representing Anaerobic Exercise (same as udaily), in kcal/hr
u5, Input Representing External Heart Rate Data, in bpm
ucarb, Input Representing Proportion of Carbohydrate (fraccarb in code)
udaily, Input Representing Daily Activity (same as u4), in kcal/hr
uexer, Input Representing Aerobic Exercise (same as u3), in kcal/hr
ufast, Input Representing Fast Carbohydrate (u1fast in code), in kcal/hr
uinj, Input Representing Insulin Injection (same as u2)

xi
uslow, Input Representing Slow Carbohydrate (u1slow in code), in kcal/hr
uHM, Input Representing Hormonal Action as a Stress Ratio (stressor parameter)
VO2max, Maximal Aerobic Capacity
wbm, Scaling Parameter of BG to Glucose Muscle Tissue (wratm in code) [g/kg muscle]
wbt, Scaling Parameter of BG to Glucose Non-Muscle Tissue (wratt in code) [g/kg]
wm, Muscle Mass (kg)
wmito, Mitochondrial Mass, as a Ratio of Muscle Mass (ratmito) (kg)
wnm, Non-Muscle Mass (kg)
xd, State Representing Glucose Digestive Forward Flow Final Path (g/hr)
xds, State Representing Low Glycemic Index (Slow) Forward Glucose Path (g/hr)
xg, State Representing Blood Glucose (mg/dl)
ẋg, State Representing Blood Glucose Derivative (mg/dl)
xgn, State Representing Endogenous Glucagon Control Action in Blood Plasma (pg/dl)
xi, State Representing Endogenous Insulin Control Action in Blood Plasma (mU/dl)
xinj-nm, State Representing Exogenous Insulin Delivery: Non-Monomeric (mU/hr)
xinj-m, State Representing Exogenous Insulin Delivery: Monomeric (mU/hr)
xm, State Representing Muscle Tissue (g/kg)
xmito, State Representing Mitochondria (g/kg)
xnm, State Representing Non-Muscle Tissue (g/kg)
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1. INTRODUCTION
It can be argued that glucose, in its many forms, is the most important
substrate in the body, providing energy for human organ functions and all
processes. Hence, a thorough mechanistic and quantitative understanding of blood
glucose (BG) regulation would help provide insight into those factors that
contribute to diabetes. Further, predictive modeling algorithms can predict BG
effects of various lifestyles. Clinicians and diabetes educators need to be able to
quantitatively explain effects of diet choice, athletics, and activity level—currently,
as seen with many diabetic patients, it is trial and error as to controlling influences
of lifestyle factors. Factors include exercise variants, daily movement activities,
tissue compartment metabolism, level of athleticism, and meal type distinction and
diet habits. Models could aide in predicting athletic performance for all individuals,
not just those with disease and/or diabetes. There is a need for a robust and
comprehensive lifestyle model, as current models reviewed throughout Chapter 2
are limited, or fail to recognize the importance of, modeling all influential factors.
A novel nonlinear 10-state lumped compartmental model is presented in
Chapter 3 that aims to address these challenges, and is designed to provide
flexibility for variable body mass, muscle ratio, mitochondrial volume, body
composition, metabolism and Type 1 and Type 2 diabetes. The model is intended for
both research and clinical use, particularly diabetes educators, and to inform
delivery design of current artificial pancreas mechanisms, as well as develop
continuous glucose monitor (CGM) feedback and prediction based on current
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activity and/or diet. It is motivated by the concept that a diabetic should be able to
manage BG with exercise, diet, and dual-hormonal control based on algorithm
feedback of a personalized model, similar to that of machine learning mechanisms.
Chapter 4, which takes an important step towards extending the general BG
regulation model of Chapter 3 to a new personalized version, particularly for trained
athletes with Type 1 diabetes. Chapter 3 remains innovative in regard to digestive
and non-muscle/muscle compartmental storage dynamics.
Chapter 4 is innovative in creating a multidisciplinary model of mass and
energy flow dynamics (common to mechanical engineering mechanisms) of the
novel glucose model combined with concepts of exercise physiology. When daily
choices become habitual, a lifestyle body type is present—for example, one could be
athletic, lean, overweight, inactive, or active. Exercise physiologists are able to
quantify metabolic differences in basal metabolism properties of various body
types, which could inform a personalized model. Chapter 4 uses an athletic Type 1
female as an example for future adaptive modeling and device learning mechanisms.
Mechanisms involve an additional state to enhance skeletal muscle dynamics in the
form of mitochondrial consumption. Additionally, a stressor parameter and input
associated with elevated intensity and exercise stress allows for improvement for
certain types of exercise modeling, such as high intensity interval training (circuits)
or sprints.
Future directions and applications for clinical use are found in Chapter 5. The
ultimate goal is to better inform clinicians to educate people with diabetes
appropriately in regard to glucose regulation on the basis of lifestyle choices that
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may become habitual. This is possible with better understanding of lifestyle types in
hope that a library of personalized adaptive models can be created. It is intended
that current device technologies will become robust in that each can ‘learn’ its user
to eliminate guesswork of bolus corrections, often used for appearance of hypo- and
hyperglycemia. Such models can inform CGM ‘trends,’ or inform a patient where
their BG is headed, based on causation effects of lifestyle inputs. A particular user
profile, if robust, could drive overall trends and baselines with instantaneous inputs
(i.e. meal GI, stress, and/or exercise) affecting immediate BG.

2. BACKGROUND
2.1 Overview of Disease
Tight regulation of BG is required for adequate metabolic function in
humans. Common target BG ranges have included a tight range of 80-120 mg/dl that
is ideal for organ performance and brain function, requiring ~130 g/day of glucose
(ADA and National Academy of Sciences, 2005). A high BG, or hyperglycemia, results
in long-term complications and defines the concept of diabetes: elevated fasting BG
levels. On the other hand, hypoglycemia, or low BG <60 mg/dl, can occur in all
individuals with lack of carbohydrate intake and/or exercise, but is especially
dangerous for people with diabetes relying on exogenous sources. Glucoregulation
modeling allows for concise predictive BG algorithms, based on controller design
and an understanding of human physiologic pathways and hormonal control. A
broader ‘acceptable’ glucose range of 70-180 mg/dl is suggested for modeling
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because of undesirable side effects of too tightly regulating BG, especially for active
people with diabetes and minimal model based insulin devices that fail to recognize
that increased insulin sensitivity and glucose consumption are dependent on
activity type (Macdonald, 1987 and McDonald, 2013). Non-diabetic comparisons of
BG response can help inform proper control via insulin and/or other solutions for
BG control: exercise, diet, and other lifestyle activities. The imperative need for
regulation is best explained by lack of regulation as common to those with a
disability, such as Type 1 or Type 2 Diabetes.
2.1.1 Type 1 and Type 2 Diabetes
In the process of medical device development, particularly those that replace
(either partially or completely) a lost biological function, it is imperative to
understand the physiology behind control mechanisms involved and the underlying
cause. According to the American Diabetes Association (ADA), Diabetes affects about
9.3% (29.1 million) of the U.S. population in 2012 and is on the rise; however, it is
important to note that only 5% of the 9.3% (1.25 million Americans) have Type 1
diabetes (T1D). People with Type 1 diabetes fail to produce insulin, or at a reduced
amount. People with Type 2 diabetes (T2D) produce insulin (usually in excess) but
do not use insulin properly, or have developed insulin resistance. Other key
differences in regard to model purposes include reduced glucagon action in T1D,
body weight differences (T2D particularly), and resting basal insulin, blood, and
tissue glucose levels. Treatment includes continuous monitoring and insulin
administration and/or pills to prevent long-term health complications such as skin
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and eye degeneration, neuropathy, ketosis, and foot complications and short-term
hypo- and hyperglycemia.

2.2 Historical Literature Review: Response Data and Older Models
Many models focus on varying aspects of blood plasma glucose regulation.
Typically BG concentration is the main dynamic model compartment, with models
ranging from very simple (2 total compartments) to complex. All have their
advantages and disadvantages, but from the present perspective, lack some key
states and processes. This section reviews past modeling strategies, and provides a
context for the proposed improvements, as such models help address knowledge
gaps in the etiology of people with Type 1 and Type 2 diabetes, often informing
controller design. Table 2.1 outlines current BG regulation models as an
evolutionary process.
One of the most cited original models, focusing on simplification, results from a
classic 3-state “Bergman minimal model” with two states including insulin dynamics
and glucose (Bergman, 1981). Bergman quantified insulin sensitivity with 3
compartments representing plasma insulin, remote insulin and plasma glucose
concentrations. The model focuses on the insulin-dependent patient, assuming all
insulin is infused exogenously and then promotes uptake of plasma glucose into the
hepatic (liver) and periphery tissues, using the form of ordinary differential
equations, multiplicative states, and about 7 known parameters. Extensions of the
Bergman minimal model include a minimal exercise model adding a critical
threshold value (on the basis of VO2max) that drives hepatic glucose production
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and glycogenolysis during exercise characterized by intensity and duration (Roy,
2007). These changes are reflected with added terms of the plasma glucose equation
of the Bergman minimal model. Further, in a review of various differential equation
approaches, Makroglou et al. (2006) presents delay modeling approaches including
those by Sturis et al. (1991), integro-differential equations, and partial differential
equations (Makroglou, 2006). The integro-differential equation approach is key for
modeling intravenous glucose tolerance test dynamics after recognizing the widely
used minimal model is improper in qualitative behavior, as the base parameter is
equal to the basal glucose level. A more realistic delay and dynamic model is needed,
recognized by many (i.e. Li, 2001 or Mukhopadhyay, 2004) and can also be
improved with Hill Kinetics, particularly Michaelis-Menten, as used in the Chapter 3
model structure of this thesis (Gesztelyi, 2012). These additions will address
fundamental limitations with added states to further insulin dynamics and the
particular need to recognized delays and oscillations (Makroglou, 2006).
Core compartmental improvements to Bergman’s model (other than diet and
exercise) include a 5-state model adding insulin (in liver) and added glucagon states
(Sorensen, 1985 and Northrop, 2000). Sorenson, as an integral part of a chemical
engineering Ph.D. dissertation, implemented a mass balance model taking into
account blood flow, compartmental exchange (with a focus on organs), and
metabolic processes adding and removing glucose, insulin, and glucagon of a 70 kg
non-diabetic individual. Clinical studies informed model parameters and estimation
curves, partially shown Figure 2.1a-b below. Key insights include the modeling of
glucagon in the form of an ordinary differential equation (ODE) with
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characterization as a result of an extensive series of rat studies. In addition to
Sorenson, Northrop also proposed a model for glucoregulation in an Introduction to
Complexity and Complex Systems (Northrop, 2011). This nonlinear model does not
address exercise, but has a main focus of various hormonal factors, such as Leptin,
insulin, and glucagon (GLC). GLC production is modeled as a simple, first-order loss
kinetics with a static, nonlinear function providing the GLC rate input to the GLC loss
dynamics ODE. The mathematical modeling of the three main sources of glucose
(diet, gluconeogenesis, and the breakdown of stored liver and muscle glycogen to
glucose) is a strong point of this model. Northrop, 2011, particularly focuses on
hormone kinetics, separating cells into insulin-sensitive and non-insulin sensitive
(see Figure 2.1c-d), with hepatic glucose flux that depends on insulin, GLC, leptin
and other regulatory hormones, not only BG. However, it fails to decipher between
types of glucose input, which will be a focus of the Chapter 3 model in addition to
modeling complexities in a simplified manner. These glucagon models are compared
to and validate the Schunk-Winters glucagon model in Section 3.5.3.
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Figure 2.1: Sorenson (1985) and Northrop (2000) Blood Glucose Regulation Block Diagrams
and Glucagon Plots. Upper Plots (a,b): Adapted from Sorenson (1985) blood glucose regulation
model (left) and associated plot of normalized rate of glucagon release as a function of normal
arterial glucose concentration (right). Lower Plots: From Northrop (2000) blood glucose regulation
block diagram model (left) with glucose loss rates in urine, into insulin-sensitive cells, into noninsulin-sensitive cells, and a hepatic glucose flux that depends on hormones insulin, glucagon, and
leptin. Normalized glucagon secretion as a function of steady-state plasma glucose concentration is
shown on the right with half-life of glucagon is 10 minutes.

Higher-order models were developed that similarly utilized Bergman massflow relations but instead utilized logistic complexities and Bernoulli-Langevin
expressions for hepatic glucose production and characterizing exogenous insulin
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profiles and delays, respectively (Neelakanta, 2006 and Sankaranarayanan, 2012).
Neelakanta et al., 2006, clinically validates hepatic glucose production on the basis
of plasma glucose and hepatic insulin concentration. A University of Colorado group
added and characterized insulin infusion profiles under necessity to characterize
infusion risks (Sankaranarayanan, 2012). A variety of potential hypoglycemic
scenario events were modeled including taking an excessive amount of insulin or
taking a bolus too early in regard to glucose ingestion (also, miscalculation of CHO
content or GI considerations). Potential hyperglycemic scenarios tested included
meal-bolus discrepancy and discrepancy between a meal’s predicted GI and actual
GI (i.e. higher than expected). It was concluded that planned meal times vs. actual
meal times indicated the highest risk for hypoglycemia, when patient’s seemed to
take a bolus far in advance of actually consuming foodstuff. This ideology that
insulin must be taken sufficiently in advance of a meal (15 minutes suggested by
clinicians, but should vary with GI) indicates an insulin absorption delay. Li and
colleagues, 2006, denote two explicit time delays: insulin secretion from beta cells
as a series of complex processes including inherent delays of GLUT2, potassium
channels, etc. on the range of 5-15 min and a time lag of the effect of hepatic glucose
production with a magnitude of half-maximal suppression between 11 to 22
minutes and half-maximal recovery between 54 to 119 minutes (Li, 2006). Perhaps
more importantly are the sigmoidal shapes of associated functions, f1-f4, informed
by literature and similar to nonlinearities present in the Schunk-Winters model.
These shapes are shown in Figure 2.2 below.

10

Figure 2.2: Li (2006) Function Shapes. Function shapes of respected states are plotted against BG
concentration indicated by f1: insulin production simulated by glucose concentration, f2: insulindependent glucose consumers, dependent on BG alone, f4: insulin-dependent glucose uptake, and f5:
glucose production controlled by insulin concentration (from Li, 2006).

Time delays are found amongst many of the other models as well, not only in
regards to insulin action and injections, but with digestive absorption and energy
and mass conservation pathways and will be discussed in Sections 2.3.1 and 2.3.2.
Most models idealize diet as a single glucose input source, ignoring the
‘quality’ of carbohydrates. Once filtered through the digestive system, there is a rate
of appearance of glucose into the bloodstream. Newer models utilize 2-3 states to
capture this digestive process, but fail to distinguish between carbohydrate type and
varying absorption rates (Dalla Man, 2014, and Hernandez-Ordonez, 2008). Leading
up, in 2007, Cobelli and colleagues developed an advanced 12-state model for
studying the effects of carbohydrates (meal) an extension approved by the FDA as a
preclinical trial tool for controller design used extensively (Cobelli, 2009 and
Kotachev, 2010). More recently, the addition of glucagon control action resulted in a
16th-order model with 7 additional parameters (Dalla Man, 2014). The model
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implements simulations representing a diversity of “virtual” users. This work
evolved into a FDA approved simulator for evaluating controllers for T1D
management (Kotachev, 2010 and Dalla Man, 2014). One significant limitation is
that it is still intended for a single meal implemented as a bolus dose of
carbohydrates.
The transient dynamics of glucose appearance is strongly influenced by
foodstuff composition, with measures such as glycemic index (GI) to document the
reality of peak glucose influx ranging from minutes to hours after ingestion (Monro,
2008). Low glycemic foodstuff results in a slower breakdown (less of the “sugar
high” spike in BG). The “sugar high” idea is long-standing and is characterized as a
strong blood insulin influx in response to high glycemic foods, triggering a sudden
“crash” in BG owing to increased flux into tissues for storage (mostly in liver and
muscle and adipose) and via energy conversion pathways into fats (Jenkins, 1981,
Wolfe, 1998, and Walsh, 2014). Only one group (Yamamoto, 2014) addressed the
need for deciphering between a food’s GI, which is well known to effect the rate at
which foodstuff is absorbed (Mohammed, 2004). In modeling meal absorption,
Yamomoto (2014) addresses glycemic index and associated insulin effect based on
replicated literature curves. A state-space representation form is used for the
carbohydrate metabolism subsystem, which distinguishes between rapidly
absorbing glucose (RAG) and slowly absorbing glucose (SAG). It is determined that
95% of RAG is absorbed within 20 minutes, with SAG between 20-120 minutes.
Therefore, SAG utilizes a 20-minute time delay, with a time constant of about 21
minutes (vs. 4.2 for RAG). There is also a first-order gastric emptying delay related
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to the time required to pass from the stomach to the duodenum. However, this
particular model is limited in its other ‘lifestyle’ inputs such as exercise and utilizes
only the Bergman minimal insulin model for subcutaneous insulin (Bergman, 1981
and Shimoda, 1997). Figure 2.3 below shows the comparison to ‘staple’ foods with
known glycemic index values—the glucose-equivalent value takes into account fiber
content and the known glucose relative (GR) function, with white bread as the
reference food and expressed as a percentage with respect to 50 grams of glucose.
This is important for simulation, as 50 grams of each staple food was used.

Figure 2.3: Yamamoto (2014) Meal Simulation Model with Insulin. Left: Simulation of four
staple foods with the proposed model compared to clinical data from Mohammed et al., 2004
(Yamamoto, 2014). Right: Simulation of subcutaneous insulin effect, as compared to clinical data
used for Bergman model verification purposes (Yamamoto, 2014).

Neelakanta et al., 2006, used early Cobelli theoretical formulations and
clinical data to form simulated results based on the modified and adapted complex
systems approach outlined in their model (Neelakanta, 2006 and Cobelli, 1985). The
main focus of this model is on hormonal controllers, specifically insulin and
glucagon, to indicate statistical bounds on BG concentration and the rate of
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appearance of glucose in the blood plasma (Neelakanta, 2006). The improvements
by Cobelli’s group are implemented in a simulation model of the glucose-insulin
system in normal life conditions for use in diabetes research (Dalla Man, 2007 and
Cobelli, 2009). The general model consists of 12-13 states, with an emphasis on
compartmental insulin kinetics and uni-directional glucose stomach states
implemented in MatLab and Simulink. Advantages of the Cobelli model include
accurate experimental parameter values and the use of Hill kinetics, introducing a
realistic non-linearity approach of parameters and states.
Exercise as an input to the models is only recent and has been kept as a
simple and single input. In fact, 3 different exercise models were proposed and
implemented in silico (Cobelli, 2009). This 2009 version by the Cobelli group
implemented three additional ‘test’ inputs for exercise, outlined in Models A-C.
Model A assumed that exercise causes a rapid on-and-off increase in insulinindependent glucose clearance and a rapid-on/slow-off effect on insulin sensitivity.
Model B relaxes the assumption that exercise causes a rapid on-and-off increase in
insulin-independent glucose clearance. Model C is similar to model A, but also
assumes that insulin action is increased in proportion to the duration and intensity
of exercise. It was determined, in assessment of quality of each prediction model,
that Models A and B predict different levels of exercise (based on heart rate) have
the same effect on glucose utilization and Model C predicts a reasonable glucose
infusion rate during euglycemic-hyperinsulinemic clamp simulations for both mild
and moderate exercise. However, other literature suggests that exercise intensity, or
different levels of exercise, does in fact have implications on glucose utilization and
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therefore Models A and B are limited compared to the Schunk-Winters exercise
model (i.e. Brooks, 1994). Heart rate (HR) is also debatable as an accurate measure
of exercise level, as HR tends to fluctuate with other factors and is intrinsic to an
individual. Hence, most exercise physiologists use factors such as percent of aerobic
capacity. That being said, HR can be an accurate predictor if an anaerobic threshold
and/or VO2max stress test has been performed and correlations between HR and
particular training zones have been determined. It can help better inform exercise
activity level and effort, as well as stress. This is further discussed in Chapter 4.
Perhaps the first model to successfully demonstrate the importance to model
exercise, as a function of working tissue uptake, plasma insulin, and hepatic glucose
release, was Roy (2007). However, the model is limited in that hepatic production is
the only additional means by which glucose is available with exercise and the insulin
model is minimal. Hernandez-Ordonez (2007) furthered exercise model validation
at low and moderate intensities and the redistribution of blood flow but do not seem
to address the effect of meals and/or varying metabolic properties of individuals.
Duun-Henrikson (2013) used a linear, three-compartment insulin model and simply
varied absorption rate as a function of exercise intensity and duration.
In 2013, a group associated with Cobelli and colleagues modified the in silico
2009 Padova type 1 simulator (Cobelli, 2009) to incorporate the effect of physical
activity after demonstrating a doubling of insulin activity (Schiavon, 2013). Subjects
were allocated into two groups: one in the absence of and one with different degrees
of reductions and durations of basal insulin infusion rates—it was shown that an
effective strategy is to reduce basal insulin by 50% 90 minutes prior to exercise and
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30% during exercise to avoid hypoglycemia. However, this is not possible in regard
to current artificial pancreas design, and exercise type and intensity are not
accounted for, both of which my further adjust what changes need to be made in
insulin dosing before, during, and after exercise. This will be a partial focus of
Chapter 4, after exercise and the metabolic properties associated with muscle
demand are modeled and able to predict proper BG control.
Originally, a 4th/5th classroom model formed by Dr. Jack Winters for a biocontrol
systems course (BIEN 3301) starting in 2012 forms the basis of the 9th/10th order
Schunk-Winters model proposed in this thesis. The original model contains 4-5
states, and included breaking tissue into separate muscle and non-muscle
compartments, the typical BG compartment, a simple 1st-order stomach glucose
filter, an insulin state viewed as a controller, and an optional 5th state for 1st-order
dynamics for exogenous insulin delivery (could be external for people with
diabetes). Advantages of this model include, but are not limited to, a basic
component for sensitivity to exercise via a glucose input sink, which acts as a
forefront for future modeling. This model is successful in modeling the severe
effects that are common to most people with diabetes; distinct parameter changes
are used to separately model Type 1 and Type 2 diabetes. Disadvantages included
lack of non-insulin control and other key hormonal regulators of BG including
glucagon, GLUT4 and GLUT2. Exercise is also limited to a subjective intensity scale.
Meals are limited to only magnitude and duration as input parameters.
In summary, models tend to move from utilizing simplified compartment
‘minimal models,’ such as Sorensen (1978) focusing on nonlinear organ glucose
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demand and Bergman (1981), the first base compartmental insulin model, to those
that exist as a system, or multiple states involving dual-control and/or separate
volume-based compartments with varying metabolic properties. Wilinska (2005)
performed an extensive study evaluating and validating insulin models, including
acceptable linear models (Shimoda, 1997), more complex and nonlinear
compartmental models (Hovorka, 2004), and those using Michaelis-Menten kinetics
which form a strong core componentry of the Chapter 3 and 4 insulin compartment
structure. Many of these are shown in Table 2.1. Other models focus on the effect of
metabolic variations and compartment loss/fluxes due to temperature, thyroid
hormones, urine loss, and mechanical workload (Northrop, 2000).
The Schunk-Winters model addresses significant knowledge gaps in terms of
digestive absorption pathways and exercise characterization, which are limited in
most models above (e.g., Cobelli, 2009, Dalla Man, 2014, Yamamoto, 2014, and Roy,
2007).

Table 2.1: Evolutionary Summary of Glucoregulation Models (NL = Nonlinear, L = Linear)
Source

Model Structure

Cobelli et al,
1985

 5 State
 Glucose Subsystem (first order):
production and utilization (L)
 Glucagon Subsystem (first order):
secretion, distribution and
metabolism(NL-rate)
 Insulin Subsystem (3rd order):
distribution and metabolism of portal
and peripheral infusion by input to
liver and plasma compartments (NL)
 12 State
 Glucose Subsystem: insulinindependent utilization and insulindependent utilization
 Insulin Subsystem: liver and plasma
 Stomach: solid phases, and gut
 Adipose and Muscle (NL)

Dalla Man et al,
May 2007

Strengths
Cobelli Group
 Dynamic model of the
glucose regulation system
enabled minimal insulin
profile with peripheral
insulin infusion to be
computed.

Limitations

Relevance

 Not adaptable to all types of
normal and diabetic
subjects.
 Meal input is limited to
single carbohydrate source
as digestive dynamics lack.

 Provides basis for
minimal insulin
model and Cobelli
group development.

 Glucose-Insulin model
graphical interface
 Insulin control at
organ/tissue and whole
body levels
 Type 1 and Type 2
Recognition

 Does not account for
varying metabolic
properties across tissues
 Meal input limited to simple
carbohydrates.
 No input for
exercise/activity

 Matlab/Simulink
simulation parameters
and graphs for a
normal, type 2, type 1
subject
 Meal input and both
open and closed loop
controls available.
 Rate of appearance
parameters are similar
and provides rate of
appearance and
production graphs for
comparison.

Dalla Man et al,
October 2007

 16th Order adding digestive dynamics
(ingestion and absorption) based on
concentration and flux
 Same compartments as Dalla Man,
May 2009, with 36 parameters
(normal and type 2)

 Meals into quasi-model subsystems: Glucose, Insulin,
Muscle and Adipose, GastroIntestinal
 Mixed Meal

 Not performed for Type 1;
only Type 2, normal
 Muscle and Adipose Tissue
are in one compartment
 Stress hormone/ glucagon
not considered

Dalla Man et al,
2009

 Utilizes 16th order (2007) model at
rest
 Exercise dynamics: 8 parameters, key
being hepatic glucose effectiveness
and hepatic insulin sensitivity

 Addition of physical activity
via 3 models in steady and
non-steady (after a meal)
state

 Only short term exercise
and do not properly
characterize intensity

Some useful exercise
parameters on the basis
of heart rate are
provided; comparative
curves (validation
lacking)
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Kovatchev et
al, 2009

 Computer simulation environment:
glucose-insulin model (Cobelli et al,
2009), In Silico Sensor, In Silico
Insulin Pump, Controller

 In silico testing of control
algorithms linking CGM and
insulin delivery

 Computer simulation only
 Only insulin delivery
method model is FDA
approved

Kovatchev et
al, 2010

 Testing of model-predictive control
(MPC) algorithm in conjunction with
CGM for 300 virtual subjects
 Closed and Open Loop control
comparison
 New additions from 2007 Model
(2009 Simulator): counterregulation
updates (liver, muscle, and adipose
tissue), new alpha cell and glucagon
kinetics and delivery (3 additional
compartments) (NL)

 Extended 2009 in silico
testing to include closedloop control (better
regulates at night)
 Improved accuracy
 Addition of glucagon
 New rules for insulin to
carbs ration and correction
factor
 Dual-Hormone control (vs.
2009 version)
Other Models
 Glucagon (GLC) modeled as
ODE
 Mass-balance modeling
approach focusing on
compartmental exchange
(organs)
 Glucose effectiveness and
sensitivity.
 Basic Insulin Model

 Only focus on type 1
diabetes

 Introduction of insulin
degradation time constants
and time delays
 Separates liver, brain and
nerves, muscle and fat

 Lumps muscle and fat
together in terms of
delays—no way to separate
exercise demand

Dalla Man et al,
2014

Sorenson,
1978

 Nonlinear, ~ 19 Variables
 Additional Compartments: Brain,
Vascular, Kidney, Renal and
Peripheral Systems

Bergman, 1981

 3 States, 7 parameters
 2 Insulin Compartments: plasma and
interstitial
 1 Glucose Compartment: plasma and
basal levels
 6 states
 Negative feedback loops: insulin
effect on glucose utilization and
production and the effect of glucose
on insulin secretion

Sturis et al
(1991)

 Results only show for a
single meal and no exercise
input capability is apparent

 Parameters estimated from
rat clinical trials (GLC is
known to behave differently
in humans)
 Minimal model

 Insight into AP
methods and
comparative graphs
provided for 24-hour
plus simulations.
 Useful parameters
and comparative
graphs provided,
especially using CGM
data
Glucagon secretion and
following glucose
appearance kinetics
parameters; graphs for
comparison

 Glucagon modeling
insights for validation
 Incorporates
compartments and
blood flow similar to
Schunk-Winters
 Basis of many glucose
regulation models in
literature.
 Minimal model that
can be built off of.
 Understand
oscillations via delays
in feedback loops
 Shape delay curves
and inform time
constants for various
compartments
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Shimoda, 1997
(from
Wilinska,
2005)
Northrop et al,
2000

Hovorka et al,
2004
Li et al, 2006

Neelkanta et al,
2006

 3 Compartment Insulin, Linear
 Depot (2 compartments) and Plasma
Insulin
 Saturable absorption rates and
disappearance
 7 State
 Glucose Compartment: loss urine
(Linear) into ISCs (1st order linear)
and NISCs (1st order Linear), hepatic
glucose flux (hormone dependent)
 Glucose Input from diet (bimodal,
Linear)
 Glucagon Production (NL-rate
provides input to 1st order loss
kinetics)
 Portal Insulin (2 states, Linear and
NL-saturated)
 ~11 Variables;
 Endogenous glucose production and
renal filtration
 Core: Two Delay Differential
Equations for glucose
production/utilization and insulin
production/clearance
 4 Glucose Sinks: Insulin-Sensitive
Cells (ISCs), Noninsulin-sensitive cells
(NISCs), kidneys (urine loss), liver or
muscle (storage)
 Glucose Input: diet, stored
fat/protein, glycogen
 Insulin secretion is NL
 Three Subsystems:
 Glucose Subsystem: 5 NL rates
 Insulin Subsystem: 5 quantity terms

 Michealis-Menten Kinetics
similar to our model
 Simplified

 No adaption to outside
influential factors
 Minimal

 Metabolic rate constant as a
function of temperature,
thyroid hormone
concentration, epinephrine
and mechanical work load if
the cells are muscle.
 Separate glucose sinks into
insulin vs. non-insulin
sensitive cells
 Bimodal glucose input rate

 Validation and
implementation
 Limited in direct application
to exercise

 Evaluated using 15 clinical
experiments in subjects
with Type 1; strong glucoseinsulin sub model
 Time delays of insulin using
mas conservation
 Oscillation replication of
glucose and insulin
 Liver glucose production
based on glucose and insulin
concentrations
 Mass-Flow Model

 Main focus is correcting
during fasting conditions
and overnight; no full day
simulations
 Only for type 1 and lacks a
bit on meal input dynamics
and glucose/energy
homeostasis understanding
 Validation and
Implementation

 Simplest form, with
saturable effects
while keeping a linear
model; used by
Yamamoto
 Hormonal importance
in regard to noninsulin mediated
pathways, key during
exercise and
increased workload

Insulin model useful for
when depletion occurs
with comparative plots
Comparative plots,
especially regarding
mass conservation and
time delays
Pertinent to predicting
and quantifying the
effect of hepatic
gluconeogenesis based
on current
concentrations
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Roy et al, 2007

 Glucagon Subsystem: 2 quantities, 1
rate
 Take three-compartment Bergman
model and add exercise
 Insulin dynamics adds circulatory
removal,
 Glucose uptake and hepatic glucose
production (exercise induced) added

HernandexOrdonez, et al,
2007

 23rd order nonlinear dynamical
system

DuunHenrikson et
al, 2013

 Linear Three-Compartment Insulin
Model: subcutaneous layer, deep
tissues, and plasma

Yamamoto et
al, 2014

 3 Compartments: Carbohydrate
metabolism, subcutaneous insulin,
glucose-insulin metabolism
 Slowly Available Glucose: 2nd order
delay system
 3-Compartment (Shimoda) Insulin
Model
 Bergman Minimal Model
 Integration of 3 Models
 Meal Absorption
 Insulin Infusion Pump
 Insulin-Glucose Regulation Model
(Hovorka, Cobelli, Sorensen)

Sankaranaraya
nan et al, 2012

 Modeling exercise effects
based on uptake of working
tissue, plasma insulin, and
hepatic glucose release

 Validate low and moderate
intensity exercise on
existing glucose-insulin
model; extrapolate for high
intensity
 Redistribution of blood flow
with exercise
 Three-compartment
artificial pancreas model
 Absorption rate as a
function of exercise
intensity and duration
 Model of digestion and
absorption from
carbohydrates based on the
Glycemic Index

 Insulin infusion pump risks
modeling and varying
insulin curve shapes

 Do not fully understand
hepatic glucose
production—this is the way
exercise effects are modeled
via increase/decrease which
is not the case
 Data from literature
 Meal simulation is limited
and not addressed
 Stress hormones and
trained vs. untrained
parameters not present

 Provides insight that
there is a need to
model exercise
 Experimental data
from literature
Insight into glucose
production
segmentation: 50%
glycogenolysis, 30%
hepatic, and 20% renal;
comparative plots

 Need validation for insulin
appearance during exercise
 Only focus on normal, but
recognize Type 1
implications
 Do not provide exercise and
some error in regards to
control algorithm discussion
and state-space equations

Combine exercise idea
into artificial pancreas
application

 Case-study only
 Assume food ingested has a
single carbohydrate source
with fixed high GI

Insulin infusion plots

Direct comparison to
meal compartment
model; type 1
applications
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2.3 Need for a Lifestyle Model
2.3.1 Lifestyle Influenced Modeling: Foodstuff Consumption
Foodstuff and varying absorption properties of foods are recognized throughout
the nutrition community particularly in regard to glycemic index (GI). Yet, glucose
compartmental models often have a single carbohydrate input source, with other
mixed meal components assumed negligible in regard to BG effect (Dalla Man, 2007,
Roy, 2007, and Kovatchev, 2010). One group does capture the kinetics behind GI,
applying bioavailability concepts into rapidly and slowly available glucose
(Yamamoto, 2014). Their model is implemented in a way to ‘test’ known GI foods
and was recreated for comparison to the Schunk-Winters digestive compartment,
outlined in the Chapter 4 case study. Clinical data is presented in regard to BG
increment after ingestion of foods partitioned by GI and clinically prescribed insulin
dosages—however, limitations still exist, especially in regard to starting states
(Mohammed, 2003 and Sekigami, 2004). Similarities exist in transient response for
varying glycemic index (i.e. blood sugar ‘spike’ for high GI vs. gradual to steady
state) and insulin response effect—oftentimes, there is ‘overshoot’ in correction for
low GI carbohydrate meals due to accommodation of fast insulin dynamics and time
delay. Due to the simple fact one type of insulin is used for any CHO ingestion and
varying digestive absorption paths, problems arise due to insulin delay and timing,
which is investigated in Chapter 3.
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Both models (Yamamoto, 2015, and Schunk-Winters, 2012) use a summing
technique for the final digestive absorption state as seen in Figure 2.3 above.
Glycemic impact curves, or “the weight of glucose inducing a glycemic response” on
BG concentration are well documented for a variety of foods (Monro, 2008) and
described in glucose forward flow implementation of Chapter 3 below. The
motivation behind modeling GI ties into the need to model in conjunction with the
subject’s other habitual lifestyle habits. For example, by experience, a T1D individual
can actually keep one’s glucose within a target range solely by eating a low GI diet
and exercising, although also dependent on whether or not the individual still
produces some insulin. It was determined that lower GI foods are typically
associated with higher fat and protein content (if overall caloric intake is kept
consistent) and could aide in ‘tight’ BG control of the patient based on absorption
properties (Jenkins, 1981) if known to the predictive algorithm.
The Dalla Man/Cobelli meal simulator model is used as additional reference and
comparison to how most models simulate diet (Dalla Man, 2007). For the purpose of
comparison and that models (other than Schunk-Winters) only display capability
and literature curves for a defined carbohydrate bolus, all use the same input of 50g
carbohydrate ingestion typically with an unknown GI (other than Kotachev, 2010),
thereby making model replication somewhat limiting. Other studies, using a similar
bolus (~50 g carbohydrate) demonstrate significantly reduced area (i.e. lower BG
levels) under the BG curve post-prandial after a low-glycemic meal vs. a highglycemic meal (Parillo, 2011).
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2.3.2 Lifestyle Influenced Modeling: Integrating Diet and Physical Activity
Diet preference and lifestyle choice can influence substrate preference and
utilization during exercise (and also rest) due to availability. This is particularly
keen for adaptive modeling—if an individual eats a largely low GI diet (hence, most
likely incorporating more fat and protein), bioavailability of CHO and glycogen
stores are most likely decreased. However, a factor of adaptability must also be
taken into consideration as if the person is also trained, CHO oxidation is decreased
in general and glycogen ‘sparing’ occurs. This phenomenon suggests a low GI diet
may be sufficient to avoid hypoglycemia due to increased fat oxidation and
mitochondrial biogenesis in adapted and trained individuals (Kiens, 1993 and
Hurley, 1986). On the other hand, a high carbohydrate and high GI diet will increase
insulin production (possibly decrease sensitivity) and influence BG concentration
and uptake flux into tissues (especially non-muscle if no muscle demand exists).
Glucose mass flow and direction is highly dependent on varying types of
energy and tissue demand, particularly in regards to anaerobic vs. aerobic exercise,
as well as daily activity. Substrate for work comes from four main sources of stored
energy: muscle glycogen, free fatty acids (intramuscular, and via triglyceride
breakdown from mostly adipose sites), liver glycogen, and in some cases muscle
proteins (Powers, 2014). A catalyst, pyruvate dehydrogenase (PDH) has entered the
research field as a key catalyst for the entry of CHO and its subsequent oxidation, in
addition to the extensively studied relationship of oxygen uptake and carbon
dioxide production as a fuel consumption estimate (CHO vs fat) (ACSM and Powers,
2014). Biochemically, fat requires more oxygen for oxidation (23 O2 vs 6 O2).
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Greater activation (and hence CHO oxidation) occurs with increasing the glycolytic
flux and rate of pyruvate production, either by increasing muscle glycogen prior to
exercise or with higher epinephrine concentration. Similarly, myoplasm calcium
increases muscle activation and (indirectly) carbohydrate oxidation as it is released
from the sarcoplasmic reticulum during skeletal muscle contraction (Harmer, 2013).
Maximal oxygen uptake and the respiratory exchange ratio aid in characterizing the
point at which FFA vs CHO utilization turnover occurs, and can influence an
individual’s basal metabolic parameters (Brooks, 1994). Variation in basal
metabolic rate explicitly demonstrates another need for a personalized adaptive
model, and in addition, it is imperative that glycolysis is understood in all forms.
Anaerobic glycolysis represents an integral component of CHO utilization at high
intensity contractions, yet the associated catalytic enzymes can be altered in regard
to physiological adaptations especially in regard to trained individuals (Ohlendieck,
2010). Aerobically, fuel oxidation assumes a mix of CHO and fat metabolism, thereby
directly requiring understanding prior to modeling the glucose regulation system.
Values such as Respiratory Exchange Ratio (RER) are direct measures of
characterizing fuel utilization if maximal oxygen uptake and ventilation parameters
are measured. An RER of 0.7 corresponds to fat oxidation while an RER of 1.0 or
higher directly correlates glucose oxidation, particularly at high intensity exercise
(Melzer, 2011). It appears trained individuals, or those who have underwent
submaximal training for extended periods of time, have a lower RER and hence
higher degree of fat utilization in addition to a higher capability to utilize muscle
triglycerides (Boyadjiev, 2004). Other mechanisms include an increased number of
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mitochondria and GLUT4 translocation in muscle cells, as well as increased enzyme
activity and decreased catecholamine effect (Boyadjiev, 2004, and Holloszy, 2011).
Effects of training are discussed further in Chapter 4.
Formation of dynamic insulin modeling systems and associated absorption
properties into the tissue and/or blood has been an intensive evolutionary process,
core to most diabetic technology systems today. There are inherent time delays
associated with insulin type, body composition, and environment (Walsh, 2014). For
example, if one with high body fat content were to inject insulin into the abdomen
vs. a slim athlete injecting insulin into the leg prior to physical activity, clearly the
athlete would absorb and utilize insulin at a much faster rate. In fact, it is well
documented that anything involved in increasing blood flow will increase insulin
absorption rate, such as hot temperatures or any form of muscle activity (Walsh,
2014). This is in addition to time delays associated with dissociation and
monomeric vs. non-monomeric absorption properties of insulin, and, changing
pharmacodynamics of insulin action depending on the size of bolus if above a
certain level (Walsh, 2014). It appears that if injected in a large proportion, there is
a saturation factor and some insulin may be lost or not fully absorbed. Both issues
can be taken into account while modeling insulin with the use of Hill and MichaelisMenten kinetics—particularly if exogenous insulin is involved. In terms of modeling,
it is proposed that the different types of insulin (injection) will take paths based
peak timing and implemented as slower non-monomeric or faster monomeric (Li,
2006 and Diabetes Services, Inc.). If a subject is insulin-independent, a time delay is
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still present and may vary due to anticipatory effects (or lack of) of diet, exercise, or
any other factor affecting BG.
Physical activity increases the rate at which insulin effects occur, known as
insulin sensitivity. It originally was hypothesized, although now currently debated,
that tissue compartments could remain hypersensitive up to 48 hours post-exercise
(MacDonald, 2006). This is a dangerous issue in regard to late-onset hypoglycemia,
which could occur at night when the patient is unaware. However, there are other
mechanisms of compensation, as typically diet is increased with intense exercise,
and insulin sensitivity becomes an adaption of trained individuals, or routine, as fat
oxidation increases therefore sparing glucose (Befroy, 2008). Maarbjerg, 2011, and
colleagues outline many stimuli contributing to increased insulin signaling and
sensitivity (hence, glucose uptake) including increased GLUT4 translocation in
active muscles and fat cells dependent on the phosphorylation of protein TBC1D4,
as well as decreased glycogen levels (Maarbjerg, 2011). As recently supported, these
phenomena are present up to 4 hours after exercise, unlike the previously cited ’48.’
Hormones, particularly catecholamine’s epinephrine and norepinephrine,
along with amylin and leptin, influence glucose energy flow amongst compartments
and are not modeled mathematically, only recognized as influences in literature
(Aronoff, 2004, and ACSM). Epinephrine has been known to cause bouts of
hyperglycemia, characteristic of the ‘fight or flight’ response—glucose will flood into
the bloodstream, aiding in the concept of an ‘adrenaline rush.’ This concept is
difficult to model, and also occurs during exercise, especially in a high intensity or
race setting (Tonoli, 2012). For that reason, studies have been done altering the
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order of anaerobic/resistance training and aerobic training to decrease the effect of
a BG ‘spike’ prior to the decrease in BG due to an aerobic session (Yardley, 2012).
Training, particularly long endurance, also decreases catecholamine action in
general, indicating a need for a personalized model. Amylin, also synthesized in
beta-cells as with insulin, acts to suppress glucagon secretion and slow gastric
emptying, thereby aiding in glucose appearance and disappearance in circulation
(Aronoff, 2014). This complementary effect of amylin to insulin acts through the
central nervous system and may prove to be important for diabetic modeling
purposes. Leptin acts to regulate the amount of excess dietary calories stored as fat
in fat cells versus the amount of glucose stored as glycogen in the liver and muscles
(Northrop, 2011). Although not clearly associated with immediate glucose
dynamics, leptin plays a role in fat accumulation based on an excess of
carbohydrates, important for long-term modeling simulations.
Clinically, it does not yet seem possible to predict BG regulation of a diabetic
athlete—diabetic athletes must discover themselves what is needed and when but
with no real clinical guidance, only suggestions based on community tips and trial
and error. For that reason, an algorithm intended to incorporate non-insulin (and
glucagon) mediated physiologic mechanisms would be highly beneficial.

2.3.3 Lifestyle Influenced Remodeling: Types 1 and 2 Diabetes
All of the above mechanisms are occurring within a living biosystem that is
inherently changing based on its use history, which reflects lifestyle. Thus various
tissues of the body can remodel in structure and composition, including in response
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to lifestyle behavior and/or clinical interventions. This in turn needs to be
considered in clinical disease management. Two common examples are reviewed.
The current diabetes epidemic taking priority today involves obesity and its
direct risk factor of Type 2 Diabetes. This is an example of remodeling: lifestyle
choices lead to a change in body type, composition, and overall metabolic
implications which can turn into insulin resistance, and hence disease.
Accumulation of excess glucose in the blood due to over-eating and lack of exercise
eventually (over a long-term period) leads to an over-production of insulin but the
inability to utilize insulin properly, as glucose can no longer enter cells due to
excess. Buildup often results in conversion to fat, an external remodeling symptom,
and insulin resistance as an internal remodeling symptom. A lifestyle model, if
performed for months, could predict implications of BG buildup with proper
thresholds, tissue volume accumulation, and summation over a significant period of
time. It has been proven that physical activity is a means of prevention and
treatment for T2D; a remodeling back to a healthy lifestyle, practically reversing
insulin resistance, is possible with increased skeletal muscle capitalization,
increased muscular GLUT4 levels, hexokinase, and glycogen synthesis of chronic,
daily aerobic exercise (Yavari, 2012). With informed models and predictors of these
effects—particularly concerning tissue metabolism changes, GLUT4 flux, and
decreased body mass—it is possible to inspire T2D to make these changes, as it is
possible to decrease glucose accumulation and levels in general. Exercise-induced
insulin sensitivity has attracted recent attention for designing effective lifestyle
changes for T2D (Maarbjerg, 2011). With lifestyle models, this effect could be
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demonstrated and would inform treatment plans and options useful in a clinical
setting.
Similarly, an athlete, especially if exercise habits are 6 (or greater) days per
week for extended time periods, will experience body composition remodeling.
Trained individuals have vastly different metabolic properties and substrate
utilization during rest and physical activity. Glucose is a key player—oftentimes, an
athlete relies more on fat oxidation than glucose oxidation while at lower intensities
of exercise and at rest. This involves changes such as increased mitochondrial
content, all of which are outlined in Chapter 4. It is important to note modeling
changes that would occur for a diabetic athlete—reliance on fat (vs. glucose),
increased muscle mass tissue volume, increased glycogen stores, and importance of
varying exercise intensity on substrate utilization (Melzer, 2011).

2.3.4 Artificial Pancreas Predictive Applications
It is recognized that there is a current need for innovative BG regulation models
correlating to the current diabetes epidemic. Many factors, mostly related to
treatment options, manipulate the basis for modeling approaches—diet, exercise,
and interventional technologies, such as insulin injection, pumps, continuous
glucose monitors (CGM’s) and the recent concept of an artificial pancreas (AP).
Recently the AP system has evolved towards a two-sensor system, using two
Dexcom, Inc., glucose sensors (for comparative proportional error calculations) with
two pumps for independent delivery of insulin and glucagon controlled by a laptop
running a custom glucoregulation control model (Jacobs, 2011). In this pilot
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strategy, delivery occurred on the basis of weight, Hemoglobin A1C (HbA1C), meals,
and carbohydrates, all of which factor into an estimation of insulin sensitivity and
dependent on proportional error from target glucose levels. HbA1C is a common
measure for how well-controlled one’s BG has been for the previous 2-3 months, as
it reflects average levels and whether or not red blood cells have become “glycated.”
Further, Dexcom, a forerunner in the CGM technology field, has an initial AP
design that is using BG models, such as the Cobelli et al. 2009 version as seen in
Table 2.1(Garcia, 2013).
The concept of using BG dynamic models for AP controller algorithms makes
considerable sense. The challenge is using models that are robust enough to capture
the diverse events in life that affect BG, including forms of exercise. The models
outlined in Chapter 3 and 4 of this thesis, particularly for personalized adaptation of
an athlete in Chapter 4, possess capability of further informing AP technology for
unique individuals. However, this is only possible by increasing the algorithm
accuracy of trend prediction, possibly beginning with integrating extensive user
profiles. An extensive user profile, that incorporates metabolic parameters (resting
metabolism, body composition, exercise data to correlate heart rate, etc.) would
generate a generic algorithm for a particular individual that then can be informed by
instantaneous events (stress, exercise, foodstuff consumption).
Only in recent clinical studies has the need to adapt dual-hormone AP designs
in regard to lifestyle, particularly exercise and trained individuals, been addressed
(Haidar, 2013). In a recent clinical study, closed loop delivery guided by advanced
algorithms was shown to improve short-term glucose control, shown with 15 T1D
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adults who underwent a 24-hour simulation with 30 minutes of exercise (Haidar,
2013). However, this still is not sufficient to predict and inform a habitual lifestyle
and parameter set of trained individuals (see Chapter 4). Limitations often involve
instability of glucagon at room temperature; however, it is known that there are
other non-hormone dependent pathways that aid in glucose and energy utilization
during exercise.
Studies have demonstrated a need for adjusting basal insulin infusion rate prior
to and during exercise—however, this has resulted in only a general suggestion,
rather than personalized, for AP adaptation by an insulin reduction of about 50%
(Shiavon, 2013). Clinicians typically advise people with diabetes, for ease, to stop
insulin altogether during exercise. This may help avoid post-exercise late-onset
hypoglycemia due to increased insulin sensitivity for long-term duration if exercise
was of high caliber (MacDonald, 2006). However, as another AP application, a
patient should not have to completely stop insulin (unless they are experiencing
hypoglycemia) with a personalized model fine-tuned to individual metabolic
parameters. It seems that insulin sensitivity is only a small implication of exercise
and late-onset hypoglycemia; stress hormones and other contraindications as a
result of training are other causes, especially if a ‘false high’ is accounted for at the
beginning of exercise. For example, at the onset of exercise, as discussed, BG can
elevate. If an AP device corrects for this, oftentimes a hypoglycemic episode ensues
with the result of BG declining due to exercise demand in conjunction with an
insulin bolus effect. Additionally, a group used the basic 3-compartment insulin
model best suggested by Wilinska, 2005, and attempted to model the absorption
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rate between subcutaneous and deeper tissue as a function of exercise intensity,
realizing this was a major challenge to the current AP (Duun-Henriksen, 2013).
However, their methodology is limited to two levels of exercise intensity, and does
not address the influence of diet as another lifestyle parameter.
Heart rate is an easily obtainable metric and is well known to inform effort (if
different than perceived) during exercise and also often elevates during various
high-stress or active events. In the case of the proposed model, HR (if available) will
be used to inform exercise and stress (hormonal) inputs, but will not be fully relied
upon, mainly due to heart rate variability and interpersonal variations that must be
quantified in order to deem HR accurate.

33

3. NOVEL MODELING APPROACH METHODOLOGY
3.1 Introduction
Modeling of the blood glucose regulation system will better inform diabetes
management on the basis of predicting trends characterized by model inputs.
Clinicians and diabetes educators need to be able to quantitatively explain effects of
diet choice, athletics, and activity level, and how these relate to drug delivery
choices. Exercise type, daily movement activities, tissue compartment metabolism,
level of athleticism, meal type distinction and diet habits play a key role in BG
prediction algorithms. There is a need for a robust and comprehensive model that
simulates lifestyle choices, as current models are limited and fail to recognize
importance of modeling all influential factors.
A goal of the model relates to improved BG prediction so that a particular
individual has confidence in respective management. As personally seen with many
diabetic patients, it is trial and error as to controlling influences of lifestyle factors—
for example, physical and mental stress become task-dependent and can elicit vastly
different responses amongst individuals. Similarly, a marathoner will treat a twohour run as a ‘walk in the park,’ whereas another individual could experience
physical and mental stress.
A novel nonlinear 10-state lumped compartmental model is presented that
aims to address knowledge gaps that go beyond those addressed by other models,
including the ability to provide flexibility for lifestyle choices, variable body mass,
muscle ratio, and more logical parametric approaches for representing people with
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Type 1 and Type 2 diabetes. The model is intended for both research and clinical
use, particularly diabetes educators, and to inform delivery design of current
artificial pancreas mechanism with a dual-hormone delivery, as well as develop
continuous glucose monitor (CGM) feedback and prediction based on current
activity and/or diet. It is motivated by the concept that a diabetic should be able to
manage BG with exercise, diet, and dual-hormonal control based on algorithm
feedback of a personalized model, similar to that of machine learning mechanisms.

3.2 Background
Many models have been proposed, focusing on varying aspects of blood plasma
glucose (BG) regulation. Typically BG concentration is one of the compartments in a
dynamic model, with models ranging from very simple (2 total compartments) to
complex. Models tend to move from utilizing simplified compartment ‘minimal
models,’ such as Bergman (1981), the iteration of a compartmental insulin model, to
those that exist as a system, or multiple states involving dual-control and/or
separate volume-based compartments with varying metabolic properties- Sorensen
(1978) presents a complex model focusing on nonlinear organ glucose demand.
Wilinska (2005) performed an extensive study evaluating and validating insulin
models, including acceptable linear models (Shimoda, 1997), more complex and
nonlinear compartmental models (Hovorka, 2004), and those using MichaelisMenten kinetics, which form a strong core componentry of the proposed model.
Other models focus on the effect of metabolic variations and compartment
loss/fluxes due to temperature, thyroid hormones, urine loss, and mechanical
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workload (Northrop, 2000). In addition to Sorenson, Northrop et al. implemented a
system producing the hormone glucagon (GLC) as a simple, first-order loss kinetics
with a static, nonlinear function providing the GLC rate input to the GLC loss
dynamics ODE. Northrop particularly focuses on hormone kinetics, separating cells
into insulin-sensitive and non-insulin sensitive, with hepatic glucose flux that
depends on insulin, GLC, leptin and other regulatory hormones, not only BG.
The classic 3-state “Bergman minimal model” with two states including insulin
dynamics and glucose (Bergman, 1981) is one of the most widely used core models.
Bergman quantified insulin sensitivity with 3 compartments, representing plasma
insulin, remote insulin and plasma glucose concentrations. Extensions to this model
include a minimal exercise model adding a critical threshold value (on the basis of
VO2max) that drives hepatic glucose production and glycogenolysis during exercise
characterized by intensity and duration (Roy, 2007). These changes are reflected
with added terms of the plasma glucose equation of the Bergman minimal model.
Further, in a review of various differential equation approaches, Makroglou et al.
(2006) presents delay modeling approaches including those by Sturis et al. (1991),
integro-differential equations, and partial differential equations (Makroglou, 2006).
The integro-differential equation approach is key for modeling intravenous glucose
tolerance test dynamics after recognizing the widely used minimal model is
improper in qualitative behavior, as the base parameter is equal to the basal glucose
level. A more realistic dynamic model is needed, recognized by many (i.e. Li, 2001 or
Mukhopadhyay, 2004) and can also be improved with use of Hill kinetics, including
the special case of Michaelis-Menten, reviewed in Gesztelyi, 2012. These additions
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will address fundamental limitations with added states to further insulin dynamics
and the particular need to recognized delays and oscillations (Makroglou, 2006).
Hepatic glucose production and release is a large part of many models, often
as a mildly-delayed dynamic response due to depleted glycogen stores and/or low
BG levels. For example, Neelkanta (2006) proposed 4 glucose sinks: insulinsensitive cells (ISCs), noninsulin-sensitive cells (NISCS), kidneys (urine loss) and
liver or muscle (storage). It is possible to model liver storage and stimuli for glucose
production when needed by using a lumped glucose/glycogen model and glucagon
control, respectively. It becomes clear that liver can be modeled as a part of the nonmuscle tissue compartment for the purposes of the Schunk-Winters model. Nonmuscle tissue releases glucose mainly on the basis of glucagon-dependent (statedependent) flux, or glycogen-to-glucose conversion particularly in regard to the
liver. Glucagon directly modulates liver delivery rate.
Most models idealize diet as a single glucose input source, ignoring the
‘quality’ of carbohydrates. Once filtered through the digestive system, there is a rate
of appearance of glucose into the bloodstream. Newer models utilize 2-3 states to
capture this digestive process, but fail to distinguish between carbohydrate type and
varying absorption rates (Dalla Man, 2014 and Hernandez-Ordonez, 2008). By 2007,
Cobelli and colleagues developed an advanced 12-state model for studying the
effects of carbohydrates (meal) an extension approved by the FDA as a preclinical
trial tool for controller design used extensively (Cobelli, 2009 and Kotachev, 2010).
More recently, the addition of glucagon control action resulted in a 16th-order model
with 7 additional parameters (Dalla Man, 2014). The model implements simulations
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representing a diversity of “virtual” users. This work evolved into a FDA approved
simulator for evaluating controllers for T1D management and has made its way
extensively into the modeling field today, forming a strong sense of nonlinear
control in regard to insulin response for both T1D and T2D, as well as more recent
additions of glucagon and exercise (Kotachev, 2010 and Dalla Man, 2014). One
significant limitation is that it is still intended for a single meal implemented as a
bolus dose of carbohydrates.
The transient dynamics of glucose appearance is strongly influenced by
foodstuff composition, with measures such as GI to document the reality of peak
glucose influx ranging from minutes to hours after ingestion (Monro, 2008). Low
glycemic foodstuff results in a slower breakdown (less of the “sugar high” spike in
BG). The control actions of insulin in response to high glycemic foods generates a
strong blood insulin influx, and trigger a sudden “crash” in BG owing to increased
flux into tissues for storage (mostly in liver and muscle and adipose) and via energy
conversion pathways into fats (Walsh, 2014, Wolfe, 1998, and Jenkins, 1981). Only
one current group (Yamamoto, 2014) appears to have addressed the need for
deciphering between a food’s glycemic index (GI), which is well known to effect the
rate at which foodstuff is absorbed (Mohammed, 2004). In modeling meal
absorption, Yamomoto (2014) addressed glycemic index and associated insulin
effect based on replicated literature curves. A state-space representation form is
used for the carbohydrate metabolism subsystem, which distinguishes between
rapidly absorbing glucose (RAG) and slowly absorbing glucose (SAG). It was
determined that 95% of RAG was absorbed within 20 minutes, with SAG between
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20-120 minutes. SAG was modeled as a 20-minute time delay plus a time constant of
about 21 minutes (vs. just a time constant of 4.2 min for RAG). There was also a
first-order gastric emptying time constant related to the time required to pass from
the stomach to the duodenum. However, this particular model is limited in its
‘lifestyle’ inputs such as exercise and utilizes only the Bergman minimal insulin
model for subcutaneous insulin (Bergman, 1981 and Shimoda, 1997). Absorption
dynamics are represented by critically-damped second-order plus delay system of
the following form (Figure 3.1).

Figure 3.1: Yamamoto (2014) Glucose Absorption Equations. From Yamamoto, 2014,
representing rapidly-absorbing glucose (RAG), xRAG, and slowly-absorbing glucose dynamics), xSAG,
with time-constant T parameters of 4.22 min for RAG and 21.1 min for SAG with a 20-minute time
delay for 95% total absorption. Values were obtained in vitro. Design specifications for RAG
absorption include complete glucose absorption for an impulse food between 0-2o minutes and the
area-under-the-curve of RAG glucose absorption equal to the glucose equivalent for the RAG
regardless of the amount and GI of the food ingested.

3.3

Need for a New Lifestyle Model
It is evident that four major contributions need to be incorporated into novel

BG models: glycemic index (GI) and digestive dynamics, glycogen/glucose lumped
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into compartments, a muscle compartment that includes the effects of exercise and
activity, and hybrid-control compartmental energetic model. Fast and slow
nonlinear pathways, as informed by meal GI, should demonstrate a ratio of
carbohydrates to protein and fat with respective Hill saturation dynamics affecting
both absorption rate and substrate availability (Gesztelyi, 2012). Unlike many
models, glycogen and glucose can allow to be lumped into compartments as one
entity since the focus is on energy flux and storage. Glucagon and control-sensitive
flux rates allow for a new and innovative way of accessing glucose without an
additional state, particularly the liver. GLUT4 and GLUT2 pathways become
particularly important, with glycogen stores following mass-conservation
throughout all tissues and glucagon as the controller mechanism.
The separation of tissue into a non-muscle and muscle compartment allows
accommodation for demand-based muscle metabolism, and different from constant
glucose sinks of non-muscle. Not included under non-muscle is a steady glucose
energy sink, particularly related to brain consumption.
The addition of a muscle compartment allows for varying muscle mass and
body composition of individuals, and type and duration of exercise. Similarly, the
addition of the internal muscle mitochondrial consumption state allows for ATP
production on the basis of the amount of mitochondria present, as this is a
parameter known to vary amongst individuals.
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3.4 Methods
3.4.1 Model Structure
The overriding model design objective was an inherently robust model of the
human glucoregulation system, using the minimal set of state variables
(summarized in Figure 3.2) and parameters necessary to simulate diverse scenarios
with adjustability to composition variation and T1D and T2D. Appendix 7.1 lists all
flux input/output parameters and terms.

Figure 3.2: Schunk-Winters Compartmental Model Block Diagram and Structure. Thick lines
represent material flow with storage and control action as unidirectional signals informed by rate
parameters and oftentimes, nonlinear, by either Hill kinetics or multiplicative states. Dashed lines
represent exogenous control, via injection or other external device. Nonlinear relations include both
flux terms and heuristics that change fitting equations based on different state or input signal ranges.
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3.4.2

Four Major Novel Contributions

The Schunk-Winters model addresses knowledge gaps found in literature,
focusing on four major contributions including both simplifications and
developments of past models: glycemic index and digestive dynamics, lumping
glycogen and glucose, addition of a muscle compartment and regulatory action, and
opportunity for a hybrid control-compartmental energetic model.
3.4.2.1 Glycemic Index and Digestive Dynamics
The inputs to this sub-model are rate and amount of oral ingestion of
foodstuff, with the carbohydrate fraction separated into ‘fast’ and a ‘slow’ inputs, as
informed by the estimated GI of meal components, available from many sources
(e.g., Monro, 2008 and Yamamoto, 2014). About 88-98% of carbohydrate is
absorbed (highest for pure high-GI carbohydrate ingestion, lowest for low-GI)
(Monro, 2008 and Yamamoto, 2014). Also inputted is the ratio of carbohydrate to
the total consumed energy including fat plus (especially) protein content in a meal
which can (mildly) influence rate of absorption and carbohydrate availability (as is
widely documented, and that Meal GI, universally, is a weighted sum of meal
constituents and associated food GI and carbohydrate (CHO) amount (Monro,
2008):
𝑀𝑒𝑎𝑙 𝐺𝐼 =

(𝐺𝐼𝐹𝑜𝑜𝑑𝐴 𝑥 𝑔 𝑎𝑣𝑎𝑖𝑙 𝐶𝐻𝑂𝐹𝑜𝑜𝑑𝐴 )+ (𝐺𝐼𝐹𝑜𝑜𝑑𝐵 𝑥 𝑔 𝑎𝑣𝑎𝑖𝑙 𝐶𝐻𝑂𝐹𝑜𝑜𝑑𝐵 )+⋯
𝑇𝑜𝑡𝑎𝑙 𝑔 𝑎𝑣𝑎𝑖𝑙 𝐶𝐻𝑂

[3.1]

The slow (low GI) signal enters a separate, slower digestive pathway that is
assumed to be first-order, but nonlinear in that the rate adjusts with the amount of
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carbohydrate and overall material. The material flow state from this pathway
converges (sums) with the direct “fast” pathway to a final first-order digestiveabsorption process. This approach appears novel, although the concept of
mathematically distributing carbohydrate into rapidly and slowly available glucose
based on GI has been published recently, but with a different (linear) strategy, with
equations outlined in Figure 3.1 above, similar to Yamamoto et al, 2014 (Monro,
2008). Meals are inputted in regard to total carbohydrate content (kcal/hr with 4
calories per gram of carbohydrate) and proportion of fast, high GI, carbohydrate
content. Other parameters include a term for dietary thermogenesis (i.e. heat lost
during digestion, assumed a function of the slow pathway) and digestive
effectiveness ratios for fast (~98% absorption) and slow (~88% absorption)
digestive inputs due to food loss during digestion in the intestine and stomach, as
well as fiber and other foodstuff that is not fully absorbed (particularly for slow
CHO).
In regards to the calculation of GI, and for purposes of model validation, fiber
content should be subtracted in order to obtain the amount of ‘available
carbohydrates.’ Cooking and reheating food tends to raise GI, and this must be
controlled for to obtain a particular GI.
3.4.2.2 Glycogen/Glucose Lumped
Glucagon and control-sensitive flux rates, specifically GLUT2 (non-muscle
glucose transporter) and GLUT4 (muscle glucose transporter), represent a new and
innovative way of accessing glucose in the model without the need for an additional
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state, typically liver. Both tissue compartments assume that glycogen is the compact
storage form of glucose and represented throughout the mass-conservation system
in all tissues assumed in the model—liver, muscle, adipose, etc. Unlike past models,
there is no state explicitly associated with hepatic production and glycogenesis;
however glucagon plays the role of control action as a function of non-muscle
storage (along with the associated flux) resulting in a ‘lumped’ modeling approach.
That being said, training can alter relative glycogen storage levels, particularly in
muscle, indicating glycogen stores will start higher and sparing often occurs
(Holloszy, 1984). It seems necessary to delineate between muscle and non-muscle
tissue as opposed to adding a liver state, as hepatic glycogenolysis and
gluconeogenesis can still be modeled with glucagon and GLUT2 action.
3.4.2.3 Muscle Compartment and Regulatory Action
Muscle is often lumped into the tissue compartment of most models, such as
‘Muscle and Adipose Tissue’ or ‘Periphery’ (Dalla Man, 2009 and Roy, 2007),
proposing significant limitations. Others simply use exercise as a glucose ‘sink’ and
decrease in BG (typically non-linear), increase in hepatic gluconeogenesis, storage,
and flux, and increase in insulin sensitivity (Northrop, 2000, and Neelkanta, 2006).
The proposed model addresses this knowledge gap by recognizing metabolic
differences of muscle vs. non-muscle tissue, and treating muscle as a separate
compartment.
Muscle glycogen storage can alter with diet and training, and act as an
immediate source of glucose for short-term, contraction-based activity. Storage

44
capacity of muscle glycogen in a healthy, non-obese, 70 kg male subject is about 350
grams, or at most 2% of total body volume (Holloszy, 1982). However, muscle
requires mass flow from BG, especially if a burst of anaerobic activity or high
intensity, >60% VO2max aerobic exercise, as glycogen stores are limited.
Contractions stimulate processes including phosphocreatine (PCr) shuttling, Ca2+
flux from the sarcoplasmic reticulum, and GLUT4. Metabolism using PCr as fuel is a
glycolytic process particularly important in the first 3 minutes of ATP need and/or
demand (i.e. exercise or daily, anaerobic, activity). The delivery of glucose parallels
the activation of contraction (Gastin, 2001).
Plasma epinephrine, a powerful stimulator of cyclic AMP formation at the
onset of exercise as well and is primarily responsible for the onset of glycogenolysis
at exercise >80% VO2max (Kjaer, 1989), is not explicitly modeled as its own entity.
However, it is indirectly modeled through the nonlinear subtraction of fat in the fuel
demand mix.
Fat metabolism is another energy fuel source, and is often a factor of training
level as related to mitochondrial volume increase, which often occurs with aerobic
endurance training (Holloszy, 2011). Maximum proportion of fat fuel consumption
occurs at low to moderate intensity exercise (Holloszy, 1996). This concept results
in the nonlinear subtraction (as a reciprocal Hill function) for both tissue glucose
states. When fat is being utilized, glucose consumption will be reduced until
intensity or anaerobic activity increases or substrate availability is altered (Hurley,
1986).
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The GLUT4 gradient and production of fuel mix (fat) are both modeled by
nonlinear Hill kinetics on the basis of fat utilization curves found in literature
(Brooks, 1994). Total aerobic exercise consumption is defined as subtracting the
total fat fuel mix consumption from the total exercise input. The model assumes by
default that fat oxidation has a maximum of 30% of total aerobic capacity, although
with training, this could increase (Brooks, 1994). Total anaerobic exercise
consumption is assumed by default to be 50 kcal/hr before switching to
mitochondrial and aerobic. GLUT4, Ca2+, and liver glycogenolysis are key regulators
and pathways for glucose access during exercise without hormonal control (i.e.
glucagon and insulin), although there is an important catecholamine effect as well.
Often exercise intensity fluctuates, and it would be useful to have a method
for informing the model about fluctuating levels of muscular demand for glucose.
Heart rate data from a smart watch and/or other form of continuous monitor, of
available, can help inform exercise and activity input signals, helping sculpt
perceived energy rate input pulses given in kcal/hr (u3 and u4).
Various measurements of fitness level and correlation between substrate
utilization, fat vs. carbohydrate fuel, during exercise of varying duration and
intensity exists and will be further examined in Chapter 4 (i.e. Yardley, 2012). Other
model capabilities involve individual fitness parameters and will be developed for
model personalization features (Chapter 4). For example, knowing anaerobic
threshold and VO2max of an individual allows characterization of heart rate ‘zones’
1-5 ranging from ‘light, recovery’ exercise (zone 1) to above anaerobic threshold
(zone 5). Often used in exercise physiology, zones can be correlated with respiratory
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exchange ratio (RER) in which an RER = 0.7, often during zones 1-2, is mainly fat
utilization while zone 5, or RER > 1.0, is mainly glucose utilization with a fuel mix in
between (Knoebel, 1984). Zones are often used in regard to exercise planning and
training, as they can be adjusted as one becomes trained, typically favoring higher
fat utilization at elevated heart rates and shifting zones upward (Millan, 2014).
There is the possibility that long durations of circuit training and/or
anaerobic exercise can elicit fuel mix responses as well; however, this is a current
debate. Heart rate (HR), assuming steady state, can be a rough crude indicator of the
amount of fat consumption, if HR zones are known and can provide an accurate
sense of intensity—further discussed in Chapter 4 as an additional external input.
3.4.2.4 Hybrid Control-Compartmental Energetic Model
A hybrid model enables the ability to have more realistic inputs than most
models. Inputs are all scaled to kcal/hr (exercise and activity) or g/hr (digestive
input, insulin) with easy conversion between each. Body composition data is easily
incorporated and scales various parameters that are influenced by body mass or
muscle/non-muscle compartment mass. Additionally, various types of insulin
resistance and type 1 effect scale the model. Lifestyle inputs also demonstrate the
need for GLUT2 and GLUT4 action, as many activities and scenarios allow even a
type 1 diabetic to be ‘OK’ without experience hypo- or hyperglycemia. For example,
a type 1 diabetic often can eat a low GI snack or exercise at a low intensity for an
extended duration without deviating from the target range due to other external
non-insulin, non-glucagon based pathways. Hill relations allow for maximum
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saturation at known quantities and limits, as well as allow tuning for rate changes
due to a particular concentration without need for conversion, and are reviewed by
Gesztelyi, 2012.

3.4.3 Nonlinear Hill Kinetics for Saturating Rates and Signal Magnitudes
The model makes use of classic Hill saturating kinetics for rates and in some
cases signal magnitudes, and is reviewed by Gesztelyi, 2012:
𝐹ℎ𝑖𝑙𝑙 (𝑥, 𝑘𝑚𝑎𝑥 , 𝑘𝑠 , 𝑛) =

𝑘𝑚𝑎𝑥 𝑧 𝑛
𝑘𝑠𝑛 +𝑥 𝑛

[3.2]

where x is a state, kmax and ks are maximum saturation and half-way x values, the Hill
coefficient n is 1 (Michaelis-Menten kinetics), 2, 4 or 6 (each with soft saturation at
both ends), and z = x for rising and z = ks for falling curves (Hovorka, 2002).
For hormonal P-action signals where 10% rather than 50% of max helps design
resting values, we map:
ks = [9mkn]1/n

[3.3]

where k=0.1 (10%) is the basis for hormone “reference” parameters, m = 1 for
rising, m = -1 for falling.
Nonlinearities of glucagon and insulin controllers (with added time delay for
insulin), meal absorption (slow and fast stomach states), tissue intolerance, and BG
loss muscle demand gradient all utilize Hill kinetics. Figure 3.3 demonstrates Hill
effects on BG based on insulin and glucagon controllers. In equations that follow,
Hill functions are seen throughout the following state equations, with values defined
in Appendix 7.1.

48

Figure 3.3: Insulin and Glucagon Hill Controllers. Insulin (solid) and glucagon (dashed) vs. blood
plasma glucose concentration as implemented with Hill based controllers.

3.4.4 Glucose Compartmental Flow
A 3-compartment “process” model for glucose distributes most of body tissue
volume (other than plasma glucose) into two compartments: skeletal muscle (~3545% body weight (BW)) and non-muscle (~35-40% of BW). The non-muscle
compartment represents unique features of tissues with specific glucose flux
pathways within blood and/or storage capacity, including liver, adipose, cardiac and
digestive. It does not include the volume of brain or blood erythrocytes (which are
assumed to provide steady flux sinks), or extracellular fluid (ECF, the volume of the
third compartment, “blood plasma/ECF”).
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Interface parameters based on relative mass are used to assure that states
and fluxes are scaled appropriately between compartments. Appendix 7.1 provides
non-muscle and muscle parameters influenced by respective BM contributions.
Glucose compartmental relations of states 𝑥𝑔 , 𝑥𝑚 𝑎𝑛𝑑 𝑥𝑛𝑚 are represented by each
flux and mass balance/flow term below with most terms nonlinear via use of Hill
kinetics for rates or magnitudes, and multiplicative control action. A stateindependent steady unidirectional glucose loss flux of (by default) 120g per day is
used to represent the energy requirements of brain and erythrocytes, based on
work by Roy (2002) and Melzer (2011). Additionally, there are two types of
specialized fluxes that are a direct function of insulin or glucagon control action: a
relatively small non-muscle flux sink associated with the slower-digestion pathway
(developed below), and potentially much larger fluxes associated with muscle
workload activities such as exercise (also developed below). The Schunk-Winters
model scales to each person by BW ratios relative to defaults for BW (70 Kg), with
similar ratios for non-muscle and muscle (see Appendix 7.1 Table for affected
parameters). Muscle mass is also composed of mitochondrial mass, defined by a
ratio parameter of percent muscle. This value becomes increasingly important with
training and as discussed in Chapter 4.
The addition of a mitochondrial consumption state within the muscle
compartment is motivated by the remarkable variation in energy demand and
consumption during exercise and activity. This allows for varying rates between
conversion pathways on the basis of total mitochondrial amount and fiber type
distinction. Type 1 muscle fibers (slow oxidative) have high mitochondrial content
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and are able to generate more work with less ATP utilization whereas Type 2
muscle fibers (fast glycolytic) require more immediate glucose as energy and have a
lower mitochondrial content (Holloszy, 2011). Mitochondrial volume increases with
endurance-trained individuals, as can energy transport capacity. For instance, one
study found that a 2-fold increase in GLUT4 expression results in a 2-fold increase in
glucose uptake at the same insulin concentration (Holloszy, 2011). This concept
relates the idea that oftentimes walking, or simple daily activity, is beneficial for
diabetes management, including those experiencing insulin resistance. For the
purposes of our model, for the x10 state, mitochondrial use of glucose only (despite
mitochondria’s important role in fat oxidation) is modeled to keep consistency with
mass glucose conservation and kcal/hr inputs. The Kreb’s cycle, which takes place
in the mitochondrial matrix, is a precursor for oxidative phosphorylation and
efficient generation of ATP from glucose fuel. We assume this process is most fully
associated with aerobic exercise, the u3 input of our model. On the other hand,
anaerobic exercise and daily activity (u4) tend to use a less efficient ATP generation
in glycolysis, or immediate glucose consumption in the cytoplasm. Any exercise
involving fast-twitch glycolytic muscle fibers (often ‘bursts’ of activity) will utilize
glycolysis. However, especially with long-lasting activity and/or anaerobic exercise,
mitochondrial action will continue to take place as a more endured energy source
but at a reduced proportion (parameter kprop).
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Figure 3.4: Skeletal Muscle and Tissue Compartmental Model.
Skeletal Muscle and Tissue Compartmental Model
um-activity : Daily Activity Muscle Input (kcal/hr)

um-exer-Ana : Anaerobic Exercise Muscle Input (kcal/hr)
um-exer-Aer : Aerobic Exercise Muscle Input (kcal/hr)
fat_Aer: Aerobic Fat Consumption (out of total exercise input) (kcal/hr)
AerCap: Maximal Aerobic Capacity (kcal/hr)

3.4.4.1 Blood Plasma Glucose State (mg/dl)
𝑑𝑥𝑔
𝑑𝑡

= 𝐾𝑏𝑑 𝑥𝑑 − [(𝐶𝑖 𝑛𝑚 (

𝑘𝑚𝑥−𝑛𝑚 𝑘𝑡𝑖𝑛𝑡𝑜𝑙 8
𝑘𝑡𝑖𝑛𝑡𝑜𝑙 +𝑥𝑛𝑚
1
𝑢

𝑘
[( 𝑚𝑥−𝑒𝑥 𝑒𝑥𝑒𝑟)
𝑘𝑠−𝑒𝑥 +𝑢𝑒𝑥𝑒𝑟

) + 𝐶𝑖 𝑚 (

(𝑥𝑔 − 𝑥𝑚 )] −

𝑘𝑚𝑥−𝑚 𝑘𝑚𝑖𝑛𝑡𝑜𝑙 8
𝑘𝑚𝑖𝑛𝑡𝑜𝑙 +𝑥𝑚

𝐾𝑏
𝑤𝑛𝑚

− (

) )] 𝑥𝑔 𝑥𝑖 + (𝐶𝑔

𝑘𝑔2𝑚𝑎𝑥 𝑥𝑔

𝑘𝑔𝑟𝑒𝑓𝑡 +𝑥𝑔

𝑛𝑚

+ 𝐶𝑔 ) 𝐾𝑔𝑡 𝑥𝑔 𝑥𝑔𝑛 −
𝑚

2

) (𝑥𝑔 )

[3.3]

where influxes are digestive (stomach) glucose (𝒙𝒅 ) and glucagon controller
(𝒙𝒈𝒏 , mostly via liver and controlled rates), with outfluxes of exercise loss (𝑢𝑒𝑥𝑒𝑟 ),
insulin (𝑥𝑖 , to tissues), brain consumption (𝐾𝑏 ), bi-directional GLUT2 loss (liver,
intestines, etc.), muscle demand consumption.
Below is a key for Equation 3.3. Equations 3.4- 3.12 follow a similar scheme,
with terms and parameters defined in the Glossary and Appendix 7.1. In particular,
Hill parameters are denoted by ks or kmx, referring to half-way saturation and
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maximal saturation, respectively. Other subscripts inform on the basis of state or
parameter. For instance, a subscript ‘m’ refers to muscle, or kgreft refers to the
parameter greft. Current state concentrations are denoted by x terms. The units of
each state are provided after each subheading or in the Glossary and Appendix 7.1.

𝑑𝑥𝑔

, Rate of Change in BG vs. Time (hr) [mg/dl]
𝑑𝑡
𝐾𝑏𝑑 , Conversion of Digestive Mass Flow (g/hr) into ECF (BG + interstitial) scaled by blood
volume (in dl) and with mass converted from g to mg
xd, Glucose Digestive Forward Rate Path [g/hr]
Cinm, Insulin Control Parameter, Non-Muscle Tissue Gain [unitless]
𝑘𝑚𝑥−𝑛𝑚 , Maximum Saturation for Non-Muscle Tissue Intolerance [/hr]
𝑘𝑡𝑖𝑛𝑡𝑜𝑙 , Reference Threshold for Non-Muscle Tissue [mg/dl]
xnm, Non-Muscle Tissue State [g/kg]
𝑘𝑚𝑥−𝑚 , Maximum Saturation for Muscle Tissue Intolerance [/hr]
𝑘𝑚𝑖𝑛𝑡𝑜𝑙 , Reference Threshold for Muscle Tissue [mg/dl]
xm, Muscle Tissue State [g/kg]
xi, Endogenous Insulin Control Action in Blood Plasma (mU/dl)
𝐶𝑔 , Glucagon Control Parmeter, Non-Muscle Tissue Gain [unitless]
𝑛𝑚
𝐶𝑔 , Glucagon Control Parmeter, Muscle Tissue Gain [unitless]
𝑚
𝐾𝑔𝑡 , Basal Tissue Elimination Rate, Scaled to Grams (for Glucagon) [/hr]
xi, Endogenous Glucagon Control Action in Blood Plasma (pg/dl)
𝑘𝑚𝑥−𝑒𝑥 , Maximum Saturation for Muscle Tissue Gradient [/hr]
𝑘𝑠−𝑒𝑥 , Half-Way Saturation for Muscle Tissue Gradient [g/kg]
𝑢𝑒𝑥𝑒𝑟 , Aerobic Exercise Input, u3 [kcal/hr]
𝑘𝑏 , Blood Glucose to Steady Consumption Sink (mostly brain) [g/hr]*, scaled by kbd conversion
to mg/dl
𝑤𝑛𝑚 , Non-Muscle Mass [kg]
𝑘𝑔2𝑚𝑎𝑥 , Maximum Rate, GLUT2 Flux [/hr]
𝑘𝑔𝑟𝑒𝑓𝑡 , Reference Threshold of BG for Non-Muscle Flux Direction [mg/dl]

Inputs u1-u4 are in kcal/hr, consistent with an energy flow model. For
glucose, 4 Kcal of energy is assumed to have a one gram mass equivalent (1 g CHO =
4 kcal). Thus for rates, 1 g/hr of glucose flux maps to 4 Kcal/hr of glucose energy
flux. Any quantity that has units of kcal/hr will be divided by 4 in order to convert to
grams/hr.
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3.4.4.2 Non-Muscle Tissue State (g/kg)
𝑑𝑥𝑛𝑚
𝑑𝑡

= [(

𝑘𝑔2𝑚𝑎𝑥 𝑥𝑔

𝑘𝑔𝑟𝑒𝑓𝑡 +𝑥𝑔

2

) (𝑥𝑔 ) + 𝐶𝑖 𝑛𝑚 (

𝑘𝑚𝑥−𝑛𝑚 𝑘𝑡𝑖𝑛𝑡𝑜𝑙 8
𝑘𝑡𝑖𝑛𝑡𝑜𝑙 +𝑥𝑛𝑚

) 𝑥𝑔 𝑥𝑖 − 𝐾𝑔𝑡 𝐶𝑔

𝑥 𝑥 ] 𝑤𝑏𝑡
𝑛𝑚 𝑔 𝑔𝑛

−

[𝐺𝑚𝑒𝑡 𝑛𝑚 +(𝐾𝑐𝑎𝑟𝑏 𝑥𝑑𝑠 )]
𝑤𝑛𝑚

[3.4]
where influxes are insulin-regulated BG delivery, brain requirement, bi-directional
GLUT2 gain (liver, intestines, etc.), and outfluxes are basal metabolic tissue loss and
glucagon-regulated delivery. Some are scaled by wbt, based on blood volume and
non-muscle mass.
Scaling and conversion is similar to that of Equation 3.3. Parameter wbt is
used for compartmental flux conversion with BG concentration (in mg/dl)
converted to amount in grams by using BG volume, then is normalized to the mass
of the segment (thus g/kg of non-muscle).

3.4.4.3 Muscle Tissue State (g/kg)
𝑘

𝑑𝑥𝑚
𝑑𝑡

=[

𝑢
𝑒𝑥𝑒𝑟

𝑒𝑥𝑒𝑟 )1 (𝑥 −𝑥 )]
( 𝑘𝑚𝑥−𝑒𝑥
𝑔
𝑚
+𝑢
𝑠−𝑒𝑥

𝐺𝑚𝑏

+ 𝐶𝑖 𝑚 (

𝑘𝑚𝑥−𝑚𝑘𝑚𝑖𝑛𝑡𝑜𝑙 8
𝑘𝑚𝑖𝑛𝑡𝑜𝑙 +𝑥𝑚

[𝑢𝑑𝑎𝑖𝑙𝑦+𝐺𝑒𝑥𝑒𝑟(𝑢𝑒𝑥𝑒𝑟 )]
4𝑤𝑚

) 𝑥𝑔 𝑥𝑖 − 𝐶𝑔 𝑥𝑔 𝑥𝑔𝑛 ] 𝑤𝑏𝑚 −

𝐺𝑚𝑒𝑡 𝑚

𝑚

𝑤𝑚

− 𝑟𝑎𝑡𝑚𝑖𝑡𝑜 𝑥𝑚𝑖𝑡𝑜

[3.5]

where influxes are insulin-managed BG delivery (scaled to this compartment) and
exercise-demanded BG delivery (scaled), and the outfluxes are basal metabolic
muscle loss, exercise-demanded muscle glucose consumption, and daily activity
related muscle glucose consumption.
Scaling and conversion is similar to that of Equation 3.3. Parameter wbm is
used for compartmental flux conversion with BG concentration (in mg/dl)

−
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converted to amount in grams by using BG volume, then is normalized to the mass
of the segment (thus g/kg of muscle).
3.4.4.4 Mitochondrial State (g/kg)

𝑑𝑥𝑚𝑖𝑡
𝑑𝑡

𝑘𝑚𝑢𝑠𝑐 (𝐺𝑒𝑥−𝑇𝑜𝑡𝑎𝑙 +𝑘𝑝𝑟𝑜𝑝

=[

𝑢𝑑𝑎𝑖𝑙𝑦
−𝑥𝑚 −𝑥𝑚𝑖𝑡 )
4

4∗𝑤𝑚𝑖𝑡

]

[3.6]

where influxes are total exercise (anaerobic + aerobic) glucose consumption
demand as a Hill function and daily activity and outfluxes are loss to muscle tissue
(demand based) and mitochondrial consumption.
3.4.4.5 Glycogen Storage Approach
It is well known that glucose is stored as glycogen in almost all tissue
compartments, with amount dependent on a variety of factors including habitual
(and recent) diet (i.e. high carbohydrate vs. high protein and/or fat), health and
athletic training status, as well as instantaneous demand of exercise. High dietary
carbohydrate is a key reason for glycogenosis within the liver and muscle, the
largest storage sites.
During high stress triggering events, whether it be a form of exercise
requiring glucose or the ‘fight-or-flight’ mechanism elicited for another external
stimulant, glycogenolysis typically occurs in the liver as shown in most models.
Despite lack of an explicit liver state, the same effect is achieved with on-muscle
demand contributing to a rise in BG on the basis of increased HR input (u5) and/or
glucagon controller response.
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3.4.5 Glucose Forward Mass Flow
This sub-model is 2nd-order, with its output state being a mass flow rate of
appearance of glucose into the blood plasma/extracellular fluid compartmental. The
proportion of carbohydrates entering into the fast vs. slow absorption path is
dependent on meal glycemic index (kfast) and the total amount of carbohydrates
inputted. There is a maximum saturation on how fast glucose can enter (if
extremely high GI, absolute path, kmax or kabs) and a limit on how much can be
absorbed based on the filling and/or gastric emptying of the stomach in grams (slow
path kmin value). Absorption is modeled with use of saturating Hill kinetics.

Digestive Lumped Compartmental Model
u1-fast* : Fast Carbohydrate (High Glycemic) Glucose Input (kcal/hr)

u1-slow*: Slow Carbohydrate (Low Glycemic) Glucose Input (kcal/hr)
Kfoodloss: Food Input Not Absorbed (Fiber, etc.) (Decimal Percent)

Ksink: Foodstuff Lost Prior to Stomach Absorption (Intestines, etc.) (Decimal Percent)

Figure 3.5: Digestive Lumped Compartmental Model
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3.4.5.1 Low Glycemic Index (Slow) Forward Glucose Path (g/hr)
𝑑𝑥𝑑𝑠
𝑑𝑡

= [𝐾𝑢𝑔𝑠 + (𝑘

𝑘𝑢𝑔𝑠 𝑥𝑑𝑠
𝑠−𝑑𝑠2 +𝑥𝑑𝑠

4

𝑢𝑠𝑙𝑜𝑤

) ] 𝑢𝑐𝑎𝑟𝑏 𝐺𝑒𝑓𝑓 (
𝑠

4

[3.7]

) − 𝑥𝑑𝑠

where influxes are glucose input and slow stomach glucose state, and outflux is the
slow path that enters the final stomach path that follows. It is important to note that
scaling occurs by a factor of 4, as for glucose 1 g of CHO = 4 kcal.

3.4.5.2 Glucose Digestive Forward Flow Final Path (g/hr)
𝑑𝑥𝑑
𝑑𝑡

(𝑘𝑢𝑔𝑓 /2)𝑥𝑑 4

= [𝑢𝑑 [(

𝑘𝑠−𝑑 +𝑥𝑑
4
𝑘𝑢𝑔𝑠 𝑥𝑑𝑠
(𝑘
)
] 𝐺𝑒𝑓𝑓 𝑥𝑑𝑠
+𝑥
𝑠
𝑠−𝑑𝑠2

(𝑘𝑢𝑔𝑓 /2)𝑥𝑑 4

) +(𝑘

𝑑𝑠

𝑠−𝑑2 +𝑥𝑑

𝑢𝑓𝑎𝑠𝑡

) ] 𝐺𝑒𝑓𝑓 (
𝑓

4

) + [𝐾𝑢𝑔𝑠 +

− 𝑥𝑑 ]

[3.8]

where the influxes are the glucose input (fast component) and the pre-filtered slow
component, each sculpted for lower rates outside of their respective digestive midranges, and the outflux is the output of the digestive process, i.e., the rate of glucose
entering the bloodstream.

3.4.6

Glucose Bio-Controllers

It is well known that xg is regulated to reach homeostatic bounds of about 80
to 120 mg/dL (sometimes higher, if diabetic) largely through hormonal control
action. Endogenous insulin production within the pancreas and secretion into the
blood increases with high glucose concentration. Glucagon is a counter regulatory
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hormone to insulin with similar mirroring dynamics for when xg is low. Glucagon
supplements the simplified hepatic glucose production process of this model.
Insulin and glucagon are implemented as nonlinear Hill controllers with n=4
to best replicate known literature curves (Sorenson, 1985, Northrop, 2000, and
Duun-Henriksen,2013) and resting levels of about 10% of maximum. These can be
viewed as nonlinear proportional action (P-action) controllers. Additionally, the
insulin biocontroller is mildly delayed, and also includes implementation of a
derivative action (D-action) control component (see Dalla Man, 2007, for former,
Dalla Man, 2014, for latter).
Relative blood flow acts as an indirect controller in the fact that both glucose
delivery from blood to different tissues and exogenous insulin delivery can both be
affected. The rate of absorption of glucose into tissues from the blood is dependent
on external factors that increase (or limit) blood flow, as well. Anything increasing
blood flow to a certain tissue, such as heat or muscle activity, will increase glucose
uptake rate into that type of tissue, of which insulin works as a signal. This mostly
reflects changes in blood flow. For instance, with endurance exercise, there is
redistribution of glucose towards muscle, heart, and skin if external temperature is
increased, with internal organs can see a decrease. For example, during a long race,
it is harder to digest foodstuff (the creation of ‘gels’ ensued) as flow becomes
demand-based, with decreased flow for digestive processes. With higher flow
perfusion to muscle and other glucose sources needed (i.e. liver), both insulindependent and non-insulin dependent fluxes should be up.
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In another example, absorption may also be affected by excess tissue or an
extremely large bolus within a short time frame, may result in limited or lowered
absorption. This is modeled by adjusting the ratio of forward-rate parameters of the
non-monomoric (slow) to monomeric (fast) parallel insulin pathways. Table 3.1
below outlines appropriate parameter adjustment. The addition of a Hill saturation
controller accounts for high dosage boluses in a short time window—linearity is
preserved at low dosages before becoming saturated (Figure 3.6).

Table 3.1: Factors Influencing Insulin Absorption Rate
Increase Ratio
(Reffect)

Decrease Ratio
(Reffect)

Effect

Slower absorption;
non-monomeric
absorption

Faster absorption;
monomeric
absorption

Physiologic
Reasoning

Injection into excess
tissue (i.e. abdomen),
large bolus, SlowActing Type

Range of
Value

0.6-1.0

Hot environment,
muscle activity,
lean tissue, Fast or
Regular Insulin
Type
0.1-0.6

Increase
Overall
Magnitude
(Kd)
Faster
Dissociation

Decrease
Overall
Magnitude
(Kd)
Slower
Dissociation
Large bolus

0.02-0.1

0.005-0.02
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Figure 3.6 Effect of Dose Size on Insulin Pharmacodynamics. (Top): From Walsh, 2014: dose size
changes pharmacodynamics of insulin. (Bottom) Recreated exogenous insulin saturation effect as
bolus size increases (mainly due to predicted tissue absorption).

Exogenous insulin, particularly injections, can be of three types with varying
peak effect and time delays—fast, regular, and long acting (Diabetes Services, Inc).
Injection modeling here uses half sine waves to account for varying effects. Dosage
depends on a clinically based sliding scale accounting for current xg level and food
GI. Peak rates and times used for curve shaping are as follows in Table 3.2.
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Table 3.2: Action Times for Insulin (adapted from Diabetes Services, Inc)
Insulin

Starts

Peaks

Ends

Humolog/Novolog/
Apidira
Regular
Lantus
Levemir

10-20 min

1.5-2.5 hr

4.5-6 hr

Low Most
Likely At:
2-5 hr

30-45 min
1-2 hr
1-3 hr

2-3.5 hr
6 hr
8-10 hr

5-7 hr
18-26 hr
18-26 hr

3-7 hr
5-10 hr
8-16 hr

Insulin ‘Black Box’ Model
Reffect: Ratio of Non-Monomeric to Monomeric Insulin
Rtissue: Tissue Absorption Factor
Rtype: Insulin Type Factor
Rflow: Blood Flow Factor
Kd: Rate Constant of Insulin Dissociation
αM: Rate Constant of Monomeric Insulin Absorption
αNM: Rate Constant of Non-Monomeric Insulin Absorption
Figure 3.7: Exogenous Insulin Model

Usage
Designed to peak,
covers meals, and
lowers high BG’s
Designed for flatter
and longest action,
basal insulin action
for keeping BG flat
when fasting
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3.4.6.1 Endogenous Insulin Control Action in Blood Plasma (mU/dl)
𝑑𝑥𝑖
𝑑𝑡

= 𝐾𝑎2 𝑥𝑖𝑛𝑗−𝑚 + 𝐾𝑎1 𝑥𝑖𝑛𝑗−𝑛𝑚 + [𝑟𝑎𝑡𝑡𝑦𝑝𝑒1𝑖 (𝑘

𝐺𝑟𝑒𝑓𝑖 𝑥𝑔
𝑠−𝑖𝑛𝑠 +𝑥𝑔

4

) + 𝑟𝑎𝑡𝑡𝑦𝑝𝑒1𝑖 𝐾𝑖𝑑 𝑥𝑔̇ ] − 𝐾𝑖 𝑥𝑖
[3.9]

3.4.6.2 Endogenous Glucagon Control Action in Blood Plasma (pg/dl)
𝑑𝑥𝑔𝑛
𝑑𝑡

𝐺𝑟𝑒𝑓𝑔 𝑥𝑔

= 𝐾𝑔𝑐 [𝑟𝑎𝑡𝑡𝑦𝑝𝑒1𝑖 (𝑘

𝑠−𝑔𝑛 +𝑥𝑔

4

[3.10]

) − 𝑥𝑔𝑛 ]

3.4.6.3 Exogenous Insulin Delivery by Injection: Monomeric
Absorption (mU/dl)
𝑑𝑥𝑖𝑛𝑗−𝑚
𝑑𝑡

[3.11]

= 𝐾𝑑 (𝑥𝑖𝑛𝑗−𝑛𝑚 − 𝑘𝑎2 ∗ 𝑥𝑖𝑛𝑗−𝑚 )

3.4.6.4 Exogenous Insulin Delivery by Injection: Non-Monomeric
Absorption (mU/dl)
𝑑𝑥𝑖𝑛𝑗−𝑛𝑚
𝑑𝑡

ℎ𝑠𝑚𝑎𝑥 ∗𝑢𝑖𝑛𝑗

= −(𝐾𝑑 + 𝑘𝑎1 ) ∗ (𝑥𝑖𝑛𝑗−𝑛𝑚 ) + ( ℎ𝑠

𝑘𝑠 +𝑢𝑖𝑛𝑗

1

)

[3.12]

3.4.6.5 Exogenous Glucagon
Exogenous glucagon would be an additional state, imperative to artificial
pancreas function. A counter regulatory hormone to insulin must exist in order for
AP technology to be possible. It is important to note that one limitation in including
Glucagon in AP design is its short shelf life (Jacobs, 2011). New artificial pancreas
(AP) research solutions (Jacobs, 2011) include one rather complex model
(Neelkanta, 2006). Due to lack of data and substance instability as a part of current
AP design, exogenous glucagon delivery is not included as a state in the SchunkWinters model. However, if added, its inclusion would be simplified as a (linear or
nonlinear) 1st-order process, making the overall model 11th-order. Due to glucagon’s
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fast dissociation, exogenous glucagon is indirectly modeled with non-muscle
compartment action on the basis of hepatic glucose production (Jacobs, 2011).

3.4.7 Additional Hormonal Actions and Methods for Inclusion
Primary glucoregulatory hormones include insulin and glucagon, as is
common to most models. However, it is known that there are other regulatory
hormones for BG—three are noted here, each including a viable method for
inclusion (e.g., as a multiplicative functional operating on one or more existing
model parameters).
Amylin suppresses glucagon and works with insulin in circulating glucose by
decreasing hepatic glucose output following ingestion, as well as slowing gastric
emptying (Aronoff, 2014). Both insulin and amylin are produced by pancreatic βcells, thereby will be absent in people with Type 1 diabetes and limited in Type 2. If
adopted, a new real-time hormonal controller could naturally modulate the
digestive rates (e.g., slow path) and thus the Kugf parameter, and perhaps the
glucagon rate for which glucose is used by tissue (i.e., modulate the Cga parameter).
A second additional hormonal controller, also real-time and anticipatory,
could involve sympathetic nervous system effects. Included would be catecholamine
action in response to an exercise and/or emotional induced stress that enhances
sympathetic drive. Enhanced sympathetic drive can result in a variety of measurable
effects including elevated HR, pupil dilation, and increased blood flow and pressure.
Oftentimes, an increase in BG is seen, even if brief. An approach for such additional
control action would be to modulate the GLUT2-mediated flux between the non-
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muscle and BG compartments. Hence, stressorrat, a parameter formed to scale
added stress other than only HR fluctuation is implemented for high-intensity and
increased stress training situations by increasing the rate at which glucose leaves xg
from xnm via the GLUT2 flux pathway in a multiplicative manner. Greft and Kg2Max
also have an effect as parameters involved in the GLUT2 Hill functional. Stressorrat
works to inform exercise of additional catecholamine action (and general
sympathetic neural system drive) that may be present.
This concept is further developed in Chapter 4, where high heart rate (within a
context) is proposed as a method to inform controller action.
The hormone leptin acts to regulate the amount of excess dietary calories
stored as fat in fat cells versus the amount of glucose stored as glycogen in the liver
and muscles (Northrop, 2011). The most significant location for leptin receptors is
on the pancreatic beta cells that secrete insulin. Leptin plays a role in fat
accumulation based on an excess of stored carbohydrates, important for long-term
modeling simulations, greater than 24-hours. The Schunk-Winters model has this
capability. This type of additional control would act as adaptive management,
particularly for long-term effects such as excess glucose building in tissues over
consecutive simulations (i.e. the ending state concentration is higher than first
initialized), as any longer-term buildup in either of the two tissue compartments is a
natural indicator of glycogen to fat transfer.
These new control action modulators are proposed here and developed in
Chapter 5 as future directions for the model.
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3.4.8 Muscle State Inputs
Inputs to the muscle state relate to glucose fuel consumption associated with
meeting muscle energy demands, here assumed to be of two forms. Inputs consume
glucose and amount is scaled appropriately according to Table 3.3 on the basis of
supply and demand.
Body composition inputs for the muscular state include muscle mass (out of
total BW), mitochondrial volume, aerobic capacity, and knowledge of one’s
anaerobic threshold zones on the basis of a VO2max stress test. The latter is not
required for the basic model, however, if HR is known, a more personalized and
refined model input can be estimated. Table 3.3 below shows input variations.

Table 3.3: Exercise and Activity Input Characterization
Input
Characterization

u3
 Primarily aerobic or
during long duration
anaerobic/circuit
training
 Continuous
 HR is ramp-like
 Can be sustained
 Sufficient oxygen is
provided to sustain
for energy
 Uses oxygen to burn
CHO and fat for
energy

u4
 Primarily daily
/training anaerobicdominated activity,
or “sprints” during
longer exercise
 Daily Activity,
Weight Training
 Fluctuating HR,
characterize by
spikes
 Increase in
glycolysis
 Increase in lactic ace
 Lower Oxygen
requirement
 Glucose = fuel

u5 (if obtainable)
 HR input
characterized by
resting (u5 = 0) and
maximum (u5 = 1)
difference
 Fluctuation or
continuous is key
to delineate
between fuel mix
type
 Characterize
anaerobic
threshold and
zones with
VO2max stress
test

Units

kcal/hr

kcal/hr

bpm
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3.4.8.1 Exercise (u3)
Exercise, dependent on intensity (kcal/hr), duration (hr), and substrate
availability (i.e. diet and fuel before and during), is inputted as either 1) aerobic or
2) anaerobic or a combination of both. The u3 input primarily relates to aerobic
exercise, as shown in Table 3.3. It is important to note that the combination, or fuel
mix, of exercise is achieved by combining the activity input with aerobic exercise
input on a scale of aerobic capacity.
Heart rate may also be inputted to better quantize the (potentially
fluctuating) aerobic “pulse input” intensity (assuming zones are known), as well as
characterize activity as anaerobic if HR fluctuations are present. Aerobic exercise is
often continuous and ramp-like in behavior. Typically, aerobic exercise can be
maintained, as sufficient oxygen is available for fat and carbohydrate consumption.
Mitochondrial action is present, especially at low to moderate intensity.

3.4.8.2 Daily Activity (u4)
Considering a resting metabolic rate around 0.82, the typical human body
derives more than half of its energy from fatty acids and the rest from glucose
(Melzer, 2011); but many tissues (including muscle) can use whatever fuel is
available. Activities requiring immediate energy typically utilize the
phosphocreatine (PCr) shuttle and hence (indirectly) glucose utilization—this
phenomena also is imperative to the onset of exercise. Many aspects of daily activity
are often characterized as anaerobic, increasing glycolysis and glucose consumption
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due to a low oxygen requirement (e.g., muscles recruitment that includes fast
glycolytic fibers). Examples are certain team sports and work around the kitchen.
In some cases lactic acid increases, and activity can be characterized as
demonstrating fluctuating heart rate due to ‘bursts’ of energy demand.
Circuit training and the end of a long aerobic session may present some
characteristics of the u4 input.
Daily activity is inputted in kcal/hr with maximum at around 200 kcal/hr,
although dependent on aerobic capacity.
3.4.8.3 Heart Rate (u5)
One advantage of our modeling framework is that dietary and exercise inputs
do not have to be bolus inputs, in contrast to most models (Dalla Man, 2007, and
Yamamoto, 2015), but are energy rates that can be a function of time. Most common
is a pulse input, i.e., an energy rate intensity over a time duration. Heart rate can be
inputted into the model to help sculpt the u3 input. A standard heart rate monitor
often measures at a frequency of 1/second, using units of beats per minute. This
quantity is converted into model’s time step, or 100 units/hour (1 unit = 36
seconds). Heart rate data at steady-state can be used to help quantify exercise
intensity (and thus, potentially, u3 level), typically on the basis of anaerobic
threshold zones, and heart rate fluctuations can be used to quantify a sudden
stressful situation, or the onset of exercise (as well as circuit training or anaerobic
exercise). Heart rate variability (HRV) due to breathing, etc. is not an issue as the
time sampling unit is 36 seconds, significantly greater than the duration of HRV.
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3.4.9 Summary of Default Parameters
For full description of parameters and values refer Appendix 7.1 and
Glossary. A majority of the core insulin sub-model was based off of literature curves
and clinical data from Cobelli (2007), Bergman (1981), Yamamaoto (2014), and
Hovorka (2004). The digestive sub-model was shaped on the basis of known
nutritional trends based on GI (Monro, 2008) and modeling approaches used by
Yamamoto (2014). Since the addition of GI digestive dynamics is new to the
modeling field, some personal clinical knowledge and data was also used for trend
shaping.
3.4.9.1 Parameter Adjustment: Person with T1D
The following parameters/relations in Table 3.4 are scaled by rattype1i (on a
scale from 0 to 1, with 0 being no insulin production):

Table 3.4: Type 1 Diabetic Parameter Adjustments for Insulin
Insulin initial state
1.0 mU/dl (default)
Insulin Controller
GCi
Residual Insulin Storage Controller
GCid
Muscle Flux Gradient
Gmgrad

The following parameters/relations in Table 3.5 are scaled by rattype1g, if
determined necessary (on a scale from 0 to 1, with 0 being no glucagon production):

Table 3.5: Type 1 Diabetic Parameter Adjustments for Glucagon
Glucagon initial state
70 pg/mL (default)
Glucagon Controller
GCg
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It is not well-known the extent of diabetes on glucagon production; however,
many other mechanisms (GLUT2/GLUT4 path, muscle contraction and calcium
influx, etc.) are redundant with glucagon’s primary actions: stimulating hepatic
production and allowing glucose to enter the blood, that the effect of glucagon
depletion is not as apparent as with insulin.
From personal experience working with a certified diabetes educator (CDE) it
is often assumed that a T1D maintains normal glucagon production (i.e. rattype1g =
1.0). That being said, glucagon emergency injection kits are prescribed to T1D’s in
the case of hypoglycemia as this will be a more concentrated and faster action dose
than pancreatic produced glucagon action (due to biological sensing time delays and
potential for delayed hepatic glycogenolysis if BG is already low and no immediate
glucose source exists). In the model there is opportunity to scale the amount of
glucagon production present, although a default of 1.0 is used.

3.4.9.2 Parameter Adjustment: Person with T2D
Modeling insulin resistance would affect the absorption rate of glucose
entering tissues. Insulin can be assumed to still be fully produced in the quantity
needed for a given food intake (often excess); however, it will not be properly
utilized, thereby resulting in elevated BG levels and eventually conversion into fats.
In the model, some degree of insulin resistance can be related to the GLUT4 and
GLUT2 gradients, since high tissue levels change this gradient. One study also
suggests moderate weakness in select skeletal muscles due to a reduction in
mitochondrial proteins in insulin-resistant fibers (Ohlendieck, 2010). As discussed
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in Section 3.4.7, leptin acts to regulate body fat storage, a well-known indication of
T2D. The potential for an additional hormonal state could incorporate this
phenomenon, as supported by Northrop (2011) in a study in which exogenous
leptin has been used successfully to cause obese mice genetically lacking the ability
to produce leptin to lose weight.
General parameter adjustments for T2D simulation (Figure 3.19) typically
include an increased BW (and most likely non-muscle tissue) as well as decreased
mitochondrial volume and changes to lifestyle habits—higher caloric intake, high GI
food intake, decreased exercise and activity, etc. may be present.

3.5 Model Validation: Exogenous Insulin, Digestive, Muscle Activity
Section 3.5.1 demonstrates comparative validation of the insulin sub-model.
Figure 3.8 shows model capabilities of an exogenous insulin bolus only with no
other inputs. A 4 Unit bolus was compared to the normalized plasma insulin effect of
3 separate sets of data, with one being clinically based (red dashed in Figure 3.8
below) with the others being modeling approaches of two validated and
comprehensive studies (Yamamoto, 2014, and Shimoda, 2004). Figure 3.9 shows
BG, insulin, and glucagon replication an in silico T1D study by Dalla Man (2007) and
a variety of parameter variants overplotted (Table 3.6). Focus was on response rate
and magnitude. Figure 3.10 demonstrates model capabilities to scale based on the
ratio of remaining insulin production of a T1D and compares non-monomeric vs.
monomeric insulin injection response as in (Cobelli, 2009).
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Section 3.5.2 demonstrates model digestive capabilities, particularly in
regard to time response and magnitude. Some inputs of other models were not
known, or did not exist, as many models do not account for GI or proportion of
carbohydrates. However, in this case, an assumption of a mixed meal and moderate
GI was used. Figure 3.11 highlights three key digestive studies (Dalla Man, 2007,
Yamamoto, 2014, and Kotachev, 2010) and comparison to the Schunk-Winters
model.
Section 3.5.3 compares the Schunk-Winters glucagon model to that of
Sorenson (1985) and Northrop (2000) in Figure 3.12.
Section 3.6.5 demonstrates mitochondrial state effects in response to
exercise input (Figure 15) in Figure 3.13.
3.5.1 Insulin Validation
Figure 3.8 compares Schunk-Winters insulin model to literature and clinical
data. Data points were obtained from curves found in literature and overplotted in
Matlab. Figure 3.9 demonstrates comparative model validation to Dalla Man (2014)
in which certain parameters were varied over the course of 18 simulation runs,
according to Table 3.6. Changed parameters (from default) are in bold. Figure 3.10
demonstrates the effect of varying insulin production and exogenous injection of
both non-monomeric and monomeric insulin paths as in Cobelli (2007).
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Plasma Insulin and Subcutaneous Insulin Effect

1.2

Schunk-Winters Model
Clinical data referenced in (Yamamoto, 2014)
Smoothing Spline Curve
1

Shimoda data referenced in (Yamamoto, 2014)
Smoothing Spline Curve
(Yamamoto, 2014) model prediction
Smoothing Spline Curve

Plasma Insulin
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% Fast-Acting (max delivery in 1 hr,ends 2 hrs): give idose, ibeg
Figure 3.8:
Validation
itype(2,1)Insulin
= 1; idose(2,1) =Submodel
18; ibeg(2,1) = 1; iend(2,1)
= ibeg(2,1) + 10; and Literature Comparison. Comparative insulin
validation approach with a constant input amongst all sources of a fast-acting insulin bolus (i.e.
Lispro in most studies) at t = 0 (1 time unit in the Schunk-Winters model for a duration of 5 time
units, or 3 minutes) of 80 U/hr, or ~4 Units. Yamamoto and Shimoda plot subcutaneous insulin effect
(min-1), or normalized so that the maximum peak is ‘1’. Clinical data is adapted from Swan (2009). All
curves are adapted from picked data points of respective sources and fit using a smoothing spline
function in Matlab.
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Figure 3.9: Model Validation with Parameter Adjustment to Dalla Man (2014). Left: Dalla Man
(2014) simulated plasma glucose, insulin, and glucagon in 100 in silico T1DM adults, adolescents, and
children. Right: Replication of Dalla Man (2014) using parameter variations listed in Table 3.6 below.
The upper plot shows plasma glucose with the middle demonstrating effective plasma insulin based
on exogenous bolus, also separated into monomeric and non-monomeric components (3 states are
shown). The lower plot depicts Hill rate and magnitude insulin kinetics. Simulations varied mainly by
BW to simulate adults vs. children with the lower plot showing insulin rate and magnitude
controllers (Hill functions). The meal input was the same for both Dalla Man and Schunk-Winters, of
50g of carbohydrates at 8:00 AM (t = 1) and an optimal insulin bolus calculated according to patient’s
own carbohydrate to insulin ratio. Dalla Man focused on varying insulin sensitivity amongst patients,
whereas in the left replication, variations focused on changing insulin sensitivity (or level of one’s
own insulin production) and BW parameters as well as muscle and non-muscle tissue mass.
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Table 3.6: Parameter Simulation Variants for Dalla Man (2014) Validation (Figure 3.9)
BM (kg)
70
70
70

Muscle
(kg)
30
35
25

NonMuscle (kg)
25
20
30

Mitochondria
to Muscle
Ratio
0.1
0.1
0.1

0
0
0

Starting BG
(mg/dl)
130
130
130

Insulin Dose
(U/hr)
20
20
20

Meal
Magnitud
e (g CHO)
50
50
50

50
90
100
40
70
70

21.5
38.7
43
21
30
30

18
32.4
36
18
25
25

0.1
0.1
0.1
0.1
0.2
0.05

0
0
0
0
0
0

130
130
130
130
130
130

20
20
20
20
20
20

50
50
50
50
50
50

70
70
70
70
70
70

30
30
30
30
30
30

25
25
25
25
25
25

0.3
0.1
0.1
0.1
0.1
0.1

0
0.5
0.25
0
0
0

130
130
130
100
120
150

20
10
15
20
20
20

50
50
50
50
50
50

Type 1
Ratio*

70
30
25
0.1
0
130
15
50
70
30
25
0.1
0
130
25
50
Note: The changed simulation parameters (from default) are highlighted in each respective column. Values were
chosen both above and below the default on the basis of sensitivity.
*Type 1 ratio refers to the amount of insulin the T1D is still able to produce. A value of 0 = no insulin
production and a value of 1.0 = non-diabetic production.
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Figure 3.10: T1D Simulations Scaled by Percent Insulin Production. T1D simulations scaled by

% remaining insulin production with 50g CHO input and simultaneous injection as in (Cobelli 2007).
Insulin absorption controllers for exogenous input are shown.

3.5.2 Digestive Validation
Figure 3.11 demonstrates meal validation and effects of varying glycemic
index and carbohydrate ratio as seen throughout literature. Figures in the left
column compare overplots of digestive input, BG and insulin. The right column
highlights replicated inputs.
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Figure 3.11: Digestive Submodel Validation and Literature Comparison
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3.5

Glucagon Validation

Figure 3.12 demonstrates glucagon effect curves found in literature vs. blood
glucose concentration. The top two plots are found in literature, with the Schunk-
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Winters model simulation on bottom. Note that glucagon is plotted vs. BG on the
right axis.

Figure 3.12: Glucagon Submodel Validation and Literature Comparison. Glucagon model
comparison with Schunk-Winters model (bottom) validated by Northrop (2000) (top left) and
Sorenson (1985) (top right) glucagon vs. blood plasma glucose plots. Note that the Schunk-Winters
model plots glucagon (dashed) scaled on the right axis.

3.5.4 Mitochondrial State Validation
In order to see mitochondrial state effect, Figure 3.13 demonstrates a 2-hour
aerobic session with and without Xmito present. Exercise input appears to smooth
out, indirectly validating that the addition allows BG to rise due to increased ATP
efficiency, particularly during aerobic exercise. The mitochondrial state will be
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further developed in Chapter 4. In Chapter 3, the state is relatively conservative and
sensitivity will be important in regards to athletes (Chapter 4) and increased
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Figure 3.13: Mitochondrial State Validation. Two hour exercise session informed by HR input with
(left) and without (right) mitochondrial state consumption present (lower plot).
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3.6 Results: Sensitivity Analysis and Simulation Output
Parameter sensitivity analysis was performed for 23 of the 68 model
parameters, with emphasis on representative parameters for various relations (e.g.,
often 1 of 3 for most Hill functions). These can be separated into control/rate
parameters, threshold values, and scaling and maximum flux rates. Increments of +
10% were used to scale parameters from the nominal value, with behaviors
extracted from state trajectories that included peaks and magnitudes at strategic
times during strategic tasks, including pre- and post-meal, as well as pre- and postexercise. It is recognized that many forms of sensitivity analysis exist; however, this
approach was most applicable in that sensitivity of a given behavior (extracted from
state trajectories) to a particular parameter could be computed. In all cases

20
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sensitivity coefficients were obtained using the following equation, defined by
Lehman et al, 1982:
(𝐵+ −𝐵− )
⁄𝐵
𝑜
.
(𝑃+ −𝑃− )
⁄𝑃
𝑜

[3.13]

(B+-B_) refers to the change in state behavior of interest (i.e. xg) and normalized to
make the quantity dimensionless, and (P+-P_) refers similarly to the parameter of
interest. Results for the default non-diabetic and Type I diabetic models are
provided in Appendices 7.6.1 and 7.6.2, respectively, for 4 tasks (see also Tables 3.93.13):





nominal steady-state level (u1=u2=u3=u4=u5=0),
meal (u1 input only for non-diabetic, also u2 for Type 1 diabetic),
snack (also u1, and u2 for Type 1 diabetic), and
moderate endurance exercise (u3 input).

Table 3.7: Sensitivity Analysis Inputs
Meal
Snack





700 kcal total
30 minute duration
175 g CHO (GI = 50, 50%
CHO)
Simulation times: 0.3
hours before, 0.3 hours
after ingestion, 1 hour
post-meal






60 kcal total
6 minute duration
15 g CHO (GI = 80, 80%
CHO)
Simulation times: 0.3
hours before, 0.3 hours
after ingestion, 1 hour
post-meal

Exercise




600 kcal/hr for 1 hour
Aerobic Capacity = 1000
Simulation times: 30 min
before, halfway, 18 min after

In general, all states exhibited sensitivity to various parameters, but as might
be expected, it was very task-specific. For instance, there are several unidirectional
pathways: digestive submodel parameters would not be expected to influence the
response to exercise since u1=0, and exogenous insulin submodel parameters
would never influence non-diabetic model responses since u2=0. As certain state
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equations are highly coupled either through compartmental or control modeling
(e.g., xg, xnm, xm, xi, xgn), it can be expected that all parameters entering into these
relations will exhibit a degree of sensitivity. Some of the key results are highlighted
in Tables 3.9-3.13 (parameters those with threshold of the value being greater
than 0.4 for a given behavior extracted from a given state trajectory) and Figures
3.14-3.15. Figure 3.16 includes a chart of overall most sensitive parameters for meal
and exercise combined.
Insensitive parameters, and therefore reaching constant value in our model, are
outlined in Table 3.8. Key values here for snack and meal are mitochondrial
associated parameters, as well as ks-ds, the ‘half-way’ Hill saturation value for the
slow digestive pathway. In regards to exercise, constant parameters include those
associated with the digestive compartment, as expected, with insulin parameters
remaining relatively insensitive (see Table 3.13), as glucagon is the main controller.
Table 3.8: Constant Parameters (Sensitivity Consistently < 0.05)
Meal
Ka2*
Ka1*
Kd*
Km-xex
Rat_ia
Hs_max
Hs_rate
Kprop
ratmito

Snack
Exercise
Ka2*
Ka2*
Ka1*
Ka1*
Kd*
Kd*
Km-xex
Kugf
Kse
Kse
Ksds
Ksds
Hs_max
Hs_max
Hs_rate
Hs_rate
Kprop
ratmito
*These parameters are associated with injection and become sensitive when injection is present (i.e.
T1D)

It was determined that steady-state levels of certain strategic states such as
xg (BG) are quite sensitive to certain parameters, especially those that directly or
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indirectly affect BG, since this is the compartmental conduit through which xg, xnm,
xm, xi, and xgn interact. These important sensitivities are provided in Table 3.10 for
the T1D model and 3.9 for the non-diabetic model, including both parameters
associated with compartmental flow rates and with controller signals.
It was determined that GLUT4 was a main driver along with insulin
controllers Cia and Cib. An example of state trajectories with variation in this
parameter is provided in Figure 3.14. In another example, during exercise, Kg2max
was key for stimulating glucagon action, summarized in Tables 3.11-3.13 looking in
the Xgn column. Other sensitive parameters during exercise include the muscle
gradient Hill parameter and reference threshold for muscle, kmintol, which also had
sensitivity during meal as well. Scaling parameters, such as wratt, were also
sensitive per their corresponding compartment (i.e. xnm). Insulin elimination rate,
Ki, was sensitive for the BG state in both meal and snack simulations, as expected.
Sensitivity analysis was also performed for both T1D simulations (Appendix
7.6.1), with key differences in that T1D show no sensitivity to certain plasma insulin
controller parameters but have high sensitivity for most states in regard to injection
parameters: kd (insulin dissociation), ka1 (non-monomeric insulin forward rate) and
ka2 (monomeric insulin forward rate). Additionally, exercise sensitivity behavior for
T1D is diminished with Cga, Kgt, ratmito, Kg2Max, and Grefg as the only sensitive
parameters. Hence, only non-diabetic sensitivity is shown with all sensitivity
behaviors and simulations in Appendix 7.6 and is more inclusive due to a lower
threshold (>0.4).

Table 3.9: Steady-State Sensitivity Analysis for Non-Diabetic with Basal Glucose Infusion of 50 kcal/hr
Xg

Xnm

Xm

Xd

Xds

Xi

Xinj-m

T = 24
hours

Ki 0.321
Cga 1.336
Kgt 1.339
Grefi 0.840
Grefg 4.653
Greft 2.726
Kg2Max -1.144

Ki -0.795
Cib 0.867
Cga 0.487
Kgt 0.472
Grefi -2.047
Grefg 1.632
Greft 0.978
Gbt 0.772
Kg2Max -0.412
Kmxex -0.644
Kse -0.463
KMintol 0.677

Ki -2.278
Cib 2.475
Cga 1.309
Kgt 1.267
Grefi -5.857
Grefg 4.380
Greft 2.625
Kg2Max -1.105
Kmxex -1.837
Kse -1.321
KMintol 1.92
Ratmito 1.648

___

___

Ki 1.878
Cga -0.890
Kgt -0.892
Grefi 4.950
Grefg -3.091
Greft -1.816
Kg2Max 0.763

SteadyState
Values

90 mg/dl

5 g/kg

10 g/kg

0

0

Xgn

Xinj-nm

Xmito

__

Cga -0.946
Kgt -0.948
Grefi -0.595
Grefg 2.532
Greft -1.929
Kg2Max 0.806

___

__

0

0.45*ratType
1g

0

0

1.0*ratType1i

Table 3.10: Steady-State Sensitivity Analysis for T1D* with Basal Infusion of 0.75 kcal/hr and Basal Insulin 0.05 U/hr
T = 24
hours

SteadyState
Values

Xg

Xnm

Xm

Xd

Xds

Xi

Cga 1.194
Kgt 1.197
Grefg 4.217
Greft 2.635
Kg2Max -1.207
110 mg/dl

Gbt 0.819
Kd 0.436

Ki -0.640
Cib 0.642
Kmintol 0.458
Kd 1.427
Ratmito 2.038
10 g/kg

___

__

Ki -1.270
Ka2 -7.894
Ka1 0.462
Kd 2.948

Ka2 9.604
Ka1 0.462
Kd 2.948

0

0

1.0*ratType
1i

0

5 g/kg

Xinj-m

Xgn
Cga -1.109
Kgt -1.112
Grefg 2.444
Greft -2.442
Kg2Max 1.114
0.45*ratType1
g

Xinj-nm

Xmito

Ka1 8.843
Kd
108.100

__

0

0

*Rattype1i = 0
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Table 3.11: Non-Diabetic Meal Simulation Sensitivity Analysis
Xmaxb

XBMc

XDMRd

XDMFe

Xg

Xnm

Xm

Xds

Xi

Ki 1.149
Cia -0.733
Kugs 0.578
Kmintol -0.784
Ki -1.879
Cia -1.225
Cib 3.090
Cga 1.461
Kgt 1.446
Grefi -4.317
Grefg 5.518
Greft 1.872
Kg2Max -0.751
Kmxex -1.233
Kse -0.921
Kmintol -4.281
Ratmito 1.079
__

Wratt 1.068
Kmintol -0.523

Cib 0.589
Kmintol 1.306

Kugs
0.662

Ki -0.796
Grefi 0.612
Grefg -1.272

___

Ki -0.550
Cib 0.732
Grefi -1.106
Grefg 1.267
Gbt 0.504
Wratt 0.496
Kmintol 0.971

Ki -0.973
Cib 1.296
Cga 0.620
Kgt 0.611
Grefi -1.952
Grefg 2.249
Greft 0.605
Kmxex -0.665
Kse -0.500
Kmintol 1.690
Ratmito 0.645

___

Ki -2.472
Cia -0.857
Cib 3.297
Cga 0.768
Kgt 0.752
Grefi -5.576
Grefg 6.373

Ki -0.845
Cib 1.201
Cga 0.533
Kgt 0.526
Grefi -1.686
Grefg 1.939
Greft 0.522
Kmxex -0.544
Kse -0.421
Kmintol 1.622
Ratmito 0.506
Cib 0.649
Kmintol 1.137

Kugs
0.717

Ki -3.031
Cia -1.147
Cib 3.129
Cga 1.311
Kgt 1.296
Grefi -4.489
Grefg 4.857
Greft 1.726
Kg2Max -0.707
Kmxex -1.252
Kse -0.936
Kmintol -4.060
Ratmito 1.083
Kid 0.890

Ki -1.165
Grefi 0.455
Grefg -0.621

Ki -0.451
Cga -0.608
Kgt -0.609
Grefi -1.002
Grefg 1.444
Greft -0.582

Ki 0.546
Cia -0.431
Kid -0.402

Ki -1.311
Cia -1.131
Cib 2.198
Cga 0.796
Kgt 0.780
Grefi -2.666
Grefg 2.966
Greft 0.894

Gbt 1.486
Kugf -1.035
Wratt -0.486
Kg2Max -1.315
Kmxex -1.125
Kse -0.848
Kmintol 2.995

Wratt 1.077
Kmintol -0.456

Kugs
0.600

Xgn

Ki -0.511
Cga 0.635
Kgt 0.636
Grefi -1.025
Grefg 1.301
Greft -0.615
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Table 3.12: Non-Diabetic Snack Simulation Sensitivity Analysis
Xg

Xnm

Xm

Xd

Xds

Xi

Xgn

Xmaxb

Ki 1.380
Cia -0.618
Cga 1.197
Kgt 1.200
Grefi 1.424
Grefg 4.366
Greft 0.991

___

Ki -0.940
Cib 1.327
Cga 0.633
Kgt 0.625
Grefi -1.760
Grefg 2.242
Greft 0.603

Kugf
0.549

Kugs 0.972

Ki -6.047
Cia -0.487
Cga 1.927
Kgt 1.932
Grefi -8.041
Grefg 6.924
Greft 1.307

___

XBSc

Ki 0.776
Cia -0.479
Cga 0.920
Kgt 0.922
Grefi 1.562
Grefg 3.415
Greft 0.890

Ki -0.534
Cib 0.778
Cga 0.449
Kgt 0.444
Grefi -1.049
Greft 1.593
Greft 0.418
Gbt 0.451
Wratt 0.549
Kmintol 0.621

Ki -1.014
Cib 1.406
Cga 0.719
Kgt 0.710
Grefi -1.994
Grefg 2.534
Greft 0.666
Kmxex -0.684
Kse -0.513
Kmintol 1.126
Ratmito 0.605

___

___

Ki 0.866
Cia -0.531
Cga 1.026
Kgt 1.028
Grefi 1.744
Grefg -2.752
Greft 0.991

XDSRd

Ki 0.774
Cia -0.479
Cga 0.921
Kgt 0.923
Grefi 1.559
Grefg 3.416
Greft 0.891

Ki -0.534
Cib 0.778
Cga 0.449
Kgt 0.444
Grefi -1.049
Greft 1.593
Greft 0.418
Gbt 0.451
Wratt 0.549
Kmintol 0.621

Ki -1.014
Cib 1.406
Cga 0.719
Kgt 0.710
Grefi -1.994
Grefg 2.534
Greft 0.666
Kmxex -0.684
Kse -0.513
Kmintol 1.126
Ratmito 0.605

___

___

XDSFe

Grefi 0.608
Grefg 1.054

Ki -0.547
Cib 0.797
Cga 0.451
Kgt 0.446
Grefi -1.076
Grefg 1.604
Wratt 0.535
Kmintol 0.653

Ki -1.009
Cib 1.399
Cga 0.711
Kgt 0.702
Grefi -1.987
Grefg 2.510
Greft 0.661
Kmxex -0.680
Kse -0.510
Kmintol 1.152

__

Kugs 0.887

Ki 54.629
Cia 12.176
Cib 7.400
Cga -23.404
Kgt -23.455
Grefi 109.876
Grefg -86.464
Greft -22.650
Kg2Max 6.985
Kmxex -3.746
Kse -2.814
Kmintol 8.313
Ki 54.629
Cia 12.176
Cib 7.400
Cga -23.404
Kgt -23.455
Grefi 109.876
Grefg -86.464
Greft -22.650
Kg2Max 6.985
Kmxex -3.746
Kse -2.814
Kmintol 8.313
Ki -0.852
Grefi -0.985
Grefg 0.619
Kugf 0.450
Kid 0.836

Ki 0.866
Cia -0.531
Cga 1.026
Kgt 1.028
Grefi 1.744
Grefg -2.752
Greft 0.991

Grefi 0.510
Grefg -1.046
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Table 3.13: Non-Diabetic Exercise Simulation Sensitivity Analysis
Xg
Xmaxb

Ki 1.819
Cia -2.214
Cib -1.456
Cga 1.168
Kgt 1.170
Grefi 2.091

Grefg 4.594
Greft 1.611
Kg2Max -0.522
Kmintol -1.315
Kid -2.706

XBEf

Ki 0.810
Cia -0.469
Cga 0.913
Kgt 0.915
Grefi 1.629
Grefg 3.388
Greft 0.877

XDEg

Cga -0.951
Kgt -0.953
Grefg -2.478
Kmxex 0.838

XRh

Cga 0.838
Kgt 0.840
Grefi 0.539
Grefg 2.788
Greft 0.470
Kmxex 0.548
Kid -0.442

Xnm

Xm

Xi

___

Ki -0.550
Cib 0.994
Cga 1.449
Kgt 1.440
Grefi -0.993
Grefg 4.197

Greft 0.675
Kmxex 0.591
Kse -0.557
Kmintol 0.692
Ratmito -1.166

Ki -0.403
Cib 0.708
Cga 0.525
Kgt 0.520
Grefi -0.738
Grefg 1.797
Greft 0.464
Wratt 0.602
Cib 0.421
Cga 0.538
Kgt 0.535
Grefi -0.460
Grefg 1.570
Wratt 0.743

Ki -0.941
Cib 1.404
Cga 0.772
Kgt 0.763
Grefi -1.756

Grefg 2.582
Greft 0.666
Kmxex -0.654
Kse -0.489
Kmintol 0.903

Ki -0.533
Cib 0.893
Cga 0.976
Kgt 0.969
Grefi -0.996

Grefg 2.902
Greft 0.572
Kse -0.432
Kmintol 0.585

Cga 0.464
Kgt 0.461
Grefg 1.355
Wratt 0.825

Ki -0.567
Cib 0.996
Cga 1.539
Kgt 1.529
Grefi -1.059
Grefg 4.433

Greft 0.711
Kmxex 0.619
Kse -0.589
Kmintol 0.673
Ratmito -1.310

Ki -2.196
Cia -0.418
Cga 0.836
Kgt 0.839
Grefi -2.160
Grefg 2.902
Greft 0.541
Kmxex 0.915
Kid 0.745
__

Ki 2.378
Cga -1.293
Kgt -1.297
Grefi 3.298
Grefg -3.808
Greft -0.541
Kmxex 0.475
Kid -0.911
Ki -0.958
Cga 0.614
Kgt 0.616
Grefi -0.910
Grefg 2.101
Kmxex 0.827
Kid 1.033

Xgn
Ki 1.043
Cia -1.337
Cib -0.901
Cga 1.429
Kgt 1.432
Grefi 1.412

Grefg -4.218
Greft 1.160
Kg2Max -0.458
Kmintol -0.789
Kid -1.682

Xmito
Grefg -0.201

Ki 0.916
Cia -0.527
Cga 1.030
Kgt 1.032
Grefi 1.839
Grefg -2.889
Greft 0.987

___

Kgt -1.197
Kgt -1.199
Grefg 1.085
Kmxex 0.874

Grefg -0.135

Ki 0.509
Cga 3.173
Kgt 3.181
Grefi 0.890
Grefg -2.388
Greft 0.983

Grefg 0.272
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Figure 3.14: Non-Muscle Gradient Sensitivity Effect. Sensitivity effect of varying the GLUT2 nonmuscle gradient parameter for a non-diabetic, Kg2Max, with an input of 600 kcal/hr exercise at t =
3.5 hours and a 700 kcal meal of duration 30 minutes (GI = 50, %CHO = 50) at t = 13 hours.
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Figure 3.15: Muscle Gradient Sensitivity Effect. Sensitivity effect of varying the gratm muscleblood glucose demand gradient parameter for a non-diabetic, with an input of 600 kcal/hr exercise at
t = 3.5 hours.
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Kugf
1%
Cia
4%

Parameter Sensitivity Frequency
Kg2Max Kid
2% 3%

Kugs
1%

Ki
10%

kmintol
7%
kse
4%

Cib
7%
Cga
10%

kmxex
6%
wratt
3%
Gbt
1%

Kgt
10%

Greft
8%

Grefi
11%

Grefg
13%

BG Parameter Sensitivity Frequency
kmxex 6.98%
Kugf 0.00%

Ki 9.30%

Kgt
11.63%

Cia
11.63%
Cib 4.65%

Cga 11.63%

Grefi 9.30%
Kid 6.98%
Kmintol 6.98%

Grefg
13.95%
Greft 6.98%

Figure 3.16: Frequency of Most Sensitive Parameters. Frequency of most sensitive parameters
using total appearances over all sensitivity trials. The most sensitive in regard to xg (Grefg, Greft, Kg2max,
and Kg4max) are also shown as a frequency plot. Bias is eliminated toward foodstuff but only including
meal and exercise simulations (snack is ignored). Top: Meal and exercise simulations combined
(overall sensitivity without bias toward meals and/or exercise). Bottom: Xg state sensitivity for both
meal and exercise combined.
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3.7 Model Predictions for 24-Hour Lifestyle Simulations
Section 3.7.1 demonstrates model digestive capabilities of varying GI vs. the
proportion of carbohydrates in a mixed meal in Figure 3.17.
Section 3.7.2 demonstrates 24-hour simulation runs and overall model
capabilities of a non-diabetic to that of a T1D (Figure 3.18) and results of a poor
lifestyle and reaching T2D implications (Figure 3.19).

3.7.1 Low vs. High GI and Proportion of Carbohydrate Variation
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Figure 3.17: Low vs. High GI Foodstuff Comparison. Low vs. High GI foodstuff comparisons with
a) kfast = 0.5 and 90% CHO vs. b) kfast = 0.5 and 20% CHO (blue BG curves) and varying GI with c)
kfast = 0.9 and 50% CHO vs. d) kfast = 0.5 and 50% CHO vs. e) kfast = 0.2 and 50% CHO. Meal
constants are for a non-diabetic subject all with 100g CHO input and a duration of 6 minutes. Note
the black solid lines of the input plot is ‘cut-off’’ due to n input of 4000 kcal/hr for 6 minutes (i.e. 400
kcal or 100g of CHO).
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3.7.2 24-Hour Simulation

Figure 3.18: Non-Diabetic and T1D 24-Hour Simulations. Four 24-hour simulations: 1) atypical
T1D with no insulin injection or exercise (BW = 80kg, wmito = 0.1), 2) Healthy T1D with meal rapidacting injections and long-acting basal injection (BW = 70, wmito =0.3), 3) same healthy T1D with no
long-acting insulin, and 4) non-diabetic with similar inputs as (2). Inputs (top plot) include 3
meals/3 snacks (black solid, red digestive state), 700 kcal/hr exercise. Muscle and non-muscle mass
is kept consistent. A Healthy (large exercise, ~2000 kcal/day and mainly low GI meals) T1D shows
natural regulation (good steady-state BG range) and can get ‘better’ than a non-diabetic with proper
injection and timing (see second vs. third meal) and basal insulin. With lack of exercise and T1D
glucose management, there is glycogen accumulation predicted, especially in non-muscle
compartment.
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Figure 3.19: T2D Precursor 24-Hour Simulation. Effects of poor lifestyle habits and how, if
continued over an extended period of time (>3 weeks), body remodeling could occur and be a T2D
precursor model.

3.8 Discussion
The model aims to predict BG regulation based on various lifestyle choices and
diabetes, while using the lowest possible number of states that can provide robust
and personalized conditions and predictions. Through its distinct framework, new
perspectives are possible.
GI, often promoted as an influential factor in people with diabetes, is predicted
to have a strong dynamic effect: a low glycemic diet (Figure 3.17) decreases glucose
spikes while also predicting reasonable insulin control action and storage in muscle
and non-muscle tissues. Low GI meal content tends to absorb slower, coinciding
with the idea that whole grains, higher fiber, and unprocessed glucose will keep an
individual feeling ‘full’ for longer. In the digestive validation section (Section 3.5.2) it
is demonstrated particularly in the non-diabetic simulation, that there are two
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peaks due to a separation of fast vs. slow carbohydrate absorption and hence rate of
appearance into the blood stream (xg)—this is common for mixed meals (i.e.
fraccarbs <1.0). It is recognized that our model has faster insulin and meal transient
dynamics than Dalla Man (2007) and Yamamoto (2014) in response to high-GI
meals; however, on the basis of collected data (Chapter 4) and a variety of
references supporting both cases (i.e. Dalla Man, 2007, vs. Shimoda, 2000) this is not
recognized as a limitation.
Further, direct validation comparisons were limited in that our digestive
submodel is more complex than most, with separation of absorption dynamics into
two states, as well as influences of body composition. This made it difficult for direct
comparison to Dalla Man (2007), as their ‘mixed meal’ could not be precisely
replicated in our model without knowledge of glycemic index and fraction of carbs
(50% was assumed for modeling purposes). The Dalla Man model and parameters
are used by many others, and resulted in an FDA approved model—particularly for
insulin, which validates our model in terms of magnitude and rate of increase for
insulin response (Section 3.6.1). Our model is highly valid for mixed meals known in
literature, with a slightly faster response to high-GI foodstuff than most, yet most
models do not have capability of differentiating high-GI.
A key insight from model validation is that daily activity, exercise, dietary
choices (GI) and body composition (including mitochondrial volume) are seen to be
important for BG management. Further, in 24-hour simulations, there were
frequently upward and downward drifts of glucose (mostly as glycogen)
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concentration in the tissues which could be associated with lifestyle choices and, for
people with diabetes, insulin management.
Steady-state sensitivity analysis (Tables 3.9 and 3.10) shows some highsensitivity parameters when inputs (all u) are set to zero, explaining some steadystate adjustments that needed to be addressed. For example, it was found that due
to an elevated starting value, glucagon was causing a drifting of BG upwards when
t<1hr, hence the model was adjusted adding this baseline sensitivity. Insulin and
glucagon controllers, along with GLUT2 and GLUT4 gradients, were consistently the
most sensitive parameters at steady-state for a non-diabetic (states xg, xnm, and xm).
Gref parameters were also sensitive, as expected (xi and xgn), for T1D as well. T1D
steady-state sensitivity was focused on glucagon controllers (xg, and xnm), as well as
GLUT2 gradient and basal tissue metabolism. Starting blood glucose value was set
higher for a T1D at 137 mg/dl vs. 100 mg/dl for non-diabetic.
Sensitivity analysis (Tables 3.9-3.13) highlights some key aspects of the model:
high sensitivity to adjustments of reference values for BG-tissue flux pathways
(Gref’s), especially to hormonal control action (as expected). This is true for BG and,
importantly, more so for both tissue compartments. Other key sensitivity data
relates to mitochondrial volume proportion in regards to exercise, and sensitivity to
basal elimination rates particularly for non-muscle and in regard to insulin (Table
3.12 and 3.13). Meal and snack sensitivities (expressed mainly through the xg, xnm,
xm, xds, xd, and xi states) include mainly insulin control and non-muscle tissue scaling
in addition to digestive forward rate controllers. Additionally, it is important to
recognize that non-diabetics can still have a BG spike at the onset of a meal due to
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this control (which is contradictory to what one believes) since with endogenous
insulin production there is no anticipatory effect (Figure 3.18).
Meal onset and insulin timing has relevance to T1D insulin sensitivity,
especially with timing: taking rapid-acting insulin 15 minutes prior to a meal (as
typically suggested clinically) was beneficial. However, the model predicts that a
T1D who does not take any insulin is able to slowly “regulate” BG, perhaps more
effectively than the experience of many T1D’s; this is a byproduct of our
implementation of the GLUT2 pathway (and some residual production), which was
hard to fine-tune because of a lack of experimental data. T1D can take their insulin
as early as necessary, and theoretically could have better control than a nondiabetic. However, that being said, spikes in non-diabetics tend to be brief, as
endogenous insulin acts much more rapidly than exogenous. T1D sensitivity
analysis additionally demonstrates exogenous insulin rate effects, particularly with
ka1, ka2, and kd, the nonlinear fast and slow insulin and dissociation parameters,
respectively.
Perhaps the most novel insight from the model is the sensitivity of model
behavior to parameters associated with the GLUT2 and GLUT4 pathways, denoted
from Figure 3.14 and 3.15, both of which are known to be influenced by factors
other than hormonal control, including physical laws (e.g., the blood-tissue glucose
concentration gradient), and are predicted to influence relative balance between BG
states and tissue. This is further exemplified by increased sensitivity to Kg2Max
(Table 3.11) and muscle gradient parameters (i.e. kse). These insights, along with
manifold predictions of high tissue concentrations with certain lifestyle protocols
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(including simulations not presented here), suggest new research directions for
helping understand the complex phenomena called insulin intolerance, and by
inference, the longer-term etiology of T2D as a function of lifestyle choices. With
possible additions of a hormonal state, leptin would help shape glucose mass
conservation via activation of conversion to fat (if in excess) and further more
possibilities for personalized lifestyle implications and T2D.
In regard to model output limitations, because insulin, glucagon and
corresponding glucose effect have a high model sensitivity in regard to control
parameters (i.e. steady-state sensitivity coefficient for Cga is ~1.8 and Cia is ~0.3)—a
slight input error would have a large effect on BG, decreasing accuracy.
Exercise also has a drastic effect and aids in BG control as seen in the 24-hour
simulations. There is an influx from BG (which decreases) as muscle glycogen
gradually becomes depleted (Figure 3.18) which in turn activates glucagon control
(xgn) in order for non-muscle glucose storage (mostly hepatic) to restore BG levels
via glycogenolysis. Consequently, non-muscle tissue glucose (xnm) decreases. Daily
activity effects are less drastic as expected, but clearly influence glucose tissue
stores, especially xm, helping prevent meal-related buildup (Figures 3.18 and 3.19)
and thus providing a natural form of advantageous glucose management.
The addition of a mitochondrial state allows for a smoother dynamic
response and glucose transfer, particularly during aerobic exercise (Section 3.5.4,
Figure 3.13), as seen with the ability for BG to rise during long duration exercise (i.e.
more efficient glycolysis and ATP utilization at moderate intensities) when
mitochondrial state is present (left of Figure 3.13) vs. when xmito is set to 0 (right).
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The antagonistic effects of insulin and glucagon control action are
documented, important for both transient and steady state behavior. Exogenous
insulin is affected by flow, body mass, and dose size, as higher saturation tends to
occur with increased tissue mass and dose (Figure 3.6 from Section 3.4.1).
T1D simulations (Figure 3.18) depict the differing effects of long-acting,
rapid-acting, and regular delivery, including timing. T2D is only indirectly modeled,
through an “intolerance” effect based on excessive (saturating) glycogen storage in
tissues and indirectly through assumptions of body composition. However, it
illustrates how “poor” lifestyle habits can cause gradual glucose accumulation in
tissue compartments (Figure 3.19). Future directions for simulations could study
longer time periods (e.g., weeks).
With regards to model capabilities and limitations, our model accurately
depicts the reactive effects of exercise, i.e., those related to utilization of glucose for
energy with HR as a separate, external input for tuning and validating predicted
exertion if accessible (Chapter 4 and Figure 3.13, as a part of mitochondrial state
validation). Anaerobic exercise elicits spikes via immediate glucose demand and
hormonal action with higher glucose utilization as intensity increases, while aerobic
efforts tend to utilize the mitochondrial state and glycolysis efficiency, often relying
more so on a fuel mix (i.e. fat). Short periods of hyperglycemia may be evident due
to release in stress hormones before or at the onset of exercise. The latter is
suggested by case study data during anaerobic exercise in Chapter 4. Along with all
other models, our model cannot yet predict the “anticipatory” adrenaline effect of a
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short rise in BG, although with the addition of HR and a hormonal state this is
possible.
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4. PERSONALIZED ADAPTED MODEL FOR DIABETIC ATHLETES:
IMPLEMENTATION OF A FEMALE TYPE 1 CASE STUDY
4.1

Introduction
A novel nonlinear 10-state lumped compartmental model was presented in

Chapter 3 and aimed to provide a robust model with default parameters.
Furthermore, it was designed to provide flexibility for variable body mass, muscle to
non-muscle ratio, and Type 1 and Type 2 diabetes. The model is intended for both
research and clinical use, particularly diabetes educators, to quantify BG effects of
these lifestyle factors. The model could help inform delivery design of current
artificial pancreas mechanism with a dual-hormone delivery, as well as develop
continuous glucose monitor (CGM) feedback and prediction based on current
activity and/or diet.
This chapter is motivated by the concept that a diabetic should be able to
manage BG with exercise, diet, and for dual-hormonal control based on algorithm
feedback of a personalized model, similar to that of machine learning mechanisms.
It takes an important step towards refining the general BG regulation model of
Chapter 3 to a new personalized version, particularly for trained athletes with Type
1 diabetes.
Oftentimes, from personal and peer anecdotal evidence, a highly-motivated
diabetic keen on health-mindedness or athletic performance will know more about
their personal adaptation mechanisms than their endocrinologist. This is something
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that needs to change, if possible, so that diabetes educators and endocrinologists
can provide quantified feedback to diversified patients.
Current diabetes technology devices predict daily choices by varying inputs
day-by-day. When daily choices become habitual a lifestyle body type becomes
present—for example, one could be athletic, lean, overweight (indicator of Type 2
diabetes), inactive, or active.
Exercise physiologists are able to quantify metabolic changes on the basis of
body composition (i.e. increased muscle mass and/or basal metabolism) for various
body types, which could inform a personalized model. Chapter 4 uses an athletic
Type 1 female as an example for future adaptive modeling and device learning
mechanisms.
One key goal is to better inform clinicians to educate people with diabetes
appropriately in regard to glucose regulation on the basis of lifestyle choices that
may become habitual. This is possible with better understanding of lifestyle types in
hope that a library of personalized adaptive models can be created. It is intended
that current device technologies will become robust in that each can ‘learn’ its user
to eliminate guesswork of bolus corrections, often used for appearance of hypo- and
hyperglycemia. Additionally, such models can inform CGM ‘trends.’ Thus a second,
longer-term goal is to provide the foundation for an “intelligent system” model
framework that could directly inform a patient where their BG is headed, based on
causation effects of lifestyle inputs. A particular user profile, if robust, could drive
overall trends and baselines with instantaneous inputs (i.e. meal GI, stress, and/or
exercise) affecting immediate BG.
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4.2 Background and Motivation
It is well accepted that exercise directly influences BG concentration, in
response to increases in muscle tissue demands for energy (in form of ATP) that
result in consumption of glucose as a source of fuel. What needs characterization
and modeling is the effect of exercise type as combined with an individual’s personal
metabolic and body composition parameters and current fed or fasting state. Many
groups characterize exercise on the basis of VO2max and gauge substrate utilization
(CHO vs. Fat) on the basis of RER and known % of total aerobic capacity. However,
this is typically only consistent with aerobic exercise performed under conditions
without other types of stressors (e.g., stress of competition).
An extensive study by Yardley (2012) that focused on exercise in TID
attempted to demonstrate the effects of resistance vs. aerobic exercise and the
timing of each. As seen in Figure 4.1 below, BG is utilized in general at a much faster
initial rate during aerobic than resistance exercise (although ultimately about the
same response is elicited). This is cause for investigation and seen in other sources.
Resistance exercise incorporates other stress mechanisms beyond those associated
with aerobic exercise (also dependent on the individual’s lifestyle), oftentimes
resulting in a slight ‘spike’ in BG at the onset or prior to a hard exercise training
(often anaerobic) session. This phenomena has been seen throughout many studies
(Yavari, 2012, and Harmer, 2008 and 2013 ) and is what clinicians warn against as
a ‘false’ high due to catecholamine action and glycogen breakdown with adrenaline,
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hormones, etc. when the ‘flight or fight’ mechanism normally associated with the
sympathetic nervous system (SNS) occurs.
Heart rate is another means of characterization, and has been used to
characterize exercise intensity and duration in a basic exercise model for glucose
utilization, although a lack of research was recognized (Dalla Man, 2007). Most
conclude that there is heightened insulin sensitivity and increased CHO oxidation,
glycogen depletion, and hepatic production as exercise intensity increases.

Figure 4.1: Yardley (2012) Resistance vs. Aerobic Exercise Training. From Yardley (2012)
demonstrating the effects of performing resistance exercise before aerobic exercise (dark filled
circle, RA) or resistance exercise after aerobic exercise (open circle, AR) in people with Type 1
diabetes.

Another source of glucose during exercise, perhaps more importantly, is
skeletal muscle glycogen. It has been found that depleted glycogen levels results in
the inability to sustain prolonged high-intensity exercise and that depletion of
glycogen stores is dependent on its localization within the muscle cells (Nielsen,
2011).
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As shown in Figure 4.2, other proposed contributions to a decrease in blood
glucose levels (G in Figure 4.2) with prolonged exercise include a decrease in
glycogenolysis (Ggly), which has been modeled using an equation dependent on
exercise intensity and duration (Roy, 2007).

Figure 4.2: Roy (2007) Exercise Modeling. From Roy, 2007: Exercise modeling of BG taking into
account exercise intensity and duration and effect on hepatic glucose production. Volume of nonmuscle, muscle, and mitochondrial compartments is also accounted for as in the Schunk-Winters
model. Parameters are defined as: p1, rate at which glucose is removed independent of insulin, Gprod,
hepatic glucose production induced by exercise, Gb, glucose concentration, Gup, glucose uptake, VolG,
glucose distribution space, and A(t), the integrated exercise intensity (with critical threshold A th).

Additionally, the dependence of glycogen depletion commencement time
(tgly) on exercise intensity (u3 in Figure 4.2) is shown in Figure 4.3. Roy, 2007, uses
an approach correlating glucose utilization with intensity, similar to what our model
does with VO2max. This is a more robust and accurate approach than relying strictly
on HR measures, as in Cobelli, 2009. However, HR has informational value, and is
used to tune the u3 input of our model, comparing to perceived intensity, which will
be investigated below.
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Figure 4.3: Roy (2007) Glycogen Depletion vs. Exercise Intensity. From Roy, 2007 plotting the
muscle glycogen depletion commencement time vs. exercise intensity.

Post exercise late-onset hypoglycemia has also been widely documented in
T1D and interestingly no link was found between those in good or excellent
metabolic control, or those making the transition from an untrained to trained state
(MacDonald, 1987); energy is a conservative quantity with consumption that can be
predicted through tissue compartments, as in Chapter 3.
A recent review of exercise models describes principal energy substrates as
muscular glycogen, plasma glucose (including liver production), plasma free fatty
acids and intramuscular triglycerides with the CHO reserves (1200-2400 kcal)
localized in the muscle (79%), liver (14%) in glycogen form and in blood (7%) as
glucose (Derouich, 2002). This model incorporates early models which recognized
increased insulin sensitivity with exercise simply by incorporating the lowering of
glucose concentration during and after exercise and increasing the insulin use by
cells (Bergman, 1981). In addition to simplified early models, the disappearance of
glucose from blood to working tissue is dependent on the ability of the exercise to
accelerate the flow of glucose via a factor that is independent of the increase of
insulin, and a second factor (insulin sensitivity), which is a function of the increase
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in insulin (Derouich, 2002). Energy remains conserved, and a variety of factors that
will be discussed relate to the source of energy and its management.
In modeling T2D and the effect of exercise type, trends follow a similar pattern
despite overall VO2max being lower on average. Therefore, the point at which
threshold is reached and overall emphasis on CHO oxidation efficiency is lower.
With less mitochondria and fewer capillaries, an unfit individual may burn more
energy based on a lower oxidative capacity. A combination of both aerobic and
resistance training led to an improvement in HbA1c and triglyceride content as
opposed to aerobic or resistance training alone (Yavari, 2012). Hemoglobin A1C
(HbA1C), related to oxygen transport capacity, is a common measure for how wellcontrolled an individual’s BG has been for the previous 2-3 months, as it reflects
average levels and whether or not red blood cells have become “glycated.” Another
recent hypothesis attributes insulin resistance in T2D and obese individuals by a
deficiency and/or dysfunction of skeletal muscle mitochondria as a result of a
decreased ability to oxidize fat (Kim, 2008). Exercise training results in
improvement in insulin action and mitochondrial volume/function and hence is
important for all people with diabetes, particularly those with T2D (Holloszy, 2011).
Exercise appears in later iterations of the Dalla Man (2007) and Cobelli
(2009) model, and was kept as a simple and single input in the 12-13 state model as
emphasis was placed on compartmental insulin kinetics. In fact, 3 different exercise
models were proposed and implemented in silico. The 2009 version by the Cobelli
group implemented three additional ‘test’ inputs for exercise. Model A assumes that
exercise causes a rapid on-and-off increase in insulin-independent glucose clearance
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and a rapid-on/slow-off effect on insulin sensitivity. Note that without separate
muscle and non-muscle compartments, a possible source for this effect (e.g., flux
between BG and muscle compartments based on demand-based GLUT4 transporter
signaling as developed in Chapter 3 and discussed further in Section 4.2.1) could not
be addressed. Model B relaxes the assumption that exercise causes a rapid on-andoff increase in insulin-independent glucose clearance. Model C is similar to model A,
but also assumes that insulin action is increased in proportion to the duration and
intensity of exercise. It was determined, that Models A and B predict different levels
of exercise (based on heart rate) have the same effect on glucose utilization and
Model C predicts a reasonable glucose infusion rate during euglycemichyperinsulinemic clamp simulations for both mild and moderate exercise. However,
other literature suggests that exercise intensity, or different levels of exercise, does
in fact have implications on glucose utilization (i.e., Brooks, 1994) and therefore
Models A and B were recognized as limiting, and motivated the development of the
Schunk-Winters exercise model (see Chapter 3). Heart rate (HR) is also debatable as
an accurate measure of exercise level, as HR tends to fluctuate with other factors
and is intrinsic to an individual. Hence, most exercise physiologists use factors such
as percent of aerobic capacity. That being said, HR can be an accurate predictor if an
anaerobic threshold and/or VO2max stress test has been performed and
correlations between HR and particular training zones have been determined. This
concept will aide in model personalization. For example, knowing anaerobic
threshold and VO2max of an individual allows characterization of heart rate ‘zones’
1-5 ranging from ‘light, recovery’ exercise (zone 1) to above anaerobic threshold
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(zone 5). Often used in exercise physiology, zones can be correlated with respiratory
exchange ratio (RER) in which an RER = 0.7, often during zones 1-2, is mainly fat
utilization while zone 5, or RER > 1.0, is mainly glucose utilization with a fuel mix in
between (Knoebel, 1984). Zones are often used in regard to exercise planning and
training, as they can be adjusted as one becomes trained, typically favoring higher
fat utilization at elevated heart rates and shifting zones upward (Millan, 2014).
In 2013, a group associated with Cobelli and colleagues modified the in silico
2009 Padova type 1 simulator (Cobelli, 2009) to incorporate the effect of physical
activity after demonstrating a doubling of insulin sensitivity and hence rate at which
glucose enters cells (Schiavon, 2013). Subjects were put into two groups: one in the
absence of and one with different degrees of reductions and durations of basal
insulin infusion rates—it was shown an effective strategy is to reduce basal insulin
by 50% 90 minutes prior to exercise and 30% during exercise to avoid
hypoglycemia. However, currently, this is not possible in regard to current artificial
pancreas design as exercise type and intensity is not accounted for, both of which
may further adjust what changes need to be made in insulin dosing before, during,
and after exercise. If type of exercise and relative intensity (which can be tuned with
HR) and duration is inputted, theoretically a CGM or artificial pancreas design would
be able to use a personalized model to predict BG fluctuations based on quantifiable
trends (later shown in Figure 4.10). Reducing insulin during exercise is necessary;
however, dependent on exercise type the amount of this decrease and timing would
differ. For example, if a subject was performing high intensity sprint training, insulin
reduction before exercise may be less than the 50% proposed above due to the
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typical increase in BG at the onset of high intensity events. On the other hand,
insulin may be reduced more if exercise is going to be more aerobically based.
Limitations of current proposed exercise models include exercise energy
intensity as a function of HR implemented as a square wave – this is only useful for
steady-state aerobic exercise and varies amongst individuals in terms of threshold
values and zones. See Table 4.1 below and Figure 4.4 for limitations in using a
square wave approach. Anaerobic exercise is not accommodated by the 2009 Cobelli
model.
Table 4.1: Cobelli (2009) vs. Schunk-Winters HR informed Exercise Intensity
Baseline HR (bpm)
Mild Exercise, 15 min
Mild Exercise, 30 min
Moderate Exercise, 15 min
Moderate Exercise, 30 min

Cobelli, 2009
Characterization
60
1.5 x baseline = 90 bpm
1.5 x baseline = 90 bpm
2 x baseline = 120 bpm
2 x baseline = 120 bpm

Schunk-Winters HR Data (Phase 2
Case Study, Section 4.4)
45
128-145
128-145
146-169
146-169

Figure 4.4: Cobelli (2009) Exercise Modeling Using Heart Rate. Cobelli (2009) simplistic
approach to modeling exercise with the use of HR.
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4.2.1 GLUT4 and Mitochondrial Biogenesis
An increase in the GLUT4 isoform of skeletal muscle tissue in addition to
(and perhaps in part in conjunction with) an increase in mitochondrial content with
endurance exercise results in roughly a linear increase in glucose uptake in
response to the same insulin concentration. For example, a 2-fold increase in GLUT4
results in a 2-fold increase in glucose uptake in response to the same insulin
concentration (Holloszy, 2011). GLUT4 expression is regulated in parallel with
mitochondrial biogenesis in response to exercise-generated signals in skeletal
muscle (Rockl, 2010). It is also important to note that GLUT4 has a short half-life
(t1/2) and the increase in GLUT4 concentration induced by exercise reverses rapidly
(Richter, 2013).
4.2.2

Trained vs. Untrained Individuals

Skeletal muscle’s glucose needs vary depending on activity level, and the
glucose flux capacity depends on trained vs. untrained state. Hence, multiple
mechanisms (other than the strictly insulin-mediated pathways) are available for
glucose uptake. Particular motivation of a case study involving trained T1D’s, based
on personal experience and conversations with other elite T1D (DSP, 2015), stems
from the ability to be carbohydrate/glycogen depleted in an insulin dependent state
and still manage to avoid hypoglycemia during prolonged exercise. Despite early
suggestions that a certain amount of insulin was necessary for muscle glucose
transport in increase with contractions, it is now apparent that many other signaling
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pathways are responsible and result in an additive effect on GLUT4 translocation,
and hence glucose energy uptake of skeletal muscle during exercise (Richter, 2013).
Due to variations of fiber type amongst ‘trained’ individuals (i.e. greater
proportion of slow Type I fibers of an endurance athlete vs. more and larger fast
Type II fibers of sprinters and power athletes), it is recognized that although
glycogen storage location may differ, total glycogen content within muscle can
fluctuate considerably, and depends on diet and recent muscle use history (e.g.,
“carbo-loading” in athletes) (Costill, 1976). This was seen in Chapter 3, where the
predicted muscle compartment levels would vary over the course of a 24-hr day,
such as in Figures 3.17 and 3.18.
Endurance training effects (i.e. decreased resting HR, increased fat oxidation,
etc.) generally follow similar trends (Nielson, 2011). However, aerobic endurance
athletes may not rely on as much CHO oxidation if intensity is kept moderate for
prolonged periods. High intensity training (i.e. >70-80% VO2max) requires a
greater proportion of glucose fuel utilization, usually reached during intense
interval training, maximal lifting, sprinting sessions, and in highly-trained athletes
capable of maintaining such high VO2 and HR levels. A key adaptation is an increase
in mitochondrial content, and hence oxidation potential in trained individuals
(Holloszy, 2011). Some studies suggest an increase in mitochondrial demand and
utilization may represent how exercise training enhances muscle insulin sensitivity,
and fatty acid oxidation in both resting and exercise states (Befroy, 2008). Factors
influencing increased insulin sensitivity are important for insulin models and
clinically informing people with diabetes so that hypoglycemia can be prevented.
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Summaries of varying adaptations of trained vs. untrained individuals between low,
moderate, and high intensity exercise is summarized below.
In studies comparing substrate utilization of untrained vs. trained subjects, a
variety of methods exist. Ahlborg et al., 1974, analyzed six healthy untrained
subjects during prolonged (4 hr) exercise on an upright bicycle at 30% of their
maximal oxygen uptake, focusing on leg metabolism of substrates including glucose,
lactate, pyruvate and individual amino acids (Ahlborg, 1974). Wolfe took varying
exercise intensity of 5 trained subjects and determined peripheral lipolysis, plasma
rate of appearance of FFA, total fat oxidation, and carbohydrate oxidation (Wolfe,
1998). The subjects were trained cyclists and performed 30 minutes at 85%VO2max
and 120 minutes at 25 and 65% VO2max randomized over a course of three days.

Table 4.2 Summary of Low Intensity Substrate Fuel Utilization in Trained vs. Untrained
Subjects
Source
Ahlborg,
1974

Characte
rization
~30%
VO2max for
prolonge
d 4 hours

Wolfe,
1998

25%
VO2max

Overall Trend
CHO
FFA
Contributi
on fell
from 40 to
30%
between
90 to 240
min.
__

Account
for
majority of
leg muscle
metabolis
m beyond
40 min to
62%.
__

*Refers to arterial concentration of substrate.

Trained

Untrained

CHO

FFA

CHO

FFA

__

__

15 μmol
glucose/(kg
*min),
about 36%
of total fuel

Total Fat
Oxidation:
26.8 μmol
FA/(kg*min
); 25.8 FFA
rate of
appearance

*Rest: 4.51
mmol/l
40 min: 4.57
90 min: 4.30
180 min:
3.53
240 min:
3.12
__

*Rest: 0.66
mmol/l
40 min: 0.78
90 min: 0.93
180 min:
1.57
240 min:
1.83
__
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While in conflict with other literature that suggests a more proportional
glucose-intensity relation (e.g., Figure 4.3), this study suggests that at low intensity
endurance exercise, FFA oxidation is prevalent with only about 10% of total energy
expended from carbohydrates (Holloszy, 1996). Sources also differ in regard to
IMTG utilization (Ahlborg, 1974).
Table 4.3 summarizes studies of fuel utilization for trained versus untrained
individuals for a moderate-intensity exercise session. Holloszy (1996) studied
energy expenditure data during 0-30 minutes of exercise at 25, 65, and 85% of
aerobic power and during 90-120 minutes of exercise performed at 25 and 65%
VO2max. Confounding factors such as nutritional state, training level, and muscle
glycogen supercompensation were taken into account for the 5 trained cyclists,
adapted from the study used by Wolfe, making the studies comparable (Holloszy,
1996 and Wolfe, 1998). In a separate study, 9 untrained male subjects underwent a
12-week training program with measurements taken before and after training
during exercise of 120 minutes at an average of 64% VO2max (Hurley, 1986). In
terms of duration and intensity, this study is comparable—however, it is important
to recognize possible confounding factors associated with untrained becoming
‘trained’ and lifestyle remodeling.
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Table 4.3: Summary of Moderate Intensity Fuel Utilization in Trained vs. Untrained
Subjects
Source
Hollosz
y, 1996

Characteriza
tion
50-75%
VO2max, 2
hours

Overall Trend
CHO
FFA
10%
Plasma
Glucose,
20%
Glycogen

Hurley,
1986

64 + 3% of
VO2max for 2
hours

Glycogen
becomes
depleted
quicker
than BG

Wolfe,
1998

65% VO2max

__

<50%
FFA, 20%
IMTG
(since
prolonged
)
Function
of
concentra
tion but in
trained
subjects
FFA
oxidation
capacity
increases;
rely on
IMTG
__

Trained

Untrained
CHO
FFA

CHO

FFA

__

Greater;
IMTG~75%
of FFA
oxidized

__

IMTG
~50% of
FFA
oxidized

~415 kcal
for energy
from CHO
after
training

~600 kcal for
energy from
fat after
training

~650
kcal for
energy
from
CHO
before
training

~390
kcal for
energy
from fat
after
training

132μmol
glucose/(kg
*min)

Total Fat
Oxidation:
42.5 μmol
FA/(kg*min);
22.8 FFA rate
of
appearance

__

__

*Refers to arterial concentration of substrate.

At a moderate exercise intensity, more emphasis is placed on CHO oxidation,
with total glucose utilization = BG + glycogen (Holloszy, 1996). IMTG utilization
increases in some trained individuals. According to Hurley et al (1986) and
calculated from RER, the proportion of caloric expenditure derived from fat
increased from 35% before training, to 57% after training while keeping relative
workload constant during exercise. Muscle glycogen utilization was 41% lower.
Kiens (1993) attributes the relative proportion of FFA uptake in exercising
muscle as a saturable process enhanced by training; lower CHO utilization in the
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trained leg was mainly a function of glycogenolysis reduction. As duration increases,
FFA uptake increases more rapidly in trained individuals and plateaus in nontrained after 60 minutes.

Table 4.4: Summary of High Intensity Substrate Fuel Utilization in Trained vs. Untrained
Subjects
Sourc
e
Hollos
zy

Characteriz
ation
>75%
VO2max up to
30 minutes

Wolfe,
1998

85% VO2max

Overall Trend
CHO
FFA
60%
Glycogen;
10%
Plasma
__

10%
IMTG;
15-20%
FFA
__

Trained

Untrained
CHO
FFA

CHO

FFA

69% of Total

Decreasing;
less release
from adipose

75% of
total

__

259μmol
glucose/(kg*mi
n)

Total Fat
Oxidation:
29.6 μmol
FA/(kg*min);
17.0 FFA rate
of
appearance

__

__

At high intensity, fat oxidation is no longer sufficient as a primary fuel source,
and carbohydrate oxidation is the dominant mode of most energy expenditure,
especially in untrained individuals (Ahlborg, 1974 and Kiens, 1993).
Sufficient data on the exercise physiology aspects of mass-conservation of
glucose with exercise allows for model personalization as long as intensity can be
characterized and inputted. The Schunk-Winters model (Chapter 3) uses an
approach to input exercise as an aerobic ‘fuel-mix’ demand source (in kcal/hr) or
from an anaerobic/daily activity standpoint (also in kcal/hr). The addition of a
mitochondrial demand consumption state allows the separation of muscle tissue
into multiple supply-demand based compartments to account for effects seen in
Tables 4.2-4.4 above and with case study results in Section 4.4 below.
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4.3 Methods
The Chapter 3 Schunk-Winters model acts as the base compartmental model
for Chapter 4 and model personalization. The main augmentations focus on the
highlighted tissue compartments in Figure 4.5, the general model, and Figure 4.6,
the skeletal muscle model proposed in Chapter 3. Further parameter
personalization and an example of application to a T1D athlete are presented in
Section 4.4 Case Study and Section 4.6, with personal adapted parameters used for
simulations throughout results outline in Methods 4.3.2.

Xmito

Figure 4.5: Schunk-Winters Model Structure with Exercise Focus. Thick lines represent material
flow with storage and control action as unidirectional signals informed by rate parameters and
oftentimes, nonlinear, by either Hill kinetics or multiplicative states. Nonlinear relations include both
flux terms and heuristics that change fitting equations based on different state or input signal ranges.
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DXA Data (body composition)
and Aerobic Capacity (from
VO2max testing)

Skeletal Muscle and Tissue Compartmental Model
um-activity : Daily Activity Muscle Input (kcal/hr)

um-exer-Ana : Anaerobic Exercise Muscle Input (kcal/hr)
um-exer-Aer : Aerobic Exercise Muscle Input (kcal/hr)

fat_Aer: Aerobic Fat Consumption (out of total exercise input) (kcal/hr)
AerCap: Maximal Aerobic Capacity (kcal/hr)

Figure 4.6: Skeletal Muscle and Tissue Compartmental Model with Added Input.

4.3.1 Case Study Phases 1 and 2 and Data Collection Protocol
Full protocol description, results, and logbook can be found in Appendices 7.2
and 7.3 for both phases, respectively. The subject completed an IRB-approved Case
Study Phase 1 in June 2014 and Case Study Phase 2 in June-July, 2015.
The phase 1 case study was an in silico 24-hour study with the model output
compared to BG monitoring of a 22-year-old T1D athletic female. 3 protocols and 1
control protocol were performed on the same day of the week for 4 consecutive
weeks. BG was collected using the subjects OneTouch Ultra Blood Glucose monitor,
requiring a finger prick every 30 minutes. Meal content (GI), exercise type, and meal
timing were variables of interest. Controls included meal magnitude, exercise
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duration, activity (time and relative intensity) and insulin injection, based on clinical
prescription. Outputs mainly resulted in determining a need to differentiate exercise
type and meal content in modeling. Limitations include inaccuracies due to finger
pricks and sampling only 2 times per hour and no control for the female’s menstrual
cycle. This study opened up the need for Phase 2.
Phase 2 featured the addition of a continuous glucose monitor (CGM, specifically
Dexcom G4 Platinum) and extended protocol length. The purpose of the study
phases was to validate known BG trends in regard to particular meals and content
(i.e. low vs. high GI) as well as differences in exercise type (intensity, duration,
aerobic, and resistance variations) similar to that of Phase 1, but with longer
duration to accommodate additions to both meal and exercise simulations. Known
literature study inputs will be replicated for comparison and are referred to in the
logbook of Section 6.4. Literature studies replicated include Yamamoto, 2014,
Kotachev, 2014, and Cobelli, 2007 amongst others.
Prior to the primary part of this study of continuously monitoring blood
glucose levels (Phase 2), clinically standard metabolic and physiological tests
related to your body composition and baseline fitness levels took place (Phase 2).
These were performed in several exercise laboratories on the Marquette University
campus. An IRB-approved maximal oxygen consumption test (VO2max test) was
performed on a treadmill. The subject wore a VO2 testing mask and followed the
laboratory protocol of increasing the treadmill grade by 2% approximately every 2
minutes until volitional fatigue or the presence of any contraindication to the
American College of Sports Medicine (ACSM) guidelines. Blood lactate was
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measured before and after to ensure that the lactate threshold was reached. Body
composition parameters and values were obtained with the use of a DXA machine
and full-body scan (further explained in Appendix 7.5).
The main part of this research study involved a planned 8-day protocol for meals
and exercise. Meal content was planned using glycemic index and load calculations
to distinguish between “fast” and “slow” carbs.
4.3.2 Model Personalization
Parameters and inputs that shape the personal integration into the SchunkWinters model are outlined below, and given in Table 4.5. These values are used for
all simulations included in Section 4.4.2 results. They will form the basis for all
future personal integration model parameter and input changes. New parameters
(in addition to those changed below) are metabolism scaling that will scale both
non-muscle and muscle tissue loss, and a stressor ratio parameter to inform the new
additional input uHM, or any hormone effect associated with added stress, i.e.
eliciting catecholamine action during exercise. This input is time dependent, with a
default value of 1.0 and scaled by stressrat, or a pulse affecting the GLUT 2 bidirectional gradient at a given time. For example, in 4.4.2 results, this parameter is
used to model circuit training. Both metab and stressrat will be defaulted at 1.0, with
a scale from 1.0-1.5 for higher metabolism or higher stress situations, respectively.
Stress ratios implemented for model simulations, particularly in regard to circuit
and sprint training, are displayed in Figure 4.11a.
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Table 4.5: Model Personalization Parameters
Schunk-Winters General Model

Personal Integration Model
Parameters

Body Mass = 70 kg
Muscle Mass = 30 kg
Non-Muscle Mass = 25 kg
Aerobic Capacity = 1000 kcal/hr
Mitochondrial Volume = 0.1
Type 1 Ratio = varies
GLUT2 Forward Rate = 6.0
Stressor Ratio (i.e. Exercise) = 1.0
Maximum Fat Consumption Capacity = 300 kcal/hr
Metabolism Scaling* = 1.0
Basal Non-Muscle Tissue Metabolic Loss* = 2.5 g/hr
Basal Muscle Tissue Metabolic Loss* = 1.5 g/hr
HR Resting = 60 bpm
HR Maximum = 200 bpm
Inputs
Exercise Duration and Single Intensity

65
30
20
1137
0.3
0.2
6.0
1.5
341
1.5
3.0 (Refer to Appendix 7.5 for body
composition)
2.25
45
212

Exercise Duration with Heart Rate
Informed Intensity
Activity—Separate Input
Activity—Separate Input or During
Exercise
Hormonal Input, uHM = 1.0
Hormonal Input, uHM = 1.0 *(Stressor
Ratio); time dependent
* Metabolic Scaling is on the basis of basal metabolism and scales both muscle and non-muscle
metabolic loss as a multiplicative entity.

An external heart rate input (if available) from a monitor or smart watch
augments the exercise input portion of the model. The following code snapshot
(Figure 4.7) from Matlab demonstrates the theory behind applying a Hill functional
to map the u3 reference input to the HR u5 reference input. Heart rate is used to
sculpt u3 when compared to a reference input value to the user. The difference is
used to add/subtract to u3 to create a new and HR informed u3. HR is first
normalized.
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urelHR(i) = (u(5,i)-HRrest)/(HRmax-HRrest);
upredex(i) =(u(3,i)/AerCap);
urelHR = upredex;
kscale = 500;
if urelHR(i) == 0
u3new(i) = u(3,i);
else
deltu3(i) = kscale*(upredex(i) - urelHR(i));
u3new(i) = u(3,i) + deltu3(i);
end
Figure 4.7: Heart Rate Code Snippet. Code snippet from Schunk-Winters model.

Another aspect of the model involves varying a subject’s fat oxidation
capacity, or the subject’s potential ability to utilize fat as an energy substrate during
exercise. This often increases with training, along with mitochondrial volume, etc.
The following curves (Figure 4.8) demonstrate the model subtraction of fat from
total energy consumption, thereby leaving glucose consumption as the main input
(in kcal/hr). Although there is not a separate fat consumption state, the model
accounts for an increase in fat oxidation by a higher magnitude/rate subtraction as a
fat fuel Hill function from total energy consumption as seen below (Rynders, 2011).
This approach automatically adjusts the fuel mix, with fat a relatively higher
proportion for low-to-moderate and moderate intensity endurance activity, then
becoming less for high-exertion endurance activities. For example, the Hill function
could be adjusted to saturate at a higher value than 300 (~30% if Aerobic Capacity =
1000 kcal/hr), such as estimated as 341 Kcal/hr for the case study. For steady
aerobic exercise, even at higher intensity, this provides a reasonable approach for
fuel distribution as a function of endurance activity.
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Red Solid Lines: Aerobic Capacity = 1000 kcal/hr; Fat Max = 300 kcal/hr
Blue Dashed: Aerobic Capacity = 1300 kcal/hr; Fat Max = 341 kcal/hr

Fat vs. Glucose Fuel Consumption (kcal/hr)
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Figure 4.8: Glucose and Fat Consumption vs. Total Energy Expenditure. Fat and glucose energy
consumption (kcal/hr) vs. total energy expenditure (kcal/hr) varying the fat consumption capacity
from 30% of aerobic capacity (red lines) to 40% (blue lines). Dashed lines indicate glucose
consumption, the main model input of total expenditure – fat consumption (solid lines).

Various types of exercise, particularly those similar to high intensity interval
training, circuit training, and sprint intervals (i.e. repeating high intensity followed
by rest), can be modeled using both u3 and u4 inputs thereby simulating both
aerobic and anaerobic components . Such high-exertion exercise protocols,
requiring discipline and concerted focus by the athlete, may be viewed as having a
stress component outside of exercise stress. In such cases, an additional
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multiplicative control function operating on tissues on the basis of anticipatory realtime sympathetic hormone effects (i.e. see hormone discussion in Section 3.4.7)
similar to glucagon effect of transferring glucose to blood from non-muscle
compartments via pathways such as hepatic over-and-above account for
fluctuations associated with such exercise types as well. Effects are quantified in
Section 4.4.2, case study phase 2 results.
Body composition variations have a large effect in terms of maximum
saturation of Hill functionals, as limits are placed based on the amount of muscle
and non-muscle volume (and hence glycogen/glucose storage) available.
Additionally, a higher muscle volume directly effects mitochondrial volume, with
both typically increased in a trained individual (can be verified by a DXA scan). In
this case, aerobic efficiency and hence u3 effects are increased.

4.4 Case Study Results and Comparative Simulation
Section 4.4.1 highlights key Phase 1 results, limited in that Phase 1 was used to
design Phase 2. Section 4.4. 2 includes Phase 2 results. Phase 2 results are separated
into an exercise section (Figures 4.9 and 4.10) demonstrating CGM data acquisition,
analysis, and model simulation replication. Exercise protocols are compared based
on similar time duration. The following section and Figure 4.11 shows and example
of a full-day protocol (Day 7), including CGM data and external heart rate input
(Figure 4.11a), foodstuff logbook and spreadsheet, and Schunk-Winters replication
(Figures 4.11b and c).
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4.4.1 Phase 1 Results
Examples of useful Phase 1 results are shown in Figure 4.9; however, most
results were used to design the more extensive Phase 2 study. Timing of insulin
prior to a meal was a useful insight as well as lingering effects of exercise type. It
was clear that some hyperglycemia exists with resistance training but could not be
quantified due to a sampling frequency of every 30 minutes.

Figure 4.9: Phase 1 Case Study: Anaerobic vs. Aerobic Exercise and High vs. Low GI Dinner.
Snapshots from Phase 1. Left: Anaerobic vs. Aerobic Exercise for a 22-year old female T1D. Right:
High vs. Low GI Dinner. X-axis denotes time in hours. For the right plot, the time scale is over a period
of two hours—each tick = 30 minutes.

4.4.2 Phase 2 Results
All results from the following sources are provided in Section 6.5 and 6.6:





DXA Scan
VO2max Treadmill Test (Bruce Protocol)
o Excel datasheet is available.
CGM Data and Calibrations
Garmin Heart Rate (HR) Snapshots
o Excel HR files are available.
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Meals/Snacks
o Magnitude, GI, proportion of CHO
o Time/Duration
o Excel datasheet available.
Daily Logbook
o Activity level/notes
o Stress level
o Resting HR
o Corrections for BG
Figure 4.10 shows the process used for data analysis in a comparison of

protocol days 4 and 8: long duration exercise. This example compares a long
duration (~2 hour) anaerobic lifting workout to a long duration (~2.5 hour) aerobic
run. CGM data is obtained alongside corresponding HR data. HR data is inputted into
the Schunk-Winters model along with perceived intensity level of exercise (in
kcal/hr as a proportion of maximal aerobic capacity) and all states are predicted as
shown in Figure 4.10 (bottom). Figure 4.11 outlines HR variation, CGM data
acquisition, and model prediction for four different exercise types.

4.4.2.1 VO2max and Body Composition
Table 4.6 and Table 4.7 provide VO2max test results and calculated aerobic
capacity, as well as training zone characterization of the subject calculated from
VO2max test results. Table 4.8 shows a general overview of subject body
composition with all results in Appendix 7.5.
Other biological factors controlled for included the female menstrual cycle and
insurance that the diet and exercise protocols would be as normal as possible to the
subject’s typical training and diet routine as to not affect basic body composition.
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Table 4.6: VO2max and Aerobic Capacity Calculation
VO2max (mL/kg/min)
VO2max (kcal/kg/hr)
Aerobic Capacity (kcal/hr)*
Anaerobic Threshold Parameters
VO2 (ml/kg/min)
% VO2max
Speed @ 1% Grade (mph)
HR (BPM) at
Maximum HR (BPM)*
Resting HR (BPM)*
Maximal Fat Consumption (kcal/hr)
Assuming ~30% Aerobic Capacity*
*Denotes Model Inputs

62.65
17.9
1137
50.4
80.4
9-9.5
170
212
45
341

Table 4.7: Phase 2 Case Study Training Zone Characterization
Training
Zones
1
2
3
4
5

Active Recovery
Easy Aerobic
Moderate
Aerobic
Threshold
Maximal

%AT
65-74
75-85

Lower Bound
(bpm)

86-95
100-105
106- max HR

Table 4.8: Subject Body Composition Overview
Date:
Height (in)
Weight (lbs)*
Age
Android (% Fat)
Gynoid (% Fat)
A/G Ratio
Total Body (%)*
BMI (kg/m^3)
Muscle Mass (kg)*
Non-Muscle Mass (kg)*

*Denotes Model Inputs

22-Jun-14
69.5
139
23.2
20.2
20.9
0.96
15.4
20.2
54.3
8.806

Upper Bound
(bpm)
111
128

126
145

146
170
180

169
180
191
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4.4.2.2 Exercise
Section 4.4.2.2 highlights key results pertaining to the Case Study exercise
sessions, with all data shown in Appendix 7.3. Figure 4.10 demonstrates an example
of personalized model progression to compare long endurance exercise, taking CGM
blood glucose clinical data, applying corresponding HR input, and replicating the
simulation inputs in a personalized version of the Schunk-Winters model so that
each state is displayed, and exercise physiology and biological glucose flow
mechanisms can be seen (i.e. mitochondrial consumption, flow to and from tissue
states, etc.). Heart rate is used to better tune and inform intensity based on taking a
perceived u3 input and known aerobic capacity with any difference based on HR
fluctuation above or below this threshold as an added or subtracted entity.
Figure 4.11a-c compares type of exercise with a constant duration. An
aerobic tempo run at 60-70% maximum aerobic capacity is compared to circuit
training, a combined bike and run aerobic session, and sprint training. Circuit
training is further informed with the personalized parameter stressrat or a stressor
value of 1.5.

Anaerobic

Aerobic

Snack at 6:30 AM with
Long Aerobic in Pink
(lower curve) and
Anaerobic in teal.
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Figure 4.10: Phase 2 Case Study: Personalized Model Progression. Example of a personalized
model progression taking Case Study Phase 2 CGM blood glucose clinical data (Top) for longduration (2-2.5 hour) aerobic vs. anaerobic exercise and using corresponding HR data (Middle) to
inform BG fluctuations and trends in summation with the model prediction(Bottom). If HR is higher
(or lower) than the predicted exertion (i.e. ~500 kcal/hr for long aerobic and bouts of 800 kcal/hr or
greater for anaerobic), the exercise and activity input is adjusted. Subject is a 65 kg T1D female with
an increased mitochondrial content ratio (0.3) due to athletic training level (mitochondrial
consumption shown in kcal/hr).

CGM (BG [mg/dl] vs. Time)

Heart Rate (bpm)
Protocol Day 2: Tempo Run

Additional Input
Stress Ratio = 1.5
Starting BG = 97 mg/dL
Basal Insulin for Simulation = 1.0 U/hr
Average HR = 162 bpm
Training Zone 3

200
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Protocol Day 3: Circuit Training
Stress Ratio = 2.0
Starting BG = 72 mg/dL
Basal Insulin for Simulation = 2.0 U/hr
Average HR = 164 bpm
Peak HR = 183 bpm
No Zone Characterization (HR spikes)
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Protocol Day 6: Bike and Run
Stress Ratio = 1.0
Starting BG = 84 mg/dL
Basal Insulin for Simulation = 1.5 U/hr
Average HR = 143 bpm
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Protocol Day 7: Sprint Training
Stress Ratio = 1.8
Starting BG = 72 mg/dL
Basal Insulin for Simulation = 2.0 U/hr
Average HR = 163 (including rest)
Peak HR = 182
Training Zone During Sprints = 4
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Figure 4.11a: Exercise Type Comparison. Comparison of days 2, 3, 6 and 7 exercise sessions, CGM clinical data and external heart rate. The additional
input column is used for Schunk-Winters simulation reference.
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Protocol Day 2: Tempo Run

Protocol Day 3: Circuit Training

Figure 4.11b: Exercise Type Comparison. Simulation Comparison of days 2, and 3 exercise sessions. In all cases, the subject had a 15 g CHO snack at
6:30 AM with exercise beginning at 7:00 AM for 1 hour. Personalized model output is shown with blue-dashed lines, while default model output is
shown in red solid.
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Protocol Day 6: Bike and Run

Protocol Day 7: Sprint Training

Figure 4.11c: Exercise Type Comparison. Simulation comparison of days 6 and 7 exercise sessions. In all cases, the subject had a 15 g CHO snack at
6:30 AM with exercise beginning at 7:00 AM for 1 hour. Personalized model output is shown with blue-dashed lines, while default model output is
shown in red solid. The parameter stressorrat was used to inform any increased exercise-induced stress, triggering non-muscle to BG flux.
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4.4.2.3 24-Hour Simulations
Figure 4.12 shows an example of a 24-hour simulation and replication. The
provided example is for Protocol Day 7, which consisted of a track workout at 7 AM
(4x400, 4x200, 1x400, 1x200, and 4x100) for about 40 minutes estimated at 700
kcal/hr, 3 meals, and 1 snack. In the simulation run, t =0 is 12:00 AM, as in the CGM
graph. The subject data is found in Appendix Section 7.5 (23-year old T1D athletic
female). Table 4.9 and 4.10 provide meal content information, including time,
duration, and GI. Other full day CGM data and meal content are found in Appendix
Section 7.4.
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Figure 4.12: 24-Hour Case Study Simulation: Day 7. (Top) Dexcom Studio CGM plot for
Protocol 7 (July 7, 2015), indicating CHO intake, insulin, and exercise. BG is plotted vs. Time.
(Bottom) Model replication of Protocol 7 showing BG, effective insulin (amount produced with
ratType1i = 0.2 + exogenous), tissue states, and mitochondrial effect.
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Table 4.9: Protocol Day 7 Meal Content
Meal 1

Meal 2

FOOD
Fiber One
Protein
Banana
Eggs
Bread ,2
slices
Peanut
Butter
Grapes/
Berries
Yoplait
Strawberry
Cheese
Turkey
Kashi
GoLean
Crunch
Instant
Potato
Quinoa
Chicken
Bell
Peppers
Red Wine
TOTALS

GI

Meal 3
Calories
(kcal)

Meal 4
Serving

CHO
(g)

Fiber
(g)

Available
CHO (g)

Fat (g)

Protein
(g)

30
60
0

120
100
140

1 bar
1 banana
2 eggs

17
25
0

5
3.1
0

12
21.9
0

6
0
8

6
0
12

60

140

2 slices

28

3

25

2

2.5

14

105

1 tbs

3.5

1

2.5

8.5

3.6

60

105

1 cup

28

0.5

27.5

0

0

35
0
0

170
110
60

6oz
1/3 cup
4 slices

33
0.5
4

0
0
0

33
0
4

1.5
9
1.5

7
7
7.6

55

95

1/2 cup

18

6

12

1.5

10

83
53
10

333.6
174.75
200

67.3 g
3/4 cup
4 oz

50
35
10

3
4
0

47
31
10

12.6
4
3

5.6
8
33.3

27
15

50
130
2033.4

300g
1 glass

8.4
5
265.4

3
0
28.6

5.4
5
236.3

0.6
0
58.2

3.6
0
50.2

Table 4.10: Protocol Day 7 Meal Duration and GI
Meal
Duration
Time (min)
GI

Meal 1

Meal 2

Meal 3

Meal 4

10

10

6

15

65.4

50

83

43.9

4.5 Sensitivity Analysis
Sensitivity analysis was performed similar to Section 3.6 with sensitivity
coefficients calculated according to the following equation, varying each parameter
by +/- 10% (Lehman et al, 1982):
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(𝐵+ −𝐵− )
⁄𝐵
𝑜
.
(𝑃+ −𝑃− )
⁄𝑃
𝑜

Inputs are outlined in Table 4.11 below for the subject in the Phase 2 Case Study.
Table 4.11: Sensitivity Analysis Inputs (Subject: BW = 65 kg, rattype1i = 0.2)
Anaerobic Exercise
Simulation
 2-Hour Lifting Workout
(Case Study 2 Protocol Day
8)
o 7:00-9:00 AM
 Bouts of 800 kcal/hr
exertions informed by HR
input

Aerobic Exercise
Simulation
 2.5 Hour Long Run (Case
Study 2 Protocol Day 4)
o 7:00-9:30 AM
 500-600 kcal/hr
informed by HR input

Snack + Exercise Simulation



1 Hour Tempo Run (Case
Study 2 Protocol Day 1)
o 7:00-8:00 AM
15g CHO snack at 6:30
(kfast = 0.8, fraccarbs =
0.8)
o No insulin

It was determined from Appendix 7.6.2 that glucagon controllers were
sensitive. Figure 4.13 below shows over plotted trajectories of varying Cga, the nonmuscle glucagon controller for exercise protocol 2: circuit training. Other sensitive
parameters included non-muscle and muscle GLUT2/GLUT4 gradient parameters,
Kg2Max and Kmintol (Xg), tissue mass and basal tissue metabolism (Xnm), demandbased Hill saturation parameter Kmxex (all states) and insulin d-action (Xi). The
subject Type 1 ratio was also varied in Figure 4.13 for the long aerobic exercise
simulation (Protocol Day 4), demonstrating the effect if a subject’s exact insulin
production is not known. This estimate is often a function of the amount of insulin a
T1D must take to maintain daily BG within the healthy range. Table 4.12 quantifies
this sensitivity.
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Figure 4.13: Model Sensitivity to Glucagon Control. Model sensitivity to Cga, the glucagon
controller using the personalized model and parameters defined in Table 4.5.

Figure 4.14: Model Sensitivity to Type 1 Diabetic Variations. Model sensitivity to ratType1i, the
T1D ratio of remaining insulin production. Simulation is of 24-hour day 7, circuit training, similar to
Figure 4.11 above.
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Table 4.12: Sensitivity Coefficients for Parameter RatType1i*
Xg
Xnm
Xm
Xi
Xgn
Xmito
Xmax
-2.20
0.00
-3.45
2.46
-5.03
-0.32
Xmin
0.00
-0.14
0.08
0.82
0.29
0.02
Before Exercise
(6:30 AM)
-0.20
0.17
0.57
0.59
-0.13
0.02
During Exercise
(8:00)
-2.11
0.34
2.08
2.97
-7.99
-0.16
Recovery (9:30)
-2.18
0.43
-4.71
2.48
-8.68
-0.30
*Long aerobic exercise simulation

4.6 Personalized Parameters for Muscle Compartment and Trained Individuals
Based on Section 4.4.2, particularly Figure 4.10, there are vast differences in
BG response to aerobic and anaerobic exercise due to reasons discussed in Section
4.2 including training effects. Training zones from Table 4.6 also are used to inform
u3 perceived exertion based on HR and % of VO2max. The 10th state, Xmito, was
added after some exercise effects, i.e. hyperglycemia at the onset and with highstress situations, could not be replicated in the Schunk-Winters model. The addition
also allows for GLUT4 action to bring glucose into muscle tissue when a u3 input is
not occurring—this is a more realistic demand-based approach.
Section 4.3.2 outlined personalized parameters used for simulations to
replicate case study data. These values were decided after analyzing case study
results; however, were presented in 4.3.2 to outline parameters used for model
simulations throughout Section 4.4. Figure 4.15 shows a model comparison by
overplot of the new, personalized model for the case study subject compared to the
prediction using only default values. Values used were outlined in Section 4.3.2. The
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only exception is a heart rate input, u5, is used in both cases, as opposed to only a

G-Flow (Kcal/hr)

predicted u3 for the default case.
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Figure 4.15: Comparison of Default and Personalized Model. Case study day 5 (Sprint Training)
using default vs. personalized parameters described in Table 4.6.

4.7 Discussion
The aim of Chapter 4 is to form a basis for adaptive personalized modeling, to
further develop algorithms for those with T1D that live an active lifestyle. This could
potentially enable a CGM to have higher accuracy in predicting ‘trends’ or where BG
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is headed based on external exercise inputs, body composition parameters, and
overall lifestyle habits.
Meal effects were one area of focus for Phase 2 results, particularly in regard
to digestive and insulin state model validation. Chapter 3 (Section 3.5) highlights
some key results, comparing to literature. Here the focus was on controlled meal
and snack inputs, often tied closely with studies from this literature, and often
designed in tandem with exercise protocols (e.g., a snack a certain time prior, or a
sustained lunch a few hours subsequent to exercise). Key insights can be seen in
glycogen replenishment with post-exercise meals, which varied on the basis of
exercise type and lingering sensitivity effects. Other insights further continued
model validation for low vs. high GI food effects particularly in regard to Yamamoto
(2014) snack simulation days. For example, the post-exercise meal after highintensity circuit training did not elevate BG as significantly as the same postexercise meal for the bike and run moderate aerobic protocol—BG levels remained
below 140 mg/dL, whereas they became elevated close to 160 mg/dL post-aerobic.
Insights here relate to total glucose consumption and glycogen depletion during
exercise—it seems that on a time-dependent basis, anaerobic components of
exercise present a lingering glycogen-depleting effect. Additionally, throughout all
protocol days, low GI mixed meals again proved (as in Phase 1) to be the best option
for BG management if a reduced amount of insulin intake is desired. For example, in
comparing barley consumption on Day 3 of Phase 2 (GI = 25) vs. an instant white
potato on Day 7 (GI = 83), BG remained significantly below the ‘high’ range for
barley as opposed to the white potato. Additionally, hypoglycemia occurred about 2
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hours post-potato—insulin was still in effect, but little to no slow absorbing
carbohydrates from the potato were present.
Pre-test data involving the DXA body composition test and VO2max stress test
point out differences of trained vs. untrained individuals recognized throughout the
exercise physiology field. Particularly, muscle mass is close to and perhaps exceeds
greatly non-muscle mass (or, only fat mass based on DXA results), resting HR is
significantly lower, and VO2max and respective training zones are significantly
higher (Tables 4.5 and 4.6 and Appendix 7.5). Trained individuals are more efficient
in terms of energy utilization and typically demonstrate higher mitochondrial
volume, which implies an ability to rely more heavily on sustained fat oxidation,
especially in trained endurance athletes with adequate fat available as fuel (see
Section 4.2.2). These phenomena are indicative of a need to characterize these
adaptations and to design a model that has the capability for personalization—
current models lack ability to model the flow of glucose as a source of energy for an
athletic individual, particularly in regard to sports with varying intensities and
durations.
Case study phase 2 was designed to better quantify differences in exercise
type in terms of BG fluctuations, as well as characterize predictors for these changes
(i.e. heart rate, level of training, fed state, etc.). After initial observation from Phase
1, Figure 4.10 made it clear that there is some anticipatory ‘stress’ effect that often
results in hyperglycemia during intense exercise. Phase 2 confirmed the presence of
this effect, particularly with fluctuations during circuit training, sprint intervals, and
anaerobic lifting (see Figure 4.11). The original model was limited to only predict
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generic end results—mainly, BG decrease due to glucose flux into the muscle
compartment. Although the rate of which this decrease occurred as well as the
magnitude could be quantified, there was no ability to show BG variation during
exercise or post-exercise during recovery. The addition of the 10th mitochondrial
state made this possible, especially for exercise involving aerobic components, as
there is now a demand-supply mechanism between BG and tissue that can occur
without activity or exercise present. The mitochondrial state is plotted in Figures
4.10 and 4.11 for varying types of inputs. Long endurance aerobic exercise showed a
significant magnitude increase in mitochondrial action, as expected—primary
energy is resultant from a fuel-mix and higher fat utilization in the personalized
model. Long anaerobic efforts demonstrated a faster rate of mitochondrial
consumption, but at a reduced magnitude than aerobic. Sprint training
demonstrated the highest rate and magnitude of mitochondrial consumption and
most significant decrease in muscle glucose. This idea is validated by CGM clinical
data, as fluctuations ensue, but resulted in lowest ending BG level of the four
protocol sessions. Sprint training has a high intensity aerobic component, despite
rest periods. Additionally, tempo run training and combined bike/run protocols had
varying mitochondrial consumption, particularly if effort variation occurred (i.e. at
the end of tempo training). Circuit training showed high mitochondrial action for the
personalized model, as expected due to higher mitochondrial volume.
It is important to note that sprint training HR data, Protocol Day 7, was not
fully representative as HR was not recorded for the first four rest periods. The
overall u3 input that was used was shortened to match the HR duration, as well as
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fluctuation characterization of just the recorded sprint events (i.e. u3 informed).
This experimental limitation makes it difficult to capture BG effects shown in the
corresponding CGM data.
Figure 4.10 is important in comparing long endurance sessions, characteristic
of trained endurance athletes. Despite beginning snack and BG relatively constant,
different responses were elicited—a long aerobic workout was characterized by a
significant decrease in BG before settling at a steady value of around 65-70 mg/dl
with a steady (straight arrow) trend seen on the Dexcom G4 CGM. This is indicative
of the low to moderate intensity of running as a fuel-mix of fat and glucose energy
oxidation, thus conserving glucose. The average HR of 147 verifies this, as it falls in
Zone 3, or moderate aerobic, according to the subject’s metabolic testing found in
Section 4.4. This trend continued for the entire 2.5 hour course (~19 mile run) with
a slight rise due to some fueling and other mechanisms such as hepatic production,
particular towards the end when stores become depleted. On the other hand, the
long anaerobic workout had a slightly different response, despite an initial trend of
decreasing BG similar to that of the long aerobic. In the anaerobic case, BG actually
elevated again after an initial decrease and continued to have fluxes throughout. The
overall trend and ending value was similar to that of long aerobic—around 75
mg/dl. The fluctuations are most likely due to varying intensities and fuel source
throughout, as HR was inconsistent (hence, zones do not apply here). Often, during
quick bursts of activity, there is an inefficient burning of glucose and hence a
separate form of glycolysis (i.e. without oxidation) is used for ATP production. Our
model has the ability to predict this with utilizing a low level u3 input
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simultaneously with the u4 anaerobic activity input, as well as mitochondrial
consumption.
In comparison of exercise type and intensity variation with constant duration
(1 hour), Figure 4.11 provides CGM data of an athletic subject to quantify these
variations. HR is also indicative of the varying intensity and exercise type in each
case. It is clear that sprint intervals and circuit training have fluxes and even ‘severe’
cases of hyperglycemia briefly (>140 mg/dl), unlike forms of aerobic exercise, such
as the tempo and run/bike combination. Sprint training is modeled as a form of u3
exercise, and hence is tuned with HR which is clear in Figure 4.11, model prediction
(right), as the model is able to predict initial rises due to onset of increased intensity
and reaching threshold HR. The model is reasonably valid for tempo aerobic activity,
and including the bike/run protocol. As expected, a higher u3 aerobic input is
indicative of higher mitochondrial action and consumption.
However, in regards to circuit training, some fluctuations were ‘missed’ most
likely due to the HR difference not being a significant enough deviation from the u3
reference value, although differences can be seen in the mitochondrial state. Most
importantly, BG was much higher than could be expected from an energetic model
that emphasized glucose consumption during exercise. An additional hormonal
input, uHM, scaled by a stressor ratio is proposed in Chapter 4, particularly on the
basis of circuit training and anaerobic results. Upon first iteration of Figure 4.11,
circuit training appeared to have a similar Schunk-Winters simulation response as
to sprint training. The two exercise types are similar in concept (high intensity with
bouts of rest), but not in terms of anaerobic vs. aerobic basis. Hence, stressorrat, a
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parameter formed to scale added stress other than only HR fluctuation, was
implemented for the circuit training simulation of Figure 4.11b by increasing the
rate at which glucose leaves xg from xnm via the GLUT2 flux pathway in a
multiplicative manner with uHM. Greft and Kg2Max also have an effect due to
increased sensitivity (Table 3.13) and as parameters involved in the GLUT2 Hill
functional. Stressorrat works to inform exercise of additional catecholamine action
(and general sympathetic neural system drive) that may be present and to generate
an added flux of glucose. Figure 4.11 now shows improved results, similar to that
predicted by CGM clinical data. This input and parameter will be used for future
exercise interactions involving HR fluctuation characterized by both aerobic and
anaerobic componentry that cannot be predicted by HR-informed u3 alone.
In the 24-hour Phase 2 case study CGM output and model
simulation/replication (Figure 4.12), the effects of insulin due to assumption that
the subject produces ~20% (and takes the rest via injection) are dominant. The
model is a strong predictor in regard to magnitude and steady-state, as well as for
exercise (circuit training is shown in the example). The model predicts meal
magnitude and the ‘drop’ overnight in BG (both start at the same time). As in
Chapter 3, it is recognized that insulin control is a bit faster than seen in CGM data
and some literature sources, however trends remain consistent. Other confounding
factors, such as exact GI, etc. could be source of error/limitation to the model.
Due to a bit of uncertainty in regard to ratType1i (i.e. how much insulin
production remaining for a T1D is often guesswork based on daily insulin amount
required), sensitivity analysis was performed. It is clear this parameter is sensitive,
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making it an important model input. Other sensitive parameters include glucagon
control, exercise-based muscle gradient, and basal metabolism parameters.
Sections 4.3.2 and 4.6 and Table 4.8 solidify the model’s ability to predict BG in
a personalized and adaptive manner. These parameters refer to those that can be
changed with emphasis on an athlete, while the inputs are also key in regard to
exercise type, intensity, duration, and HR which furthers model capabilities
compared to current BG predictive modeling techniques. Figure 4.9 demonstrates
the ability to adjust the amount of maximum fat consumption and its effect on
glucose consumption input to the model—an important adjustment for trained
individuals with higher fat oxidation capacity. This idea explains why long distance
endurance athletes tend to avoid severe cases of hypoglycemia as there is less
reliance on BG for energy when fat can be used as a primary substrate during
moderate intensity (i.e. 500 kcal/hr) for an extended period of time as seen in
Protocol Day 8 CGM data (Figure 4.10). BG declines at the onset of a 2.5 hour
running session, but tends to steady at around 75 mg/dl without any risk of
hypoglycemia, assuming the subject is well-fed and maintains moderate intensity
(i.e. does not start sprinting and elevating HR).
Figure 4.15 of Section 4.6 provides a key insight and summary of the purpose
behind model personalization. Although the exercise session is small and meals are
quite larger than normal for the simulated subject, it can be seen that even on an
‘unhealthy’ day, our model predicts that a trained individual demonstrates higher
basal metabolism, higher aerobic capacity and potential for mitochondrial state
consumption, and an overall more lifestyle-based and robust model.
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As a result of personal experience, interactions with diabetes support and
educational groups, endocrinologist’s experience, and speaking with other elite
athletes living with T1D, it is clear that adaptations and BG trends/management
differ from many other T1D. Elite T1D athletes must use trial and error to predict
BG and know what intensities/sports have the most drastic effect. In the future, a
personalized model such as described here, augmented with adaptive learning
algorithms to continually improve the personalized parameters, could work as a
sort of “personal assistant” that provides ever-improving predictions that can help
inform the athlete.
The Schunk-Winters model is not limited to athlete personalization—other
parameters, such as GLUT2 gradient, tissue intolerance, and mass ratios can be
adjusted for T2D implications and predictive of a more sedentary lifestyle.
Additional applications involving conversion of excess glucose will be discussed in
Chapter 5.
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5. CONCLUSION AND FUTURE DIRECTIONS
Chapter 3, the general Schunk-Winters model, is intended for both research
and clinical use, particularly diabetes educators, and to develop medical device
technologies in order to eliminate guesswork of bolus corrections, often in error due
to unknown food GI or exercise effects. This may help people with diabetes manage
BG with exercise, diet, and dual-hormonal control based on algorithm feedback.
Chapter 3 provides a model that can take a wider variety of lifestyle inputs than
most CGM and artificial pancreas designs, enhancing where BG is headed before it
occurs. For example, a device working under the Schunk-Winters default model
would inform a person eating a 50g low GI meal vs. a 50g high GI meal differently,
and furthermore make different predictions based on different consumption times
for the same meal content. It can then be used to inform a person or an artificial
pancreas algorithm to adjust any insulin bolus given—other models do not do this
and hypoglycemia may occur in the low GI and slow consumption case, if the same
insulin amount is taken for both high and low GI of the same CHO amount.
As discussed in Section 3.4.7, additional hormonal controllers may provide
increased control in addition to strictly glucagon and insulin. Oftentimes, gradients
of glucose to blood plasma exist, without means of foodstuff ingestion, etc.
Additional hormone control could be categorized into 3 cases: 1) real-time rate
controlling for both digestive rates (i.e. slow path) and glucagon tissue effects
during periods of high BG, in particular slowing down glucose delivery fluxes
(operating somewhat in tandem with insulin, e.g. similar to the role of amylin
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hormone), 2) real-time ‘anticipatory’ for sympathetic nervous system “stress”
effects, and 3) longer-term adaptive adjustments for energy storage.
The real-time anticipatory hormonal state would aid in quantizing stress
hormones (catecholamine’s such as epinephrine) and would most likely be a
function of the GLUT2 non-muscle demand gradient, HR or other stress predictor.
This concept was initiated in Sections 3.4.7 and a base implementation for this
hormone, with additional input uHM and parameter stressorrat, acts as a multiplier
of the GLUT2 bi-directional gradient for BG and non-muscle-tissue. With further
tuning and other multiplying factors, the model now has capability of modeling
inputted events that have an effect on BG other than foodstuff intake, activity, and
exercise.
The third class is illuminated by 24-hour plus simulations and would be
‘slow’ due to excessive tissue glycogen buildup over time (e.g., over days, weeks,
months) – an effect that can be highlighted in the present model because of
framework glucose conservation. A steady state value at the end of a 24-hour day
that is consistently higher than the initial value (which already may be high based on
a previously simulated day) would indicate need for adaptive processes for dealing
with excess glucose. This would involve characteristics similar to the hormone
leptin, and would play a key role in the transport of excess glucose build up and
tissue intolerance overtime, converting to fat (i.e. transport to the proposed fat
compartment from BG). Such longer-term effects are especially relevant to study of
the etiology of T2D.
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Chapter 3 demonstrated that with proper modeling, there are in fact
limitations with current device design, as with the initial GI example. This same idea
can be applied to exercise, as indicated by the need of implementing uHM. For
example, if a diabetic wearing a dual-hormonal controlled artificial pancreas begins
high intensity exercise, a BG spike, or hyperglycemia, may occur. A device that does
not account for exercise would provide insulin on the basis of elevated BG, which
should not occur—a phenomenon known as a ‘false high’ to most diabetes
educators. They recognize BG will most likely drop after exercise and that a
corrective bolus should not be taken. However, if the educator is not present, a
device should have this capability, as modeled in Chapter 3.
This was the motivation behind Chapter 4, which takes an important step
towards extending the default BG regulation model of Chapter 3. By expanding
personal input parameters and mechanisms such as ability to take external HR data
and distinctions between exercise types, a ‘library’ of adaptive models can be
formed. One example was shown in comparing the personalized model to the
default in Section 4.6. By expanding a subject base, a majority of these curves could
be built for different lifestyles. Once developed, as a form of adaptive learning, a
particular user profile would drive overall trends and baselines with instantaneous
inputs (i.e. meal GI, stress, and/or exercise) affecting immediate BG. Long-term,
basal metabolism adjustment parameters play a role.
As discussed throughout Chapter 4, glucose and its conservation throughout
the human body can, in most cases, single-handedly provide energy for human
organ function and all processes. However, fat and protein are also key, with fat
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breakdown as another energy source, along with fatty acid and protein
supplementation. This can also affect the digestive state absorption parameters and
fuel mix in regard to exercise. Although not a state in the model, fat consumption is
subtracted off of total glucose exercise consumption and is increased in a trained
individual. However, the addition of a ‘fat’ associated compartment and state could
improve model capabilities and actually be modeled in conjunction with glucose
consumption during exercise—i.e. completely quantifying ‘fuel-mix’ which occurs
throughout daily activity, and especially with moderate intensity exercise. On the
other hand, a fat compartment could provide a means of storage for excess glucose,
thereby overcoming two model limitations: 1) fat buildup overtime and increase in
BW and steady-state levels, as well as 2) a more personalized ‘T2D’ or ‘unhealthy’
lifestyle model.
An aim of the Schunk-Winters model is to take real-time glucose monitoring
and experience from a T1D and aide in algorithm development for predictive
modeling and artificial pancreas design in the future. Many opportunities exist to
better improve current models, as most lack adaptation to athletes. As it stands,
many elite T1D athletes are forced to learn by trial and error or through community
advice, instead of relying on expensive medical devices which should provide this
capability. Additionally, trends can be sport dependent. For example, T1D triathletes
must take a separate approach for each sport in a multi-hour race. It is often noted
in blog posts, etc. that one endurance sport can have vastly different BG response;
for example, a runner who is swimming (i.e. their ‘weaker’ sport) would have a
different uHM response during this portion than a practiced swimmer might. Other
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factors also must be taken into account, such as body composition, fuel intake, and
intensity. For this reason, programs such as the Diabetes Sports Project exist so as to
better inform the diabetic population on BG effects and the difficulty in management
during endurance sports of varying intensities, especially for those that are
beginners (DSP, 2015). An algorithm such as the Schunk-Winters personalized
model would be of interest so as to quantify effects and trends before they occur,
thereby preventing trial and error.
Future versions could also involve the use of a Simulink (Matlab software
extension) ‘artificial pancreas’ framework, as has been used throughout classroom
design competitions. Future iterations and simulations could gain interactive insight
from this Simulink framework, as it takes a multitude of inputs ranging from
digestive foodstuff (and future GI additions), exercise, and body parameters. The
ability for an interactive environment provides more efficient model
personalization, as well as potential to be incorporated into a medical device.
Theoretically, algorithms such as those in Chapter 4 could also have market
value for general, non-diabetic athletic performance. Algorithms would better
inform performance, characterizing and predicting when one’s blood glucose may
be elevated, or, more importantly, when tissue is becoming depleted—therefore,
proper timing for sports performance aides such as gels, drinks, etc. would be better
informed. Chapter 3 demonstrates the importance of knowledge behind glycemic
index control, as well as insulin type. Integrated into Chapter 4, modeling can
inspire and inform sports performance for T1D athletes, as well as T2D beginning an
exercise program, and potentially for non-diabetic population enhancement.
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7. APPENDICES
7.1 Model Parameters

Parameter

Value (default)

Literature Explanation

Units

Body Mass; for 70 Kg, muscle ~30, fat~15, brain ~1.3, liver ~1.4, blood plasma~3, RBC’s
~2.2
Body mass of muscle for normalizing f2
Body mass of non-muscle for normalizing f3 (brain, liver, etc.)
Ratio of body mass to the default 70 Kg for scaling purposes
Ratio for muscle relative to default value of 30 Kg
Ratio for non-muscle relative to default value of 35 Kg
Proportion of muscle mass that is mitochondria
Mass of mitochondria
Added stressor value for hormonal action, uHM; default of 1.0
Proportion of glucose consumption (activity) that reaches mitochondria
If Type 1, ratio of insulin still produced by beta cells; 1.0 = normal
If Type 1, ratio of glucagon still produced; 1.0 = normal
If type 2, ratio of insulin resistance
Insulin Elimination Rate
Basal tissue elimination rate, scaled to grams
Non-Muscle Uptake (e.g. liver) without insulin signal
Reference threshold of blood glucose in mg/dl for insulin control action; normal blood
glucose is 80-120 and is cited in many sources
Reference threshold of blood glucose for glucagon control action
Reference threshold of blood glucose for non-muscle flux direction (due to GLUT2)
Maximum rate associated with non-muscle GLUT2 flux
Reference threshold for non-muscle tissue in mg/dl—estimated from J. Nielson’s study
before and after aerobic exercise

Kg

Glucose Compartmental Flow
bm

Varies (70)

wmu
wnm
ratBM
ratMUSC
ratNONM
ratmito
wmito
Stressrat
kprop
ratType1i
ratType1g
ratType2i
Ki
Kgt
Knm_up
Grefi

Varies (30)
Varies (25)
bm/70
wmu/30
wnm/35
Varies (0.1)
ratmito*wmu
Varies (1.0)
0.2
Varies
Varies
Varies
3.0
1.0*0.287
1.0
70

Grefg
Greft
Kg2Max
Ktintol

110
90
6.0
12.0*ratNONM

Kg
Kg
None
None
None
None
Kg
None
None
Decimal %
Decimal %
Decimal %
/hour
/hour
/hour
mg/dl
mg/dl
mg/dl
/hr
mg/dl
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Kmintol
Kbr**

14.0*ratMUSC
((20/4(*ratNONM))

Reference threshold for muscle tissue
Blood glucose to steady consumption sink, no storage (mostly brain, also erythrocytes)

Metab
Gbt**

Varies (1.0)
Metab*(10/4)*ratNONM

Gbm**
Kbd
wratm

Metab*(6/4)*ratMUSC
8*ratBM
(1/drat)/wmu

Wratt

(1/drat)/wnm

Gratm

0.01*wmu

Metabolism scaling; fit individuals range from 1.0-1.5 with default of 1.0
Basal elimination rate to non-muscle tissue scaled by amount of non-muscle tissue due to
metabolism (but not brain)
Basal metabolic elimination rate to muscle tissue scaled by amount of muscle tissue
Ratio of volume of blood plasma to volume of non-muscle tissue
Scaling from glucose blood concentration (mg/dl) to glucose muscle tissue amount in grams,
normal to mass of segment (g/Kg of muscle)
Scaling from glucose blood concentration (mg/dl) to glucose non-muscle tissue amount in
grams, normal to mass of segment (g/Kg of non-muscle)
Blood-Muscle Glucose Gradient (e.g. exercise demand)

mg/dl
Kcal/hr/4
= g/hr
None
g/hr
g/hr
(mg/dl)/g
(g/kg)/(m
g/dl)
(g/kg)/(m
g/dl)
mg/dl

Glucose Controllers
Cinm
Cim
Cgnm
Cgm
Kid
Insulindel
Kg
Kugf
Kugs
Kui
Kgc
rat_ia
kai
Ka2
Ka1
Kd

0.3
0.4
0.4*0.287*100
0.001*0.287*100
0.04
0.15
0.4
5.0/ratBM
0.3/ratBM
1.0/ratBM
8
0.5 (varies)
0.02*60
rat_ia*kai
(1-rat_ia)*kai
10*0.0164*60

Insulin Control Parameter, Non-Muscle Tissue; gain
Insulin Control Parameter, Muscle Tissue; gain
Glucagon Control Parameter, Non-Muscle Tissue scaled to pg/dl
Glucagon Control Parameter, Muscle Tissue scaled to pg/dl
Derivative, d-action parameter
Delay of insulin action
P-Action for glucagon, from Cobelli
Forward rate (1/tau) of bolus (glucose-fast)
Forward rate of bolus (glucose-slow)
Forward rate of bolus (insulin)
Glucagon Addition Rate
Ratio of non-monomeric: to monomeric (slow:fast) insulin absorption paths
Scaling for base rate constant (estimated from Cobelli, 2007)
Rate constant of monomeric insulin absorption
Rate constant of non-monomeric insulin absorption
Rate constant of insulin dissociation

None
None
Pg/dl
Pg/dl
None
Hours
/hour
1/tau
1/tau
1/tau
/hour
None

Conversion of digestive mass flow in grams into the blood
Forward rate of bolus for slow glucose path; estimated with Cobelli model
Carbohydrate scaling for dietary thermogenesis (normalized thermic effect of food)

mg/dl
1/tau

/hour
/hour
/hour

Glucose Forward Mass Flow
drat
Kuga
Kcarb

30
2.0
0.2
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Gugf
Gugs

0.98
0.88

Digestive effectiveness ratio, fast carbs
Digestive effectiveness ratio, slow carbs

Decimal %
Decimal %

Efficiency in performing physical work (typically 20-25%, higher for skilled tasks)
Maximum capacity mapped to aerobic/mitochondrial metrics
Intensity of exercise out of maximum aerobic capacity
Rate of delivery to muscle
Resting heart rate
Maximum heart rate

Decimal %
Kcal/hr
Kcal/hr
/hour
bpm
bpm

Exercise and Activity
WorkEff
AerCap
Intens
Kmusc
HRrest
HRmax

0.22 (varies)
1000 (varies)
Varies
20.0
Varies (60)
Varies (180)

Additional Hill Parameters
Kg2-Max
10.0
Maximum Saturation for Glut 2 Pathway (muscle)
ks-ex
40.0
Half-way value for muscle gradient
kmx-nm
1.0
Maximum Saturation for Non-Muscle Intolerance
Kmx-m
1.0
Maximum Saturation for Muscle Intolerance
ks-ds
5.0
Half-way value for slow digestive pathway (rising)
ks-ds2
10.0
Half-way value for slow digestive pathway (falling)
ks-d
5.0
Half-way value for fast digestive pathway (rising)
ks-d2
30.0
Half-way value for fast digestive pathway (falling)
ks-ins
12.0
Half-way value for endogenous insulin controller
ks-gn
2.0
Half-way value for endogenous glucagon controller
hs_max
45
Maximum saturation for exogenous insulin infusion controller (magnitude)
hs_ks
23
Half-way value for exogenous insulin infusion controller (magnitude)
Hs_rate
20
Maximum saturation for exogenous insulin infusion controller (rate)
**Add up to basal metabolism, e.g. Kbr+Gbt+G

1/tau
1/tau
1/tau
1/tau
1/tau
1/tau
1/tau
1/tau
1/tau
1/tau
1/tau
1/tau
1/tau
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7.2 Case Study Phase 1 Protocol
Case Study Control Protocola
Time
Wednesday Protocol (4 consecutive weeks)
7:00 AM
7:30 AM

10:30 AM

9:00 AM- 11:00 AM
12:30 PM

2:30 PM

4:15 PM

6:00-8:00 PM
8:30 PM

Totals

a BG

Wakeup
 4 Units of Fast-Acting Insulinf (breakfast)
Breakfast
 GI =52.6
 400 Calories
 55 g carbohydrates
Snack (No Insulin)
 GI = 70
 120 Calories
 50 g carbohydrates
Activity (soccer camp, walking, etc.)
Lunch (5 units fast-acting insulinf)
 30 min. maximum
 GI = 58
 560 Calories
 66 g carbohydrates
Exercise
 Long, moderate aerobic running workout for 1 hour at 800 kcal/hr
 Consistent distance (~8 miles)
Snack (No Insulin)
 GI = 20
 100 Calories
 15 g carbohydrates
Activity (beach volleyball…etc.)
 Higher than morning activity
Dinner (6 units fast-acting insulinf)
 GI = 35
 610 Calories
 65 g carbohydrates
 15 Units Fast-Acting Insulinf
 14 Units Long-Acting Insulinf
 1800 Calories
 220 g carbohydrates

was tested every 30 minutes upon waking, measured using a FDA approved glucose meter (OneTouch
Ultra Mini, LifeScan Inc., Wayne, PA).
bProtocol 1 is control as outlined above.
cProtocol 2: high GI dinner with 690 calories (constant), 103 g carbohydrates (constant), and GI = 70.
d Protocol 3: track interval anaerobic running workout at 1100 kcal/hr with timing and duration constant.
eProtocol 4: lunch and exercise timing, with exercise occurring prior to lunch (snacks occur in same suit).
f Insulin dosage calculated based on clinical prescription of 1 unit per 12 g of carbohydrates.
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7.3 Case Study Phase 2 Protocol
Dates: June 24-June 28, 2015, and July 5-July 9, 2015
IRB Approval: June 18, 2015
Simulation Day 1: ‘Non-Exercise’ Protocol 1 (Kotachev Morning Meal, Parillo
Low Glycemic)
 Date: Monday, June 24, 2015
 7:30 AM Breakfast: KOTACHEV, CGM Simulation (starting night before)
o 50 g CHO bolus with optimal insulin bolus
 Ensure Plus
o GI = 44
o Total Calories = 350
o Total Carbs = 50
o Insulin = 4 U (following about a 1:15g CHO ratio; may be adjusted
based on exercise)
 Fasting until ~ 1 PM to see full effects of meal
 1 PM Lunch
o 400 Calorie Meal A
 4 PM Snack (50 g CHO)
o Yamamoto, White Bread
o 50g CHO, 105 g portion size, GI = 76
 Dinner Meal Simulation Parillo Simulation-Starting BG: ~120 mg/dl
 See Excel Meal Substitute, Record time to replicate Day 5
o Replicating Low GI: Pasta (90 g), beans (70g), Tomato (300 g), tuna
fish (80g), olive oil(25g), apple(150g)
o Meal Sub: Brown Rice, Chicken, Black Beans, Tomato/Veggies, Red
Wine, Dark Chocolate
 Total Cals: 796
 Carbs: 102.4
 GI = 36
 Bedtime at around 11 PM, Blood glucose around 120 mg/dl
 RECORD GI, TOTAL CHO INTAKE, TOTAL CALORIES, INSULIN IN EXCEL
SPREADSHEET
Simulation Day 2: Exercise Protocol 1 (Aerobic Endurance Exercise)
 DATE: Thursday, June 25, 2015
 Wakeup 6 AM, adjust glucose levels accordingly
o Banana and/or granola bar, (15 g CHO typical)
 7 AM Run, <60 min. at moderate intensity continuously (~60% VO2max)
o Thursday AM running group
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o Characterize intensity based on HR and VO2max test results
9 AM Breakfast B (or equal amount)
o Banana and/or similar fruit (calories, GI, etc.)
 100 calories, 25 g CHO, GI = 60
 0 g fat, 0 g protein
o 2 eggs
 GI eggs = 0
 0 g CHO (eggs)
 8 g fat (eggs)
 8 g protein(eggs)
o Whole Wheat Toast (2 slices if eggs)1 TBS PB
 70 calories/slice
 Toast, 1 wheat slices, 1 g fat, 14 g CHO, ~ 2 g protein, GI = 60
 Peanut Butter = 105 calories, 8.5 g Fat, 3.5 g CHO, ~3.5 g
protein, GI = 14
o GI = 57.1
o Total Calories = 485 (eggs and toast)
o Total Carbs = 56.5 (eggs and toast)
o Insulin = 4 U (following about a 1:15g CHO ratio; may be adjusted
based on exercise)
Fasting until ~ 1 PM to see full effects of exercise + meal
1 PM Lunch (~400 kcal)
o 400 Cal Option A
3 PM: Keep blood glucose consistent around 110 mg/dl (could change
based on first day
4 PM Snack (50 g CHO)
o Yamamoto protocol
 Spaghetti, 50 g CHO portion (72.3g)
Dinner (timing flexibility)
o About 800 Calories to fulfill daily calorie, protein, fat, CHO quota.
Bedtime at around 11 PM, Blood glucose around 120 mg/dl

Simulation Day 3: Exercise Protocol 2 (Circuit Training)
 DATE: Friday, June 26
 Wakeup 6 AM, adjust glucose levels accordingly
o Banana and/or granola bar
 Circuit Training 7AM
o Work Capacity Circuit x 8
 100 Jump Rope, 20 Air Squats, 15 Push-Ups, 16 Step-Ups, 12
Burpees, 30 Full Sit-ups (1 round takes approx.. 3.5-4 minutes)
o This is routine to the subject and will be performed with a certified
strength and conditioning coach at Marquette University.
 9 AM Breakfast B
 Fasting until ~ 1 PM to see full effects of exercise + meal
 1 PM Lunch (~400 kcal)
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o 400 Calorie Dalla Man Protocol (1 x BW in CHO = ~63 g CHO)
3 PM: Keep blood glucose consistent around 110 mg/dl (could change
based on first day
4 PM Snack (50 g CHO)
o Yamamoto protocol
 Barley, 50g CHO, 79.6 g portion size
Dinner
o ~800 Calories or fulfill remaining nutritional goals
Bedtime at around 11 PM, Blood glucose around 120 mg/dl

Simulation Day 4: Exercise Protocol 3 (Long Aerobic Run)
 DATE: Saturday, June 27
 Wakeup 6 AM, adjust glucose levels accordingly
o Banana and/or granola bar, (15 g CHO typical)
 7 AM Run, ~1.5-2hr (or combined with ‘brick’ biking workout) at moderate
intensity continuously (~60% VO2max)
o Lake Park with Badgerland Striders (14 miles)—subject to change
o Characterize intensity based on HR and VO2max test results
o Snack if subject starts to experience hypoglycemia (<60 mg/dl), 15 g
CHO
 Breakfast B (or equal amount) post-exercise
 Fasting until ~ 1 PM to see full effects of exercise + meal
 1 PM Lunch (~400 kcal)
o 400 Cal Option A
 Afternoon/Nighttime (Flexible) Alcoholic Protocol Test
o 2-3 Alcoholic drinks recording CHO, timing, etc. This will be compared
to the effect of only one drink resulting as part of a separate protocol
day.
 Remaining 2 meals will be based on individual’s needs due to intense
morning exercise. It will be important to record differences in
choices/hunger effect of Days 4 and 8.
 Bedtime and ending blood glucose flexible, but important for recording.
Simulation Day 5: ‘Non-Exercise’ Protocol 3 (Dalla Man, 2007, Parillo High GI)
 DATE: Sunday, July 5
 7:30 AM Breakfast: KOTACHEV, CGM Simulation (starting night before)
o 50 g CHO bolus with optimal insulin bolus
 Ensure Plus
o GI = 44
o Total Calories = 350
o Total Carbs = 50
o Insulin = 4 U (following about a 1:15g CHO ratio; may be adjusted
based on exercise)
 Fasting until ~ 1 PM to see full effects of exercise + meal
 1 PM Lunch- Kotachev, 75 g CHO meal (will repeat Day 7)
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o Kotachev 75 g, 5 U insulin Simulation (~365 cal)
4 PM Snack (50 g CHO)
o Yamamoto, Pineapple Juice
72.3 g portion size, 0.5 pg, GI = 46
Meal Simulation #6: Parillo High Glycemic Index – Starting Glucose ~120
Same time as Day 1 Dinner Meal
See Excel Substitutes
o High GI: Rice, Artichoke, Tomato, Tuna Fish, White Bread, Banana
o Substitutions: White Rice, Chicken, Vegetables, Corn, ICEE from 711
Bedtime at around 11 PM, Blood glucose around 120 mg/dl

Simulation Day 6: Exercise Protocol 4 (Continuous Bike/Swim/Run <60 min.)
 DATE: Monday, July 6, 2015
 Wakeup 6 AM, adjust glucose levels accordingly
o Banana and/or granola bar, (15 g CHO typical)
 7 AM Workout, <60 min. at moderate intensity continuously (~60%
VO2max)
o Characterize intensity based on HR and VO2max test results
 9 AM Breakfast B
 Fasting until ~ 1 PM to see full effects of exercise + meal
 1 PM Lunch (~400 kcal)
o 400 Cal Option A or similar
 3 PM: Keep blood glucose consistent around 110 mg/dl (could change
based on first day
 4 PM Snack (50 g CHO)
 Dalla Man, UVA/PADOVA Model Simulation
 Protein bar, fulfilling 50 g CHO requirement
 Dinner (timing flexibility)
o About 800 Calories to fulfill daily calorie, protein, fat, CHO quota.
 Bedtime at around 11 PM, Blood glucose around 120 mg/dl
Simulation Day 7: Exercise Protocol 5(Sprint Intervals)
 Date: Tuesday, July 7
 Wakeup 6 AM, adjust glucose levels accordingly
o Banana and/or granola bar
 7AM Sprint Intervals, < 60 minutes
o Track workout consisting of high intensity (~80-90% VO2max)
intervals with full recovery in between
o 5x400’s (1:15-1:20)
o 8x200’s(35 seconds or faster)
 9 AM Breakfast B
 Fasting until ~ 1 PM to see full effects of exercise + meal
 1 PM Lunch (~400 kcal) –Repeated from Day 5
o Kotachev 75 g, 5 U insulin Simulation (~365 cal)
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3 PM: Keep blood glucose consistent around 110 mg/dl (could change
based on first day
4 PM Snack (50 g CHO)
 Yamamoto: Instant Potato, 50 g CHO, 67.3g
Dinner- typical to subject, record first day and keep somewhat consistent or
note variation
Bedtime at around 11 PM, Blood glucose around 120 mg/dl

Simulation Day 8: Exercise Protocol 6 (Fatigue Inducing Anaerobic ‘Brick’)
 Performed last, in case of any lingering soreness. DATE July 8, 2015
 Wakeup 6 AM, adjust glucose levels accordingly
o Banana and/or granola bar
 7 AM Anaerobic (Lifting) Exercise Session (Duration 105 Minutes)
o 4 sets of 8-10 seconds of heavy lifting exercise (last few repetitions
should be stopped due to muscle fatigue and glycolytic limitations)
 Set #1
 Squats (50 kg), Pull-Ups (with 20 lb weight vest)
 Set #2
 Deadlifts (80 kg), Seated Rows (120 lbs)
 Set #3
 Push Press (35 kg), Back Extensions (10 kg)
 Set #4
 Cable Twists (10 kg), Split Lunges (100 lb)
 Set #5
 Hip Thrusters (90 kg), Kettle Bell Russian Twists (35 lb)
o Significant rest between each set
 2-4 minutes
o Bike sprint (gear 20 for 20 seconds) and row machine (8 pulls, ~10
seconds) in between each set
 Breakfast B (same time as Day 4)
 Fasting until ~ 1 PM to see full effects of exercise + meal
 1 PM Lunch (~400 kcal)
o 400 Cal Option A
 Afternoon/Nighttime (Flexible) Alcoholic Protocol Test
o 2-3 Alcoholic drinks recording CHO, timing, etc. This will be compared
to the effect of only one drink resulting as part of a separate protocol
day.
 Remaining 2 meals will be based on individual’s needs due to intense
morning exercise. It will be important to record differences in
choices/hunger effect of Days 4 and 8.
 Bedtime and ending blood glucose flexible, but important for recording.
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7.4 Logbook and Results
Recorded by CGM (replaced every 7 days; takes 2 hours to replace):
o Blood glucose (1 sample every five minutes)
o TRENDS
o Calibration by finger prick every 12 hours
o Insulin amount and time stamp
o CHO amount and time stamp
o Exercise time and duration
o Also record HR with Garmin
Recorded in EXCEL spreadsheet
o Meals/Food
o GI, serving size, CHO, fat, protein
Summary Of Dates and Protocols Performed
Date
Main Protocol
Day 1: June 24 (Wed)
Day 2: June 25 (Thurs)
Day3: June 26 (Fri)
Day4: June 27 (Sat)
Day5: July 5 (Sun)

Non-Exercise
Aerobic < 60 min.
Circuit Training <60 min.
Intense Long Run/Brick
Non-Exercise

Day6: July 6 (Mon)
Day7: July 7 (Tues)
Day8: July 8 (Wed)

Swim (Flexible) < 60 min
Sprint Training < 60 min
Anaerobic Brick Workout

Other Important Notes
(Stress levels, etc.)
Minimal
Some midday
Yes- AM
Relaxing day
Some, driving to
Chicago
Stressful Working Day
Hard Workout
Fluxes of Stress

Approximate Caloric Intake Days 2, 3, 6, 7
Meal
Calories
CHO
Starting BG
(grams)
1
~500 (Exercise)/
50-56 g
100 + 5 (before exercise), 85 + 5
350 (Non-Exercise)
non-exercise
2
400 (+/-)
Varies
Dependent on protocol
3
200 (+/-)
50
120 mg/dl
4
800
Varies
Dependent on protocol
Total
1900
*On days 4 and 8, caloric intake will be expected to be higher and will be
documented accordingly.
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Meal Timing
Meal
1
2
3
4

Exercise Day
9 AM
1 PM
4 PM
Flexible

Non-Exercise
7:30 AM
1 PM
4 PM
Flexible

Day Before Simulation Day 1
Day Before Protocol Set (Date: June 23)
Total Calorie and
1915 Calories, 256 g CHO
Carbohydrate Intake
Exercise (Time/Intensity), Warmup strides, VO2max test
Activity Level
Blood Lactate Levels: 1.5 and 18.8 mmol/L (before
and after VO2max test)
Schlitz Mile: 5:07, ~ 3 miles total with warmup/cool-down
Food Logbook (and
Greek yogurt, 120 cal, 19 g CHO
Insulin intake), Dinner
GoLean 1 cup, 220 cal, 41 g
should be similar to what Peanut Butter, 1 TBS, 95 cal, 3 g
is typical for subject and
Coffee
kept consistent
Turkey Sandwich, 220 cal, 25 g CHO
throughout.
Pretzels, 220 Cal, 46 g CHO
NOTE: For KOTACHEV
Coconut Water, 90 cal
Simulation, starting at
Nature Valley Bar, 140 cal, 10 g
21:30, readings will need Chocolate Blueberries, 100 cal, 14 g
to be recorded
Riesen, 40 cal, 7 g
Banana, 100 cal, 23 g
Beer, 300 cal, 20 g
PB, 90 cal, 3 g
½ cup brown rice, 110 cal, 23 g
2 emergenc, 70 cal, 16 g
bell peppers/tomatoes, 50 cal, 5g
almond milk, 40 cal
Blood Glucose Level
Before Bed (mg/dL)

76

Simulation Day 1- Non- Exercise Protocol 1
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Description: Non-Exercise 1, Kotachev morning meal and Parillo Low GI
Protocol Day 1, Date: June 24 (Dexcom Studio, half of this day saved as 6/24/14)
Blood Glucose and Time of 7:30 AM Ensure Plus Nutritional- wakeup 7 AM (4
Wake-up, Breakfast
U insulin at 7:20); 6 grapes 5 AM (low BG)
Option
Lunch Notes
Insulin 10 min before with a few almonds; 4 U for
62 g; however only 70 mg/dl
3 PM Blood Glucose,
Yamamoto, White Bread ; 102—had a peach ~14 g
adjusting for 4 PM
total to get to 120 (NOTE: Insulin 4U) 5 min before;
Snack—Note this value
Before starting: BG 98 mg/dl (had to have a
and replicate
caramel at 4:45 since low!)
Food/Insulin/BG levels
before dinner protocol
and correction needed to
reach 120 mg/dl + 5
mg/dl

Grapes/cheese as snack to increase BG
Start at 116 mg/dl
Unfortunately a LATE dinner due to JDRF event
(8:50 PM insulin, 6 U), ate at 9:06 PM
NEW dinner window: 6:30 – 9 PM

Calibration Times and
Levels/ Status of CGM and
Sensor
Blood Glucose Level
Before Bed (mg/dL)
Total Daily Calorie, CHO,
Fat, Protein Intake, GI

Morning 7 AM, within 2 mg/dl; 8:30 PM, within 6
mg/dl

Meal 1

Meal 2

Meal 3

FOOD

GI

103
1965 Cal, 281 g CHO, 25 g Fat, 90 g Protein

Calories

Meal 4
SERVING
SIZE

CHO (g)

10 grapes

9

0.5

8.5

0.1

0.4

5.4

Fiber (g)

Available
CHO

PROTE
IN(g)

FAT (g)

LOAD

Grapes

60

34

Ensure Plus

44

350

1 bottle

50

0

50

11

13

22

Turkey
Bread ,2
slices

0

60

4 slices

4

0

4

1.5

7.625

0

60

140

2 slices

28

3

25

2

2.5

16.8

Spinach

0

25

1/2 cup

3.5

0.7

2.8

0.5

1.625

0

Pretzels

83

100

1 oz

22

0.9

21.1

0

3

18.26

Almonds

7

80

0.5 OZ

4.5

2

2.5

6.5

2.5

0.315

Peach
White
Bread

28

59

14

2.2

11.8

0.4

1.4

3.92

71

250

50

0

50

3

8

35.5

Brown Rice

65

220

1 peach
105g (~4
slices)
1 cup
cooked

46

3.5

42.5

2

4.5

29.9

Chicken

10

200

4 oz

10

0

10

3

33.25

1
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Black Beans
Tomato/
Carrots

40

105

1/2 cup

21

15

6

0

5.25

8.4

45

51

300 g

8.4

0.5

7.9

0.6

3.6

3.78

Red Wine
Dark
Chocolate

15

130

1 glass

5

0

5

0

0

0.75

40

90

2 pieces

12

1.5

10.5

6

1

4.8

Celery/PB

14

105

1 tbs

3.5

1

2.5

8.5

3.625

0.49

281.9

30.8

260.1

45

90.9

Totals

1965

Meal
Duration
Time (min)
GI
CHO
FracCarbs

Meal 1
1
44
50
0.57

Meal 2
10
64
62
0.61

Meal 3

Meal 4
5
71
50
0.8

15
59
102
.51

Wednesday, June 24,
2015
7:20 AM
7:30 AM
12:50 PM
1:00 PM

Insulin 4 units
Carbs 50 grams
Insulin 4 units
Carbs 62 grams

Tuesday, June 24, 2014
3:00 PM
8:52 PM
11:36 PM

Carbs 15 grams
Insulin 4 units
Insulin 12 units
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Simulation Day 2- Exercise Protocol 1
Description: Aerobic Endurance Exercise <60 minutes Running

Date: June 25 (6/25/14 In Dexcom Studio)
Blood Glucose at 6 AM,
97—Cascade Farms granola bar (and a few banana
Correction Needed to
chips)
reach 100 + 5 mg/dl
BG seemed slightly uncalibrated
Soreness and Fatigue
No—a bit fatigued during
Present?
HR Before Exercise
After Warmup: 130
Peak HR
Average HR
Training Zone
Post-Exercise Meal
BG at 1 PM lunch,
corrections needed?

180
162
3
Hot Shower 8:35; 4 U insulin at 8:50, breakfast at
9:00 AM; Low glucose alarm at 11:00 AM (was
actually 75)
4 U, 119 mg/dl, took a bit late @ 12:54; ate at 1:00
(1:04 so 10 min post-insulin)

3 PM Adjustment to get
BG to around 100 mg/dl
(consistent each week)

Was ~120, took 2 U and ate a peach
3:15—111 mg/dl, 3:55—92, 4 U 5 min before

4 PM 50 g CHO snack

Yamamoto, Spaghetti

Dinner Notes and Timing
(Note the flexibility here)

109 mg/dl (116 night prior); Insulin at 7:55, BG
was a bit higher since had some chocolate
(originally for dinner). however; started at similar
value to 6/24, took 5 U and ate at 8:00 PM

Calibration Times and
Levels/ Status of CGM and
Sensor

Was off around 3 PM (registered too low) so
calibrated

Total Daily Calorie, CHO,
Fat, Protein Intake, GI

1990 cal, 293 g CHO, 37 g Fat, 90 g Protein

Blood Glucose Level
Before Bed (mg/dL)

~116, steady, bed at 10:00
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Meal 1
FOOD
Cascade
Farms
Granola

Mea
l2

Meal 3

GI

Calories

Meal 4
SERVING
SIZE

CHO (g)

Fiber(g)

Available
CHO

FAT (g)

PROTEIN(g)

LOAD

30

90

1 bar

15

1

14

2.5

2

Banana

60

100

1 banana

25

3.1

21.9

0

0

15

Eggs
Bread ,2
slices
Peanut
Butter

0

140

2 eggs

0

0

0

8

12

0

60

140

2 slices

28

3

25

2

2.5

16.8

14

105

1 tbs

3.5

1

2.5

8.5

3.625

0.49

Grapes
Greek
Yogurt
Kash
GoLean

60

105

1 cup

28

0.5

27.5

0

0

16.8

33

140

15

0

15

0

12

4.95

55

142.5

3/4 cup

27

8

19

2.25

3.5625

14.85

Peach

28

59

1 peach

14

2.2

11.8

0.4

1.4

3.92

Spaghetti

41

270

72.3g

50

6

44

2

9

20.5

Chicken
Black
Beans
Bell
Peppers
Dark
Chocolate

10

200

4 oz

10

0

10

3

33.25

1

40

155

3/4 cup

30

20

10

0

7.875

12

45

50

300 g

8.4

0.5

7.9

0

0

3.78

40

90

2 pieces

12

1.5

10.5

10

0

4.8

Red Wine

15

130

5

0

5

0

0

0.75

Barley

25

1 glass
1/3 cup
uncooke
d

37

5

32

0.5

5

9.25

36.65

90.2125

TOTALS

160

1

1986.5

Meal
Duration
Time (min)
GI

292.9

Meal 1

Meal 2
6
65

Meal 3
8
60

Meal 4
6
47

15
42

170

171

Thursday, June 25, 2014
6:15 AM
9:00 AM
8:50 AM
12:54 PM
1:04 PM
3:00 PM
2:58 PM
8:02 PM
7:55 PM
7:00 AM
minutes)
9:47 PM

Carbs 15 grams
Carbs 56 grams
Insulin 4 units
Insulin 4 units
Carbs 67 grams
Carbs 14 grams
Insulin 2 units
Carbs 100 grams
Insulin 5 units
Tempo Run (50
Insulin 11 units

Simulation Day 3- Exercise Protocol 2
Description: Circuit Training at Al
Date: June 26 (Dexcom 6/26/14…Thursday)
Blood Glucose at 6 AM,
72, had granola bar (15g) and some berries; higher,
Correction Needed to
~135
reach 100 + 5 mg/dl
Soreness and Fatigue
No
Present?
HR Before Exercise
96 bpm
Peak HR
Average HR
Training Zone
Post-Exercise Meal

183 (spikes with circuits)
164
3
4 U at 8:50, had some low calorie Gatorade
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BG at 1 PM lunch,
corrections needed?

No—steady at 80; 4 U at 12:50, same lunch as 6/24

3 PM Adjustment to get
BG to around 120 mg/dl
(consistent each week)

~94 mg/dl, steady, no adjustments

4 PM 50 g CHO snack

Yamamoto, Barley

Dinner Notes and Timing
(Note the flexibility here)

Dinner earlier, during USA game—hungrier today
as well. 4 U at 7:10, dinner ~7:20, BG around 84
mg/dl

Calibration Times and
Levels/ Status of CGM and
Sensor

Had a low alarm at 5:30, maybe due to hot shower?
It was actually 67 (not <55); otherwise, daily
readings were accurate

Total Daily Calorie, CHO,
Fat, Protein Intake, GI

1950 cals, 270 g CHO, 45 g Fat, 28 g Protein

Blood Glucose Level
Before Bed (mg/dL)

116 mg/dl @ 10:45

Meal 1

Meal 2

Meal 3

Meal 4

FOOD
Cascade Farms
Granola

GI

Calories

SERVING SIZE

30

90

60
0

Bread ,2 slices
Peanut Butter

CHO (g)

Fiber(g)

Available
CHO

FAT (g)

PROTEIN
(g)
14

2.5

LOAD

1 bar

15

1

14

1

100

1 banana

25

3.1

21.9

0

0

15

140

2 eggs

0

0

0

8

12

0

60

140

2 slices

28

3

25

2

2.5

16.8

14

105

1 tbs

3.5

1

2.5

8.5

3.625

0.49

0

60

4 slices

4

0

4

1.5

7.625

0

60

140

2 slice

28

3

25

2

2.5

16.8

Spinach

0

25

1/2 cup

3.5

0.7

2.8

0.5

1.625

0

Pretzels

83

100

1 oz

22

0.9

21.1

0

3

18.26

Banana
Eggs

Turkey
Bread ,2 slices

Almonds
Barley
Dove Dark
Blueberries

7

80

0.5 OZ

4.5

2

2.5

6.5

2.5

0.315

25

215

79.6g

50

5

45

1

7

12.5

50

200

42g

28

2

26

10

2

14
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Black Beans

40

105

1/2 cup

21

15

6

0

5.25

8.4

Red Wine

15

130

1 glass

5

0

5

0

0

0.75

Chicken

10

200

4 oz

10

0

10

3

33.25

1

Corn Tortillas

52

120

2 tortillas

23

2

21

1.5

2

11.96

45.5

98.875

TOTALS

1950

Meal
Duration
Time (min)
GI

Meal 1

270.5

Meal 2
Meal 3
Meal 4
8
6
4
15
65.36437247 63.85379061 27.77777778 53.10294118
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Thursday, June 26, 2014
9:00 AM
6:15 AM
8:50 AM
7:02 AM
12:50 PM
1:00 PM
4:00 PM
3:55 PM
7:23 PM
7:15 PM

Carbs 56 grams
Carbs 15 grams
Insulin 4 units
Exercise Medium (40 minutes)
Insulin 4 units
Carbs 63 grams
Carbs 50 grams
Insulin 4 units
Carbs 85 grams
Insulin 4 units

Simulation Day 4- Exercise Protocol 2
Description: Fatigue-Inducing Long Aerobic Brick Workout
Date: June 27 (Long Run, 19 miles, 2 hr 30 minutes)
Blood Glucose at 6 AM,
72, had granola bar (same one) and handful banana
Correction Needed to
chips at 6:15; spiked to 144
reach 100 + 5 mg/dl
Soreness and Fatigue
Yes, back and arms, but did not affect running
Present?
HR Before Exercise
120
Peak HR
Average HR

165
150

175
Training Zone
Post-Exercise Meal

3
10:20, with insulin (4 U) at 10:10

BG at 1 PM lunch,
corrections needed?

2:20 lunch, steady @ 92, no corrections but only 3
U since walking/exercising

3 PM Adjustment to get
BG to around 120 mg/dl
(consistent each week)

N/A (Cappucino, no insulin before, at 2:00 before
lunch)

Dinner Notes and Timing
(Note the flexibility
here)/ Alcohol Protocol

Low BG around 5 PM, grapes and corona, no
insulin; Dinner at Belair—tortilla chips appetizer
(6:30), Insulin 4 U, 2 tacos—mahi mahi and Korean
beef each with 2 corn tortillas
Beers at Downer, Strawberry Margarita
2 Beers at bar after

Calibration Times and
Levels/ Status of CGM and
Sensor

Well Calibrated; left CGM in car from 11:50-12:20

Total Daily Calorie, CHO,
Fat, Protein Intake, GI

2700 Calories, 321 g CHO, 52 g Fat, 97 g Protein

Blood Glucose Level
Before Bed (mg/dL)

150 mg/dl @ midnight

Meal 1

Meal 2

Meal 3

FOOD
Cascade Farms
Granola

GI

Calories

Meal 4
SERVING
SIZE

CHO (g)

Fiber(g)

Available
CHO

FAT (g)

PROTEIN(g)

LOAD

30

90

1 bar

15

1

14

1

14

Almond Milk

0

80

1 Cup

4

1

3

2.5

2

Watermelon

72

50

10

1

9

0

1

7.2

Banana

60

100

1 banana

25

3.1

21.9

0

0

15

0

140

2 eggs

0

0

0

8

12

0

Bread ,2 slices

60

140

2 slices

28

3

25

2

2.5

16.8

Peanut Butter

14

160

1.5 tbs

5

1

4

12.5

7

0.7

Cappuccino

25

100

12 oz

12

0

12

4

8

3

Grapes

60

105

1 cup

28

0.5

27.5

0

0

16.8

Greek Yogurt

33

140

15

0

15

0

12

4.95

Kash GoLean

55

142.5

27

8

19

2.25

3.5625

14.85

Eggs

1
3/4 cup

2.5
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VegaOne
Protein

90

23.3 g

4

0

0

0

15

0

Grapes

60

105

1 cup

28

0.5

27.5

0

0

16.8

Corona light

15

105

12 0z

5

0

5

0

0

0.75

Margarita

45

160

1 glass

15

0

15

0

0

6.75

Belair Tacos

52

450

2 tacos

40

2

38

15

20

20.8

Tortilla Chips

55

200

20 chips

40

1

39

5

0

22

Fat Tire

20

320

24 0z

20

0

20

0

0

4

321

22.1

294.9

52.25

97.0625

TOTALS

2677.5

Meal
Duration
Time (min)
GI

Meal 1

Meal 2
6
65

Meal 3
10
60

Meal 4
20
51.8556701

177

178

Friday, June 27, 2014
6:15 AM
9:53 AM
7:00 AM
10:08 AM
10:25 AM
2:07 PM
2:20 PM
6:30 PM
6:20 PM
5:17 PM
7:36 PM
8:43 PM
9:16 PM
11:30 PM

Carbs 15 grams
Carbs 10 grams
Exercise Light (150 minutes)
Insulin 4 units
Carbs 56 grams
Insulin 3 units
Carbs 60 grams
Carbs 77 grams
Insulin 4 units
Carbs 15 grams
Carbs 10 grams
Carbs 10 grams
Carbs 10 grams
Insulin 11 units
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Day Before Simulation Day 5
Date: July 4
Total Calorie and
2630 cals, 299 g CHO
Carbohydrate Intake
Exercise (Time/Intensity), 6 miles easy run with Lauren and Megan, low
Activity Level
intensity

Food Logbook (and
Insulin intake), Dinner
should be similar to what
is typical for subject and
kept consistent
throughout.
NOTE: For KOTACHEV
Simulation, starting at
21:30, readings will need
to be recorded

PB (2 Tbs), 190 cals, 4 CHO
Pretzels, 200 cals, 25 g CHO
GoLean 190 cals, 40 g CHO
Shrimp/Smoked Salmon, 200 cals,
Chicken Noodle Soup, 140 cals, 20g
Sourdough Bread, 210 cals, 43 g
4 Chocolates, 210, 21 g
Banana, 100, 15
Bloody Mary, 120, 4 g
Wine, 120, 2 g
Chips/guac, 280 cals, 40 g
Cake (small), 200 cals, 30 g
Coors Light, 200 cals, 8 g
Chicken Tenders, 170, 14 g
Quinoa, 100, 15 g

Blood Glucose Level
Before Bed (mg/dL)

126

Simulation Day 5- Non- Exercise Protocol 2
Description: Non-Exercise 1, Kotachev morning meal and Parillo High GI
Date: July 5
Blood Glucose and Time of
Wake-up, Breakfast
Option
Lunch Notes

7:30 AM Ensure Plus Nutritional (late night before,
had some snacks); 187—high! slight exercise to
~80
In car driving, 4 Units, 12:50, 75 g Kotachev (added
turkey)
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3 PM Blood Glucose,
adjusting for 4 PM
Snack—Replicate Day 1
Value

Yamamoto, Pineapple Juice
Somewhat up in the air BG
At 3 PM—115 to 125
Fresh (premium brand) 100% juice

Food/Insulin/BG levels
before dinner protocol
and correction needed to
reach 120 mg/dl + 5
mg/dl
Calibration Times and
Levels/ Status of CGM and
Sensor
Blood Glucose Level
Before Bed (mg/dL)
Total Daily Calorie, CHO,
Fat, Protein Intake, GI

Went low at 5:45, had a bit of juice, rose to 81
Insulin, 6 U (consistent with Day 1) at 7:50 PM
Dinner at 8:00 PM (Parillo High Glycemic)
Low at 9:30—pretzels and PB

Meal 1

Meal 2

Meal 3

FOOD

GI

Calories

Ensure Plus

44

350

Banana
Yoplait
Strawberry

60

100

35

170

Cheese

0

Turkey
Kashi
GoLean
Crunch

Meal 4
SERVING
SIZE

~120, rose with grapes, pretzels
2016 cals, 296 CHO, 49.6 g fat, 50 g protein

CHO (g)

Fiber (g)

Available
CHO (g)

FAT (g)

PROTEIN
(g)

LOAD

50

0

50

11

13

22

25

3.1

21.9

0

0

15

6oz

33

0

33

1.5

-28.125

11.55

110

1/3 cup

0.5

0

0

9

7

0

0

60

4 slices

4

0

4

1.5

7.625

0

55

95

1/2 cup

18

6

12

1.5

-10.875

9.9

Tortilla Chips
Pineapple
Juice
White Rice,
Instant

55

100

8 chips

25

1

24

5

0

13.75

46

160

72.3 g

50

89

200

1 cup

40

2

38

3

4

35.6

Chicken
Tomato/Veg
gies

10

300

6 oz

0

0

0

14

43.5

0

27

51

300g

8.4

3

5.4

0.6

3.6

2.268

Corn
Chobani
Tube

60

120

5.5v oz

28

12

16

0.5

0.875

16.8

85

100

2 tubes

15

0

15

2

10

12.75

Pretzels

83

100

1 oz

22

0.9

21.1

0

3

18.26

318.9

28

290.4

49.6

53.6

TOTALS

2016

1 bottle

Within Range

50

23
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Meal
Duration
Time (min)
GI
CHO (g)
FracCarbs

Meal 1

Meal 2
1
5
44 51.41043724

Meal 3

Meal 4
3
15
46 90.6155914
91.4
47.4

Sunday, July 5, 2015
7:20 AM
Insulin 4 units
6:30 AM
Exercise Light
(30 minutes)
7:30 AM
Carbs 50 grams
12:50 PM
Insulin 4 units
1:00 PM
Carbs 75 grams
7:50 PM
Insulin 6 units
8:00 PM
Carbs 100 grams
10:18 PM
Insulin 11 units

Simulation Day 6- Exercise Protocol 4
Description: Continuous Bike/Swim/Run <60 min

Date: July 6 (Bike 10 mi, Run 2 mi..45 minutes total)
Blood Glucose at 6 AM,
84, half of a granola bar; 115 at 6:40
Correction Needed to
reach 100 + 5 mg/dl
Soreness and Fatigue
No
Present? Exercise Chosen
HR Before Exercise**
119
Peak HR
Average HR
Training Zone

~150? (HR monitor died, used app on phone)
143
2

Post-Exercise Meal

BG slightly rising, 4 U insulin at 8:50

BG at 1 PM lunch,
corrections needed?

~125, consistent from breakfast, 4 units
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3 PM Adjustment to get
BG to around 120 mg/dl
(consistent each week)

~75, checked late (3:55—4 U insulin)

4 PM 50 g CHO snack

Dalla Man, UVA/PADOVA (Protein/ Granola Bar)
Low at 5:45, 10 g CHO (pretzels)
Insulin, 5 U at 7:05
Dinner @7:15 PM

Dinner Notes and Timing
(Note the flexibility here)

Calibration Times and
12 mg/dl, low during morning calibration
Levels/ Status of CGM and
Sensor
Total Daily Calorie, CHO,
~2000 (1940), 261 g CHO, 51 g fat, 108 g Protein
Fat, Protein Intake, GI
Blood Glucose Level
Before Bed (mg/dL)

125 mg/dl

**NOTE: Exercise was redone in order to get HR data

Meal 1

Meal 2

Meal 3

FOOD
Fiber One
Protein

GI

Calories

Meal 4
SERVING
SIZE

CHO (g)

Fiber (g)

Available
CHO (g)

FAT (g)

PROTEIN
(g)

LOAD

30

120

1 bar

17

5

12

6

6

5.1

Banana

60

100

1 banana

25

3.1

21.9

0

0

15

Eggs
Bread ,2
slices
Peanut
Butter

0

140

2 eggs

0

0

0

8

12

0

60

140

2 slices

28

3

25

2

2.5

16.8

14

105

1 tbs

3.5

1

2.5

8.5

3.625

0.49

Grapes
Greek
Yogurt
Kashi
GoLean
Luna
Protein
Bar

60

105

1 cup

28

0.5

27.5

0

0

16.8

33

140

1

15

0

15

0

12

4.95

55

142.5

3/4 cup

27

8

19

2.25

3.5625

14.85

33

350

2 Bars

48

7

41

11

21

15.84

Quinoa

53

174.75

3/4 cup

35

4

31

4

8

18.55

Chicken
Bell
Peppers

10

200

4 oz

10

0

10

3

33.25

1

27

50

300g

8.4

3

5.4

0.6

3.6

2.268

7

80

0.5 OZ

4.5

2

2.5

6.5

2.5

0.315

40

90

2 pieces

12

1.5

10.5

10

0

4.8

Almonds
Dark
Chocolate

183
TOTALS

1937.25

Meal
Duration
Time (min)
GI

Meal 1

261.4

38.1

223.3

51.85

108.0375

Meal 2
Meal 3
Meal 4
1
6
12
20
65.36437247 59.51219512
33 45.34175084

184

185

Monday, July 6, 2015
6:11 AM
Carbs 15 grams
8:50 AM
Insulin 4 units
9:00 AM
Carbs 57 grams
12:50 PM
Insulin 4 units
5:54 PM
Carbs 10 grams
4:00 PM
Carbs 50 grams
3:55 PM
Insulin 4 units
7:00 AM
Exercise Medium
(45 minutes)

Simulation Day 7- Non- Exercise Protocol 5
Description: Sprint Intervals at Track

Date: July 7 (4x400’s, 4x200’s, 1x400, 1x200, 4x100’s)
Blood Glucose at 6 AM,
Low, ~60, had 18 g granola bar at 6:00 (earlier than
Correction Needed to
other days)
reach 100 + 5 mg/dl
Soreness and Fatigue
Some but didn’t affect exercise
Present?
HR Before Exercise
130 after warmup
Peak HR

163

186
Average HR
Training Zone
Post-Exercise Meal

182
3-4
High, took an extra unit, 5 U

BG at 1 PM lunch,
corrections needed?

Adjusted a bit with some berries to get ~96 (4 U)

3 PM Adjustment to get
BG to around 120 mg/dl
(consistent each week)

Took 2 units since at 140 mg/dl; dropped to ~118

4 PM 50 g CHO snack

Yamamoto, Instant Potato (4 U, 5 min before)

Dinner Notes and Timing
(Note the flexibility here)

Something came up; no dinner until 9:30 PM, 3 U
insulin, 58 g CHO

Calibration Times and
Levels/ Status of CGM and
Sensor

All seemed well calibrated

Total Daily Calorie, CHO,
Fat, Protein Intake, GI

2003 calories, 263 g CHO, 53 g fat, 58 g Protein

Blood Glucose Level
Before Bed (mg/dL)

120

Meal 1

Meal 2

Meal 3

FOOD
Fiber One
Protein

GI

Calories

Banana
Eggs
Bread ,2
slices
Peanut
Butter
Grapes/
Berries
Yoplait
Strawberr
y

Meal 4
SERVING
SIZE

CHO (g)

Fiber (g)

Available
CHO (g)

PROTEIN(
g)

FAT (g)

LOAD

30

120

1 bar

17

5

12

6

6

5.1

60

100

1 banana

25

3.1

21.9

0

0

15

0

140

2 eggs

0

0

0

8

12

0

60

140

2 slices

28

3

25

2

2.5

16.8

14

105

1 tbs

3.5

1

2.5

8.5

3.625

0.49

60

105

1 cup

28

0.5

27.5

0

0

16.8

35

170

6oz

33

0

33

1.5

-28.125

11.55

Cheese

0

110

1/3 cup

0.5

0

0

9

7

0

Turkey

0

60

4 slices

4

0

4

1.5

7.625

0

187
Kashi
GoLean
Crunch
Instant
Potato

55

95

83

333.6

Quinoa

53

174.75

Chicken
Bell
Peppers

10

Red Wine
TOTALS

1/2 cup

18

6

12

1.5

-10.875

9.9

67.3 g

50

3

47

12.6

5.56

41.5

3/4 cup

35

4

31

4

8

18.55

200

4 oz

10

0

10

3

33.25

1

27

50

300g

8.4

3

5.4

0.6

3.6

2.268

15

130
2033.35

5
265.4

0
28.6

5
236.3

0
58.2

0
50.16

0.75

Meal
Duration
Time (min)
GI

1 glass

Meal 1
1
65.36437247

Meal 2

Meal 3
10
50

Meal 4
6
15
83 43.90661479

188

189
Tuesday, July 7, 2015
9:00 AM
8:50 AM
1:00 PM
12:25 PM
12:50 PM
3:55 PM
4:00 PM
9:38 PM
9:30 PM
7:00 AM
11:41 PM

Carbs 57 grams
Insulin 5 units
Carbs 75 grams
Carbs 10 grams
Insulin 5 units
Insulin 4 units
Carbs 50 grams
Carbs 50 grams
Insulin 4 units
Exercise Heavy (45 minutes)
Insulin 11 units

Simulation Day 8- Exercise Protocol 6
Description: Long Anaerobic Fatigue-Inducing Brick Workout

Date: July 8
Blood Glucose at 6 AM,
Correction Needed to
reach 100 + 5 mg/dl
Soreness and Fatigue
Present?
HR Before Exercise

72, ate Fiber One Bar (15 g CHO)
Yes, some
120 after jogging

Peak HR
Average HR
Training Zone
Post-Exercise Meal

169
126
1-2
A Couple of snacks (nuts, pretzels) right after; had
meal, 4 U, similar breakfast

BG at 1 PM lunch,
corrections needed?
3 PM Adjustment to get
BG to around 120 mg/dl
(consistent each week)

Snacked on half a bagel then had meal (~1:00
snack, 1:45 meal)
N/A

Dinner Notes and Timing
(Note the flexibility
here)/ Alcohol
Protocol/Hot
Environment

Chicken and Broccoli, 3 Units
Chips at 5:00 PM
3 glasses wine between 7:00-9:00
Chocolate

190
Calibration Times and
Levels/ Status of CGM and
Sensor

Off by >10 after exercise in the morning

Total Daily Calorie, CHO,
Fat, Protein Intake, GI

2209 cals, 274 g CHO, 47 g Fat, 94 g protein—more
hungry today!

Blood Glucose Level
Before Bed (mg/dL)

Had late snack, so ~105 but rising

Meal 1

Meal 2

Meal 3

FOOD
Fiber One
Protein

GI

Calories
30

Meal 4
SERVING
SIZE

120 1 bar

Available
CHO (g)

Fiber (g)

FAT (g)

PROTEIN(g)

LOAD

17

5

12

6

6

5.1

4.5

2

2.5

6.5

2.5

0.315

Almonds

7

Pretzels

83

100 1 oz

22

0.9

21.1

0

3

18.26

Banana

60

100 1 banana

25

3.1

21.9

0

0

15

Eggs
Bread,2
slices
Peanut
Butter
Coconut
Water
Semi-Sweet
Chocolate

80 0.5 OZ

CHO (g)

0

140 2 eggs

0

0

0

8

12

0

60

140 2 slices

28

3

25

2

2.5

16.8

14

160 1.5 tbs

5

1

4

12.5

7

0.7

90 16 oz

22

0

22

0

0

0

40

70 1 tbs

10

0

10

4

1

4

Grapes
Greek
Yogurt

60

200 2 cups

52

3

49

0

0

31.2

33

140

15

0

15

0

12

4.95

Turkey

0

60 4 slices

4

0

4

1.5

7.625

0

Broccoli

30

60 2 cups

12

3

9

0

0

3.6

Quinoa

53

174.75 3/4 cup

35

4

31

4

8

18.55

Chicken

10

10

0

10

3

33.25

1

Red Wine

15

200 4 oz
2.5
375 glasses

12.5

0

12.5

0

0

1.875

274

25

249

47.5

94.875

TOTALS

1

2209.75

Meal
Duration
Time (min)
GI

Meal 1
15
44.6

Meal 2

Meal 3
10 N/A
53.2

Meal 4
30
40.0

191

192
Wednesday, July 8, 2015
6:15 AM
7:03 AM
10:00 AM
9:50 AM

Carbs 14 grams
Exercise Heavy (105 minutes)
Carbs 50 grams
Insulin 4 units

193

7.5 DXA and VO2Max Data

194

195

196

197

Blood lactate level (mmol/l) at end of VO2max stress test. Lactic threshold was reached. Initial level
was 1.7 mmol/l.

Vo2 Max Stress Test: June 23, 2015
Schunk

Sofie

Date:
Program
Marquette
Milwaukee
Speed Ramp Test (0.5 miles/min) @ 1%
Grade
Test Duration

6/23/15
Exercise Science
University
WI

11 min 08 sec

198

VO2max (mL/kg/min)

62.65

Anaerobic Threshold Parameters
VO2 (ml/kg/min)
50.4
% VO2max
80.4
Speed @ 1% Grade (mph)
9-9.5
HR (BPM)
170
*Note: Entire RER Table and HR Values are Available

140
120

VE (L/min)

100
80

60
40
20
0
0

100

200

300

400

500

600

700

Time (s)

70
60

VO2 (mL/kg/min)

50
40
30
20
10
0
0

100

200

300

400

Time (s)

500

600

700

199

5
4.5
4

VCO2 (L/min)

3.5
3
2.5
2
1.5
1
0.5
0

0

0.5

1

1.5

2

2.5

VO2 (L/min)

3

3.5

4

4.5

7.6 Sensitivity Analysis

7.6.1 Chapter 3 Sensitivity Analysis
Inputs





Meal
700 kcal at 13 hours
30 minute duration
175 g CHO
o GI = 50, 50% CHO
Insulin bolus (Fast) = 50






Snack
60 kcal at 10 hours
6 minute duration
15 g CHO
o GI = 80, 80% CHO
No Insulin





Exercise
600 kcal/hr for 1 hour
Aerobic Capacity = 1000
Simulation times
o 30 min before
o 30 min after start
o 18 min after end
(Recovery)

Full Sensitivity Analysis Table Non-Diabetic—Most Sensitive Parameters (>0.4, bold >1.0)
Xg

Xnm

Xm

Xd

___

___

Xds

Xi

Xinj-m

Xgn

Xinj-nm

Xmito

Meal Simulation
Xmina

Xmaxa

Ki 1.149
Cia -0.733
Kugs 0.578
Grefg -0.463
Kg2Max -0.476
Kmintol -0.784

Wratt 1.068
Kmintol -0.523

Cib 0.589
Kmintol 1.306

___

Kugs 0.662

Ki 2.756
Cia 3.007
Cga -3.025
Kgt -3.025
Grefi 2.630
Grefg -2.821
Greft -2.999
Ki -0.796
Grefi 0.612
Grefg -1.272

___

___

___

___

200

XBMb

Ki -1.879
-1.225
Cib 3.090
Cga 1.461
Kgt 1.446
Grefi -4.317
Grefg 5.518
Greft 1.872
Kg2Max -0.751
Kmxex -1.233
Kse -0.921
Kmintol -4.281
Ratmito 1.079

XDMRc

XDMFd

Ki 0.546
Cia -0.431
Kid -0.402

Ki -0.550
Cib 0.732
Grefi -1.106
Grefg 1.267
Gbt 0.504
Wratt 0.496
Kmintol 0.971

Ki -0.973
Cib 1.296
Cga 0.620
Kgt 0.611
Grefi -1.952
Grefg 2.249
Greft 0.605
Kmxex -0.665
Kse -0.500
Kmintol
1.690
Ratmito 0.645

___

___

Ki -1.311
Cia -1.131
Cib 2.198
Cga 0.796
Kgt 0.780
Grefi -2.666
Grefg 2.966
Greft 0.894
Gbt 1.486
Kugf -1.035
Wratt -0.486
KgwMax -1.315
Kmxex -1.125
Kse -0.848
Kmintol 2.995
Wratt 1.077
Kmintol -0.456

Ki -0.845
Cib 1.201
Cga 0.533
Kgt 0.526
Grefi -1.686
Grefg 1.939
Greft 0.522
Kmxex -0.544
Kse -0.421
Kmintol
1.622
Ratmito 0.506

Kugs 0.717

Cib 0.649
Kmintol
1.137

Kugs 0.600

Ki -3.031
Cia -1.147
Cib 3.129
Cga 1.311
Kgt 1.296
Grefi -4.489
Grefg 4.857
Greft 1.726
Kg2Max -0.707
Kmxex -1.252
Kse -0.936
Kmintol 4.060
Ratmito 1.083
Kid 0.890

Ki -2.472
Cia -0.857
Cib 3.297
Cga 0.768
Kgt 0.752
Grefi -5.576
Grefg 6.373
Greft 1.191
Kg2Max -0.540
Kmxex -1.338
Kse -1.001
Kmintol -4.043
Ratmito 1.060

Ki -1.165
Grefi 0.455
Grefg -0.621

Ki -0.451
Cga -0.608
Kgt -0.609
Grefi -1.002
Grefg 1.444
Greft -0.582

___

Ki -0.511
Cga 0.635
Kgt 0.636
Grefi -1.025
Grefg 1.301
Greft -0.615

Snack Simulation
Xmina

___

___

___

Ki 2.479
Ciaa 2.697
Cga -2.629
Kgt -2.629
Grefi 2.390
Grefg -2.423
Greft -2.658
Kmintol 2.702

___

Grefg 0.621

___

201

Xmaxa

Ki 1.380
Cia -0.618
Cga 1.197
Kgt 1.200
Grefi 1.424
Grefg 4.366
Greft 0.991
Kmintol -0.471

___

Ki -0.940
Cib 1.327
Cga 0.633
Kgt 0.625
Grefi -1.760
Grefg 2.242
Greft 0.603
Kmxex -0.611
Kse -0.459
Kmintol
1.150

Kugf
0.549

Kugs 0.972

Ki -6.047
Cia -0.487
Cga 1.927
Kgt 1.932
Grefi -8.041
Grefg 6.924
Greft 1.307
Kid 1.261

XBSb

Ki 0.776
Cia -0.479
Cga 0.920
Kgt 0.922
Grefi 1.562
Grefg 3.415
Greft 0.890

Ki -0.534
Cib 0.778
Cga 0.449
Kgt 0.444
Grefi -1.049
Greft 1.593
Greft 0.418
Gbt 0.451
Wratt 0.549
Kmintol 0.621

Ki -1.014
Cib 1.406
Cga 0.719
Kgt 0.710
Grefi -1.994
Grefg 2.534
Greft 0.666
Kmxex -0.684
Kse -0.513
Kmintol
1.126
Ratmito 0.605

___

___

Ki 54.629
Cia 12.176
Cib 7.400
Cga -23.404
Kgt -23.455
Grefi 109.876
Grefg -86.464
Greft -22.650
Kg2Max 6.985
Kmxex -3.746
Kse -2.814
Kmintol 8.313

Ki 0.866
Cia -0.531
Cga 1.026
Kgt 1.028
Grefi 1.744
Grefg -2.752
Greft 0.991

XDSRc

Ki 0.774
Cia -0.479
Cga 0.921
Kgt 0.923
Grefi 1.559
Grefg 3.416
Greft 0.891

Ki -0.536
Cib 0.778
Cga 0.448
Kgt 0.442
Grefi -1.053
Grefg 1.587
Greft 0.417
Gbt 0.452
Wratt 0.548
Kmintol 0.626

Ki 1.014
Cib 1.405
Cga 0.718
Kgt 0.708
Grefi -1.995
Grefg 2.530
Greft 0.666
Kmxex -0.684
Kse -0.513
Kmintol
1.135

___

___

Ki 0.864
Cia -0.531
Cga 1.026
Kgt 1.028
Grefi 1.739
Grefg -2.746
Greft 0.991

XDSFd

Grefi 0.608
Grefg 1.054

Ki -0.547
Cib 0.797
Cga 0.451
Kgt 0.446
Grefi -1.076
Grefg 1.604
Greft 0.426
Gbt 0.465

Ki -1.009
Cib 1.399
Cga 0.711
Kgt 0.702
Grefi -1.987
Grefg 2.510
Greft 0.661
Kmxex -0.680

Ki 55.564
Cia 12.392
Cib 7.468
Cga -23.805
Kgt 23.587
Grefi 111.732
Grefg -87.947
Greft -23.045
Kg2Max 7.110
Kmxex -3.786
Kse -2.844
Kmintol 8.532
Ki -0.852
Grefi -0.985
Grefg 0.619
Kugf 0.450
Kid 0.836

Kugs 0.887

___

Grefi 0.510
Grefg -1.046
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Wratt 0.535
Kmintol 0.653

Kse -0.510
Kmintol
1.152

Exercise Simulation
Xminc

___

___

Xmaxa

Ki 1.819
Cia -2.214
Cib -1.456
Cga 1.168
Kgt 1.170
Grefi 2.091
Grefg 4.594
Greft 1.611
Kg2Max -0.522
Kmintol -1.315
Kid -2.706

___

XBEe

Ki 0.810
Cia -0.469
Cga 0.913
Kgt 0.915
Grefi 1.629
Grefg 3.388
Greft 0.877

Ki -0.403
Cib 0.708
Cga 0.525
Kgt 0.520
Grefi -0.738
Grefg 1.797
Greft 0.464
Wratt 0.602

XDEf

Cga -0.951
Kgt -0.953
Grefg -2.478
Kmxex 0.838

Cib 0.421
Cga 0.538
Kgt 0.535
Grefi -0.460
Grefg 1.570
Wratt 0.743

XRg

Cga 0.838
Kgt 0.840
Grefi 0.539
Grefg 2.788
Greft 0.470
Kmxex 0.548

Cga 0.464
Kgt 0.461
Grefg 1.355
Wratt 0.825

___
Ki -0.550
Cib 0.994
Cga 1.449
Kgt 1.440
Grefi -0.993
Grefg 4.197
Greft 0.675
Kmxex 0.591
Kse -0.557
Kmintol 0.692
Ratmito 1.166
Ki -0.941
Cib 1.404
Cga 0.772
Kgt 0.763
Grefi -1.756
Grefg 2.582
Greft 0.666
Kmxex -0.654
Kse -0.489
Kmintol 0.903

___

___

___

___

Ki -0.533
Cib 0.893
Cga 0.976
Kgt 0.969
Grefi -0.996
Grefg 2.902
Greft 0.572
Kse -0.432
Kmintol 0.585
Ki -0.567
Cib 0.996
Cga 1.539
Kgt 1.529
Grefi -1.059
Grefg 4.433

___

___

___

___

Ki -0.510
Grefi -0.501
Grefg 0.674
Ki -2.196
Cia -0.418
Cga 0.836
Kgt 0.839
Grefi -2.160
Grefg 2.902
Greft 0.541
Kmxex 0.915
Kid 0.745

Ki 42.380
Cia 9.306
Cib 6.628
Cga -18.140
Kgt -18.185
Grefi 85.304
Grefg -66.975
Greft -17.457
Kmxex -3.283
Kse -2.465
Kmintol 4.891
Ki 2.378
Cga -1.293
Kgt -1.297
Grefi 3.298
Grefg -3.808
Greft -0.541
Kmxex 0.475
Kid -0.911
Ki -0.958
Cga 0.614
Kgt 0.616
Grefi -0.910
Grefg 2.101
Kmxex 0.827

Grefg 0.696

___

___

___

Ki 1.043
Cia -1.337
Cib -0.901
Cga 1.429
Kgt 1.432
Grefi 1.412
Grefg -4.218
Greft 1.160
Kg2Max -0.458
Kmintol -0.789
Kid -1.682

___

___

___

Ki 0.916
Cia -0.527
Cga 1.030
Kgt 1.032
Grefi 1.839
Grefg -2.889
Greft 0.987

___

___

___

Kgt -1.197
Kgt -1.199
Grefg 1.085
Kmxex 0.874

___

___

Ki 0.509
Cga 3.173
Kgt 3.181
Grefi 0.890
Grefg -2.388
Greft 0.983

___
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Kid -0.442

Greft 0.711
Kid 1.033
Kmxex 0.619
Kse -0.589
Kmintol 0.673
Ratmito 1.310
edge For these cases, extremer behaviors occur at the beginning or end of respective time windows for the subtask event.
a All maximum behaviors occur at a peak during meal and snack simulation subtasks.
b Sensitivity behavior values were taken 0.5 hrs prior to this subtask (meal XBM, snack XBS), to document initial fluctuations.
c Rising sensitivity behavior measured at 0.3 hrs after start of this subtask (meal XDMR, snack XDSR).
d Falling sensitivity behavior measured at 1.0 hrs after the start of this subtask (meal XDMF, snack XDSF).
e Sensitivity behavior values were taken 0.3 hrs prior to exercise subtask event, to document initial fluctuations.
f Behaviors values taken during exercise subtask, 0.5 hrs after its start.
g Behavior values taken during exercise ‘recovery’ phase, at 0.25 hrs after the end of exercise (i.e., 1.25 hrs after its start).
* Exception to the >0.1 threshold.

Full Sensitivity Analysis Table T1D—Most Sensitive Parameters (>0.4, bold >1.0)
Xg

Xnm

Xm

Xd

Xminb

Ki -5.444
Cga -5.529
Kgt -5.529
Grefg -4.969
Kd 5.133

Ki 0.799
Cib -1.153
Grefg -1.120
Gbt -0.547
Wratt -0.655
Kmintol 6.498
Ka1 -0.439
Kd -5.966

___

___

Xmaxb

Ki 1.605
Cga -0.655
Kgt -0.659
Kugs 1.136
Grefg -1.924
Kmintol -1.237
Ka2 -1.936
Ka1 -0.773
Kd -2.294
Grefg 0.550
Greft 0.418
Ka2 0.596

Xds

Xi

Xinj-m

Xgn

Xinj-nm

Xmito

Meal Simulation

XBMc

Kmintol
2.073

Wratt 0.743
Kmintol
1.402

Kmintol
2.039
Kd 1.007

___

___

___

Kugs 0.662

Ki -0.866
Ka2 0.933
Ka1 0.429
Kd 1.216

Ka1 0.439
Kd 1.555

___

Ki -0.996
Ka1 0.571
Kd 2.423

Ka2 -0.733
Ka1 0.512
Kd 2.543

Ki -1.042
Cia 0.959
Cga -0.792
Kgt -0.792
Grefg 0.800
Greft -0.542
Kmintol 0.797
Ka1 0.546
Kd 2.294
Cia -0.877
Cga -1.464
Kgt -1.468
Kugs 0.782
Grefg -1.608
Ka2 -1.446
Kd 0.458
Ki -0.936
Cia 0.779
Cga -1.026

___

Kmintol 0.483

Ka1 1.418
Kd 3.283

___

___
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Kd 0.664

XDMRd

Kgt -1.027
Kmintol 0.806
Ka1 0.563
Kd 2.304
Ki -0.817
Cia 0.619
Cga -0.983
Kgt -0.984
Greft -0.459
Kmintol 0.600
Ka1 0.436
Kd 2.021

Grefg -1.579
Gbt 0.433
Wratt -4.717
Kmintol 4.846
Kd -6.107

Ki -0.420
Kmintol
2.065
Ka2 -0.455
Kd 1.081

Kugs 0.717

Ki -1.057
Kd 0.574
Kd 2.563

Ka2 -0.877
Ka1 0.543
Kd 2.683

Kugs 0.600

Ki 0.617
Ka2 1.260
Kd -1.780

___

Ki -0.772
Cia 0.579
Cga -0.935
Kgt -0.936
Greft -0.474
Kmintol 0.557
Ka1 0.408
Kd 1.913

Kd 0.431

___

Ki -0.531
Cia 0.411
Cga -0.578
Kgt -0.578
Grefi 2.390
Kmintol 0.413
Kd -2.493
Ki -2.160
Cia 1.670
Cga -2.350
Kgt -2.353
Grefg 0.694
Greft -0.932
Kmintol 1.680
Ka1 1.226
Kd 5.343

___

XDMFe

Kd -0.710

Grefg 0.455
Wratt 1.914
Kg2Max 0.480
Kmintol 0.491
Kd 1.656

Kmintol
2.154
Ka2 -0.473
Kd 0.821

Xminb

Grefg 0.446

Wratt -0.434
KMintol -0.625
Kd -0.587

___

___

___

Xmaxb

Ki -2.927
Cia 2.278
Cib 0.419
Cga -3.595
Kgt -3.600
Grefg 11.472
Greft -1.303
Kmintol 2.281
Ka2 -0.425
Ka1 .1655
Kd 7.322

___

Ki -0.506
Cib 0.675
Grefg 0.649
Kmintol
1.197
Kd 1.181

Kugf 0.549

Kugs 0.972

Ki -1.026
Ka1 0.588
Kd 2.478

Ka2 -0.971
Ka1 0.530
Kd 2.563

XBSc

Ki -1.462
Cia 1.094
Cga -1.668
Kgt -1.671

Ki -0.410
Cib 0.585
Grefg 0.682
Wratt 0.764

Ki -0.538
Cib 0.726
Grefg 0.714

___

___

Ki -1.026
Ka1 0.588
Kd 2.478

Ka2 -0.971
Ka1 0.530
Kd 2.563

Ka1 0.930
Kd 3.419

Kmintol 0.406

Snack Simulation

Ki -1.541
Cia 1.140
Cga -1.755
Kgt -1.758

Ka1 0.577
Kd 1.734

___

Ka1 0.577
Kd 1.734

___
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Grefg -5.019
Greft -0.515
Kmintol 1.122
Ka1 0.849
Kd 3.562

Kmintol 0.843
Kd 0.941

Kmintol
1.056
Kd 1.240

XDSRd

Ki -1.522
Cia 1.148
Cga -1.745
Kgt -1.747
Grefg -5.285
Greft -0.550
Kmintol 1.179
Ka1 0.894
Kd 3.721

Ki -0.408
Cib 0.580
Grefg 0.674
Wratt 0.766
Kmintol 0.865
Kd 0.938

Ki -0.533
Cib 0.718
Grefg 0.707
Kmintol
1.080
Kd 1.232

XDSFe

Ki 1.668
Cia -1.277
Cga 1.277
Kgt 1.278
Grefg 4.2267
Greft 0.605
Kugf 0.799
Kmintol -1.307
Ka1 -0.964
Kd -4.094

Ki -0.402
Cib 0.578
Grefg 0.664
Wratt 0.766
Kmintol 0.923
Kd 0.929

Ki -0.525
Cib 0.701
Grefg 0.685
Kmintol
1.132
Kd 1.218

Greft -0.534
Kmintol 1.160
Ka1 0.891
Kd 3.725
___

___

Ki -1.034
Ka1 0.592
Kd 2.503

Ka2 -1.000
Ka1 0.536
Kd 2.586

Ki -1.565
Cia 1.167
Cga -1.791
Kgt -1.793
Greft -0.556
Kmintol 1.192
Ka1 0.905
Kd 3.797

Ka1 0.580
Kd 1.766

Kugs 0.887

Ki -1.049
Ka1 0.598
Kd 2.555

Ka2 -1.065
Ka1 0.546
Kd 2.633

Ki -9.343
Cia 7.058
Cib 1.797
Cga -9.803
Kgt -9.815
Grefg 6.947
Greft -3.447
Kugf -3.078
Ksds 0.633
Kmintol 7.205
Ka1 5.389
Kd 22.855

Ka1 0.586
Kd 1.839

Exercise Simulation
Xminb

___

___

___

___

___
___

Xmaxb

Cga 0.562
Kgt 0.563
Grefg 2.168
Greft 0.988
Kg2Max -0.563

___

Ratmito
0.812

___

___

___

XBEf

Cga 0.562
Kgt 0.563
Grefg 2.168
Greft 0.989
Kg2Max -0.563

Grefg 0.891
Greft 0.415
Gbt 0.584
Wratt 0.416

Ratmito
.5421

___

___

___

Grefg -0.529
Greft 0.529

___

___
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XDEg

Cga 0.562
Grefg 0.784
Ratmito
___
___
Kgt 0.563
Gbt 0.633
0.530
Grefg 2.168
Greft 0.988
Kg2Max -0.563
XRh
Cga 0.562
Grefg 0.694
Ratmito
___
___
Kgt 0.563
Gbt 0.674
0.819
Grefg 2.168
Greft 0.988
Kg2Max -0.563
edge For these cases, extremer behaviors occur at the beginning or end of respective time windows for the subtask event.
b All maximum behaviors occur at a peak during meal and snack simulation subtasks.
c Sensitivity behavior values were taken 0.3 hrs prior to this subtask (meal XBM, snack XSM), to document initial fluctuations.
d Rising sensitivity behavior measured at 0.3 hrs after start of this subtask (meal XDMR, snack XDSR).
e Falling sensitivity behavior measured at 1.0 hrs after the start of this subtask (meal X
DMF, snack XDSF).
f Sensitivity behavior values were taken 0.3 hrs prior to exercise subtask event, to document initial fluctuations.
g Behaviors values taken during exercise subtask, 0.5 hrs after its start.
h Behavior values taken during exercise ‘recovery’ phase, at 0.25 hrs after the end of exercise (i.e., 1.25 hrs after its start).

___

___

Grefg -0.529
Greft 0.529

Grefg -0.529
Greft 0.529

___

___

7.6.2 Chapter 4 Sensitivity Analysis
Inputs (Subject: BW = 65 kg, rattype1i = 0.2, wmu = 30, wnm = 25)
Anaerobic Exercise Simulation
Aerobic Exercise Simulation
 2 Hour Lifting Workout (Case Study  2.5 Hour Long Run (Case Study 2
2 Protocol Day 8)
Protocol Day 4)
o 7:00-9:00 AM
o 7:00-9:30 AM
 Bouts of 800 kcal/hr exertions
 500-600 kcal/hr informed by HR
informed by HR input
input

Snack + Exercise Simulation
 1 Hour Tempo Run (Case Study 2
Protocol Day 1)
o 7:00-8:00 AM
 15g CHO snack at 6:30 (kfast = 0.8,
fraccarbs = 0.8)
o No insulin
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Full Sensitivity Analysis Table—Most Sensitive Parameters (>0.4)
Xg

Xnm

Xm

Xd

Xds

Xi

Xinj-m

Xgn

Xinj-nm

Xmito

Exercise Simulation 1 Long Anaerobic
Xminb

Xmaxb

Before
Exercise
(6:45)

Halfway
During
Exercise
(8:00)

Cib
Grefi
Grefg
Kmintol

Ki
Cia
Grefg
Kg2Max
Kmintol
Ki
Cia
Cib
Cga
Kgt
Grefi
Grefg
Greft
Kg2Max
Kmxex
Kse
Kmintol
Ratmito

___

Wratt
Kmintol

Cib
Kmintol

___

Ki
Cib
Grefi
Grefg
Gbt
Wratt
Kmintol

Ki
Cib
Cga
Kgt
Grefi
Grefg
Greft
Kmxex
Kse
Kmintol
Ratmito

___

Ki
Cib
Cga
Kgt
Grefi
Grefg
Greft
Gbt
Kg2Max
Kmxex
Kse
Kmintol

Ki
Cib
Cga
Kgt
Grefi
Grefg
Greft
Kg2Max
Kmxex
Kse
Kmintol
Ratmito

___

Ki
Cia
Cga
Kgt
Grefi
Grefg
Greft
Kmintol
Ki
Gref
Grefg

___

___

Ki
Cia
Cib
Cga
Kgt
Grefi
Grefg
Kg2Max
Kmxex
Kse
Kmintol
ratmito

___

___

Kid

___

Ki
Cia
Cga
Kgt
Grefi
Grefg
Greft
Kmintol

___

___

___

Wmu

Ki
Cia
Cib
Cga
Kgt
Grefi
Grefg
Greft
Kg2Max
Kmxex
Kse
Kmintol
Ratmito

___

Ki
Cia
Cib
Cga
Kgt
Grefi
Grefg
Greft
Kg2Max
Kmxex
Kse
Kmintol
Ratmito
Wmu

Ki
Cga
Kgt
Grefi
Grefg
Greft

___
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Recovery
(9:45)

Ki
Cia
Kid

Wratt
Kmintol

Xminb

Grefg

Xmaxb

Cga
Kgt
Grefg
Kmxex
Kse

___

Before
Exercise
(6:45)

Cga
Kgt
Grefg
Kg2Max

Grefg
Gbt
Wratt

Halfway
During
Exercise
(8:00)

Cga
Kgt
Grefg
Kmxex
Kse

Grefg
Gbt
Wratt

Recovery
(9:15)

Cga
Kgt
Grefg
Kmxex

Grefg
Wratt

Cib
Kmintol

___

___

Ki
Grefi
Grefg

___

Ki
Cga
Kgt
Grefi
Grefg
Greft

Long Aerobic Exercise Simulation
___

___

Ki
Grefg

___

Grefg

___

Ki
Cib
Cga
Kgt
Grefi
Grefg
Kmxex
Kse
Kmintol
Ka1

___

___

Ki
Cga
Kgt
Grefg
Kmxex

___

Cga
Kgt
Grefg
Kmxex

___

Ki
Cib
Cga
Kgt
Grefi
Grefg
Kmintol
Ka1
Ratmito
Ki
Cib
Cga
Kgt
Grefi
Grefg
Kmxex
Kmintol
Ka1

___

___

Ki
Cga
Kgt
Grefg
Kg2Max

___

Cga
Kgt
Grefg

___

___

___

Ki
Cga
Kgt
Grefg
Kg2Max
Kmxex
Kse
Ksds

___

Ki
Cia
Cga
Kgt
Grefg
Kg2Max
Kmxex
Kse
Ka2

___

Ki
Cib
Cga
Kgt

___

___

Ki
Cga
Kgt
Grefg

___

Ki
Cia
Cga
Kgt

___

Grefg

Grefg
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Kse

Grefi
Grefg
Kmxex
Kse
Kmintol
Ka1

Kmxex

Grefg
Kg2Max
Kmxex
Kse
Ka2

Exercise Simulation 3: Snack + Tempo
Xminb

___

Xmaxb

Cga
Kgt
Grefg

___

Before
Exercise,
after snack
(6:36)

Cga
Kgt
Grefg
Kg2Max

Grefg
Gbt
Wratt

Halfway
During
Exercise
(7:30)

Ki
Cia
Cga
Kgt
Kugs
Grefg
Kg2Max
Kmxex
Kse
Ksds
Ka2

Cib
Grefg
Gbt
Ka1

___

___

Ki
Cia
Cib
Cga
Kgt
Grefi
Grefg
Kg2Max
Kmxex
Kse
Kmintol
Ka2
Ka1
Ratmito
Ki
Cib
Cga
Kgt
Grefi
Grefg
Kmintol
Ka1
Ratmito

___

___

Ki
Cga
Kgt
Grefg
Kg2Max
Kid

___

___

Ki
Cga
Kgt
Grefg
Kg2Max

Ki
Cib
Cga
Kgt
Grefi
Grefg
Kg2Max
Kse
Kmintol
Ka1

___

___

Ki
Cia
Cga
Kgt
Kugs
Grefg
Kg2Max
Kmxex
Ka2

Ki
Grefg
___

___
___

___

Wmu 1.120

___

Cga
Kgt
Grefg

___

Wmu -0.972

___

Ki
Cia
Cga
Kgt
Kugs
Grefg
Kg2Max
Kmxex
Kse
Ka2

___

Kugs
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Recovery
(8:15)

Cga 0.204
Kgt 0.204
Grefg 0.746

Cga
Kgt
Grefg

Grefg
Gbt
Wratt

Ki
___
Ki
Cia
Cga
Cib
Kgt
Cga
Grefg
Kgt
Kmxex
Kugs
Kid
Grefi
Grefg
Kg2Max
Kmxex
Kse
Kmintol
Ka2
Ka1
Ratmito
edge For these cases, extremer behaviors occur at the beginning or end of respective time windows for the subtask event.
b All maximum behaviors occur at a peak during exercise subtasks.

___

Cga
Kgt
Grefg

___

Kugs
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8. CODE
% STARTER CODE, GLUCOSE 8- or 10-STATE
% States: x1: Glucose, Blood/plasma; also key regulated output
%
x2: Glucose, Tissue (non-muscle, lumped);
%
x3: Glucose, Muscle Tissue
%
x4: Glucose, Stomach (final path, fast & slow converge);
%
x5: Glucose, Stomach (slow food path, converges to x4)
%
x6: Insulin, Blood (controller; glucagon is ~mirror)
%
x7: Insulin, Local Tissue (for external input only), monomeric
%
insulin absorbtion
%
x9: Insulin, Local Tissue (for external input only), nonmonomeric
%
insulin absorbtion
%
x8: Glucagon, Blood (controller; insulin is ~mirror)
%
x10: Mitochondrial Consumption State
% Inputs: u1: Food ingestion (meals): Lines 36-38, via x4 (1st-ord filter)
%
u2: Insulin injection or pump: Lines 39-40, via x7 (1st-ord filt)
%
u3, exer: exercise of certian intensity in kcal/hr
%
u4,activity: activity as a randomized input of certian intensity
%
with max of 200 kcal/hr
%
u5: External Heart Rate (bpm)
%
uHM: Hormonal Stress
% Key Output: y: Blood glucose (x1)
% Notes: This is set up as 1 model, but has an embedded NL controller for
%
insulin & glucagon
%
Type I: change ratType1i/g; add u(2,i) exogenous insulin
%
Type II: change (at minimum) starting levels, BM, wmu/wnm,
%
insulin rate, GLUT2 rate
clear all;
%PARAMETERS:
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bm = 70;
% Body Mass, in Kg; for 70, muscle ~30, fat ~15, brain ~ 1.3, liver 1.4 each, bplasma ~ 2.8, interstit ~ 10, RBCs ~2.2?
wmu = 30;
% BM of skeletal muscle, in Kg, ~40-45% healthy (less if obese), for normalizing in
f3, etc
wnm = 25;
% BM, "Non-Musc" in Kg, of: "BM - BMskeletal - BM_ECF - BM_brain+RBCs", for
normalizing in f2, etc
ratBM = bm/70.;
ratmito = 0.1; %proportion of muscle mass that is mitochondria; mitochondrial volume increases with
training
ratMUSC = wmu/30.; ratNONM = wnm/25.; % ratios for musc and non-musc relative to "normal"
wmito = ratmito*wmu; %Mass of mitochondria in kg
kprop = 0.2; %Proportion of glucose consumption (activity) that reaches mitochondria
stressrat = 1.0; %scaling for stressors for GLUT2; i.e. >1.0 will dump more glucose from non-muscle
%i.e. competitiveness of athletes >1.0; circuit/sprint
%training; 2.0 = MAXIMUM
metab = 1.0; %Basal Metabolism adjustment >1.0 = fit; <1.0 = unfit (default = 1.0); 2.0 = MAXIMUM
ratType1i = 1.0;
Type 1
ratType1g = 1.0;
Type 1
ratType2i = 1.0;

% If Type 1, ratio of insulin still produced by beta cells; 1.0 = normal, lower for
% If Type 1, ratio of glucagon still produced by beta cells; 1.0 = normal, lower for
% If Type 2, level of insulin resistance as ratio

Cia = .3; %1.0 %0.035;
Cib = 0.4; %1.0 %0.03;
Cga = 0.4*.287*100;
%
Cgb = 0.001*.287*100; %
insulindel = 0.15;
%
Kid = 0.04;
%

% Insulin Control Param, Non-Muscle Tissue; Gain
% Insulin Control Param, Muscle; now Cia + Cib = original C1; JW: .019 to .024
Glucagon Control Param, Non-Musc scaled to pg/mL
Glucagon Control Param, Muscle scaled to pg/mL
Delay in hours (Man-Cobelli use 10 min, 0.15=9 min)
derivative

%NEW PARAMS FROM COBELLI INSULIN MODEL--INSULIN ABSORPTION
rat_ia = 0.5; %ratio of nonmonomeric:monomeric (slow:fast) insulin absorb. paths
kai = 0.02*60;
ka2 = rat_ia*kai; %rate constant of monomeric insulin absorption; originally 0.018*60
ka1 = (1-rat_ia)*kai; %rate constant of nonmonomeric insulin absorption converted to /hr from /min;
originally 0.0018*60
kd = 8*0.0164*60; %rate constant of insulin dissociation
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Kg = 0.4;
% /hr, Cg, ~P-action for glucagon, .4 or 1 NOT USED?
Ki = 3.0;
% /hr, a4, Insulin elinimation rate
Kgt = 1.0*.287;
% /hr, a5, Basal tissue elimination rate JW: WHY??? NOT WELL-USED (Mult by Cia,
Cgb)?
Kugf = (5./ratBM);
% forward rate (~1/tau) of glucose bolus (JW: now min rate, mid-range max nearly
double)
Kugs = (0.4/ratBM);
% min slow path rate (~1/tau) of glucose bolus (can be as high as double this double)
Kugd = (5./ratBM);
% max digestive absorbtion rate (can be half of this at very low or high)
Gugf = 0.98;
% digestive effectiveness ratio, fast carbs
Gugs = 0.88;
% digestive effectiveness ratio, slow carbs
Kui = 1./ratBM;
% forward rate (1/tau) of insulin bolus
Kuga = 2.0;
% forward rate of bolus for slow glucose path
Kgc = 8.;
% /hr, glucagon addition rate
Knm_up = 1.0;
% /hr, non-muscle uptake (e.g., liver) without insulin signal
Kmusc = 20.0;
% rate of delivery to muscle - for example, "10" would be a time constant of 6 min
Grefi = 70;
% Ref thresh (BG) for insulin control
Grefg = 110;
% Ref thresh (BG) for glucagon
Greft = 90;
% Ref thresh (BG) for Non-muscle flux direction (due to GLUT2)
Kg2Max = 2.0;
% Max for Non-muscle GLUT2 flux (gradient, without control action
Ktintol = 12.*ratNONM; % Ref thresh for non-musc tissue, g/Kg ( (typical body can store 2000 Kcal = 500 g
of glycogen
Kmintol = 14.*ratMUSC; % Ref thresh for muscle (means 75% = 0.25 + 0.5 passed),
% insref = 30; %pmol/L; %glucref = 120; %glucagon max pg/mL
% Next three should add to basal metabolism, e.g., Kbr+Gbt+Gbm is "low side" of (glucose) basal metab (if
fully sedentary, no complex foods)
Kbr = ((20./4)*ratNONM);
% BG to steady consumption sink, no storage (mostly to brain, also
erythrocytes), in Kcal/hr/4 = g/hr
Gbt = metab*((10./4)*ratNONM);%/wnm;
% Non-musc tissue basal metabolic elimination (not brain, but liver,
cardiac, adipose...), Kcal/hr/4;
Gbm = metab*((6./4)*ratMUSC);%/wmu;
% muscle basal metabolic elimination rate, Kcal/hr/4;
Kcarb = 0.2;
% NEW: Carb scaling for dietary thermogenesis (normalized digestive
thermic effect of food, using x5)
%ADDED HILL PARAMETERS
%note: for glut2 hill function, half is Greft and max is kg2max
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kmxex = 10.0; %maximum gmgrad
kse = 40.0; %half gmgrad
kmxnm = 1.0; %max gtintol (half is ktintol)
kmxm = 1.0; %max gmintol (half is kmintol)
ksds = 5.0; %half slow digestive (max is kugs) - JW: not use?
ksds2 = 20.0; %half slow digestive falling (min is kugs)
ksd = 10.0; %half fast digestive (max is kugf)
ksd2 = 100.0; %half fast digestive falling (max is kugf)
hs_max = 45;
hs_ks = 23;
hs_rate = 20;
% Mapping/scaling Params:
vratm = 0.1;
% ratio of volume_blood-plasma to volume_muscle tissue ... not used
vratt = 0.1;
% ratio of volume_blood-plasma to volume_non-muscle tissue ... not used
drat = 8.0*ratBM;
% NEW: Conversion of digestive mass flow in grams into ECF (blood plasma +
interstitial) in mg/dL, scaled by BW
wratm = (1/drat)/wmu; % CHANGE: scaling from gluc blood conc (mg/dL) to gluc musc tissue amount in g, norm
to mass of segment (g/Kg_musc)
wratt = (1/drat)/wnm; % CHANGE: scaling from gluc blood conc (mg/dL) to gluc non-musc tiss amount in g,
norm to mass of segment (g/Kg_n-m)
gratm = 0.01*wmu;
% for blood-muscle glucose gradient (e.g., exercise demand)
gratt = 0.01*wnm;
% not used
% NOTES: % "normal" (70Kg BW) amount in blood plasma: (100 mg/dL)*(0.55*5L of blood) = (1 g/L)*(2.75L) =
2.75g ~ 3 g total (lit ~ 4g)
% Adding in most of interstitial that is assumed to rapidly equilibriate for glucose: ~3.5*BP,
thus let ECF = 12.5 L, so norm ~ 12.5 g total
% Consistent with Man-Cobelli: V = 1.88 dL/Kg * 70 = 132 dL = 13L
% "normal" amount in muscle: 0.012*30Kg ~= 350 g (or 1400 Kcal) - ~25x more in musc than BP_ECF
% "normal" amount in mon-musc (mostly liver): ~5 (3-8)?%*2.8Kg liver + ~1% adipose + other = 150
g other (lit)
% side note: humans consume ~300 g/day, but OK with about 100 or so ... so multi-day store if no
exercise?
% Ex, let density=1: if change of 10 mg/dL = 100 mg/L = 100 mg/Kg_ECF then 1300 mg transfer, or
1.4 Kg to 30 Kg = .047 g/Kg
% Ex, conc grad: 100 mg/dL = 10 mg/L = 10 mg/Kg_ECF = .01 g/Kg_ECF) = .01*wmu g/Kg_tissue
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% Ex, for drat: if 12.5 g/hr added to, say, 12.5 L of BP, then added 1 g/L or 100 mg/dL added in
1 hour, so mult by ~8
% PREP FOR SIMULATION:
delt = 0.01; tmin = 0; tmax = 24;
% delt, tmax = 12 means 12 hours
JW CHANGE TO CHECK LONG_ACTING
t = tmin : delt : tmax;
% t=0 is wakeup (e.g., 8 AM); t=16=midnight
idel = insulindel/delt;
% number of samples for delay
%CHOOSE Sofie Protocol HR Input
%u = HRin_prot1(); %Tempo
%u = HRin_prot2(); %Circuit Training
%u = HRin_prot3(); %Long Run
%u = HRin_prot4(); %40 min bike + 20 min run
%u = HRin_prot5(); %Sprint Intervals
%u = HRin_prot6(); %Long Anaerobic
u = HRin_noinput; %IF HR DATA IS NOT PROVIDED
deltu3 = zeros(1,2401);
ug = 0.0; ui = 0.0; ua = 0.0; % init input matrix; residual produc levels
% %u = [ug*ones(1,length(t)); ui*ones(1,length(t)); zeros(1,length(t)); ua*ones(1,length(t))];
u1fast = ug*ones(1,length(t)); u1slow = ug*ones(1,length(t)); u1carb = ones(1,length(t));
% u = [ug*ones(1,length(t)); ui*ones(1,length(t)); zeros(1,length(t)); ua*ones(1,length(t));
zeros(1,length(t))]; % JW: added u5
u1fast = ug*ones(1,length(t)); u1slow = ug*ones(1,length(t)); u1carb = ones(1,length(t));
x = [zeros(5,length(t))];
% init state matrix size

% SETTING INPUTS (time and magnitude):
% Input 1: FOODSTUFF (MEALS)
nmeals = 6; %define beginning:end of meals
<0,1>):
mbeg(1) = 50;
mend(1) = 75;
mtot(1) =
Kcal/hr, area under curve is Kcal)
mbeg(2) = 500;
mend(2) = 550;
mtot(2) =
Kcal/hr, area is ph*pw Kcals)
mbeg(3) = 1300; mend(3) = 1350; mtot(3) =
mbeg(4) = 1800; mend(4) = 1810; mtot(4) =

(every 10 is 6 min), total Kcal/hr rate, prop fast carbs (on
800.;

kfast(1) = 0.8; FracCarbs(1) = 0.8;

800.;

kfast(2) = 0.8;

1400.; kfast(3) = 0.5;
600.; kfast(4) = 1.0;

% breakfast (in

FracCarbs(2) = 0.7; % lunch (in
FracCarbs(3) = 0.5; % dinner
FracCarbs(4) = 1.0; % snack#1
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mbeg(5) = 1000; mend(5) = 1010; mtot(5) = 600.; kfast(5) = 0.2;
FracCarbs(5) = 0.5; % snack#2
mbeg(6) = 800;
mend(6) = 810; mtot(6) = 2000.; kfast(6) = 0.5;
FracCarbs(6) = 0.8; % snack#3
xtot(1:nmeals,1:5) = 0.0; scale4(1:nmeals) = 0; scale5(1:nmeals) = 0; lost4(1:nmeals) = 0.0;
for i = 1 : nmeals
% Pre-run to scale glucose conservation
u1fast(i,length(t)-1) = 0.0; u1slow(i,length(t)-1) = 0.0;
u1fast(i,mbeg(i):mend(i)) = mtot(i)*kfast(i);
% Area under fast meal curve in Carb-Energy
u1slow(i,mbeg(i):mend(i)) = mtot(i)*(1-kfast(i));
utotf(i) = (mend(i) - mbeg(i) + 1)*mtot(i)*kfast(i);
utots(i) = (mend(i) - mbeg(i) + 1)*mtot(i)*(1-kfast(i));
xx(4,1) = 0.0; xx(4,1:length(t)-1) = 0.0;
% Glucose, Stomach, fast meal path
xx(5,1) = 0.0; xx(5,1:length(t)-1) = 0.0;
% Glucose, Stomach, slow meal path
for ii = 1 : length(t) - 1
Gfast = fhill((xx(4,ii)),(Kugf/2),5,4) + fhillr((xx(4,ii)),(Kugf/2),30,4); % Kugf is mid-range max
Gslow = Kugs + fhillr(xx(5,ii),Kugs,10,4);
% Kugs is min, mid-range max nearly double August
Fit
f(4) = Gfast*(Gugf*(u1fast(i,ii)/4) - xx(4,ii)); % + x(5,ii); % 1st-order on glucose bolus, coud be
f8old %JW changed!
f(5) = Gslow*(Gugs*(u1slow(i,ii)/4) - xx(5,ii));
%%
for j = 4 : 5
xx(j,ii+1) = xx(j,ii) + f(j)*delt;
% Euler integration
xtot(i,j) = xtot(i,j) + xx(j,ii+1);
end
end
scale4(i) = (xtot(i,4)/utotf(i));
scale5(i) = (xtot(i,5)/utots(i));
end
for i = 1 : nmeals
% setting up input #1 (foodstuff)
u1fast(1,mbeg(i):mend(i)) = mtot(i)*kfast(i);
u1slow(1,mbeg(i):mend(i)) = mtot(i)*(1-kfast(i));
if i < nmeals
u1carb(1,mbeg(i):mbeg(i+1)-1) =FracCarbs(i);
elseif i == nmeals
u1carb(1,mbeg(i):length(t)) = FracCarbs(i);
end
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end
% Input 2: Insulin Injections, as half-sine: 1: Regular (max in 2 hrs); 2: Fast (max in 1 hr); 3: Longacting (max in 6 hrs)
%ninjec = 3; %define beginning:end of meals (every 10 is 6 min), total Kcal/hr rate, prop fast carbs (on
<0,1>):
% Prep:
t2r = [0 : 1 : 400];
u2r(1:length(t2r)) = sin(pi*(t2r/400)); % Regular half-sine
t2f = [0 : 1 : 20];
u2f(1:length(t2f)) = sin(pi*(t2f/20)); % Fast half-sine
t2s = [0 : 1 : 1200]; u2s(1:length(t2s)) = sin(pi*(t2s/1200)); % Slow half-sine
itype = [zeros(3,4)]; idose = [zeros(3,4)]; ibeg = [zeros(3,4)]; iend = [zeros(3,4)];
itbeg = tmin/delt; itend = (tmax/delt)+1;
% Regular (max delivery in 2 hrs, through 4 hrs): give idose, ibeg
itype(1,1) = 1; idose(1,1) = 0; ibeg(1,1) = 10;
iend(1,1) = ibeg(1,1) + 400;
itype(1,2) = 1; idose(1,2) = 0; ibeg(1,2) = 475; iend(1,2) = ibeg(1,2) + 400;
itype(1,3) = 1; idose(1,2) = 0; ibeg(1,2) = 2100; iend(1,2) = ibeg(1,2) + 400;
% Fast-Acting (max delivery in 1 hr, ends 2 hrs): give idose, ibeg
itype(2,1) = 1; idose(2,1) = 0; ibeg(2,1) = 1;
iend(2,1) = ibeg(2,1) + 10;
itype(2,2) = 1; idose(2,2) = 0; ibeg(2,2) = 1325; iend(2,2) = ibeg(2,2) + 20;
itype(2,3) = 1; idose(2,3) = 0; ibeg(2,3) = 475; iend(2,3) = ibeg(2,3) + 20;
% Long-Acting (max delivery 6 hrs, ends 12 hrs): given idose, ibegitype(2,1) = 1; idose(2,1) = 5; ibeg(2,1)
= 100;
iend(2,1) = ibeg(2,1) + 400;
itype(3,1) = 1; idose(3,1) = 0; ibeg(3,1) = 10; iend(3,1) = ibeg(3,1) + 1200;
itype(3,2) = 1; idose(3,2) = 0; ibeg(3,2) = 1800; iend(3,2) = ibeg(3,2) + 1200;
for i = 1 : 3
for ii = 1 : 4
if iend(i,ii) > itend
% e.g., if end of day, then shorten array
iend(i,ii) = itend;
end
if ibeg(i,ii) < itbeg
ibeg(i,ii) = 0;
end
if idose(i,ii) > 0
if i == 1
% regular
u(2,ibeg(i,ii):iend(i,ii)) = u(2,ibeg(i,ii):iend(i,ii)) + 1.414*idose(i,ii)*u2r(1:(iend(i,ii)ibeg(i,ii)+1));
end
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if i == 2
% fast
u(2,ibeg(i,ii):iend(i,ii)) = u(2,ibeg(i,ii):iend(i,ii)) + 1.414*idose(i,ii)*u2f(1:(iend(i,ii)ibeg(i,ii)+1));
end
if i == 3
% slow
u(2,ibeg(i,ii):iend(i,ii)) = u(2,ibeg(i,ii):iend(i,ii)) + 1.414*idose(i,ii)*u2s(1:(iend(i,ii)ibeg(i,ii)+1));
end
end
end
end
%IF/THEN CODE FOR DECIDING ON KA_RATE FOR SLOW VS FAST INSULIN PATHWAY
%k as a function of insulin type, tissue at area of injection/infusion, and
%increased blood flow of localized area
%Fast if fast-acting insulin, increased blood flow (i.e. heat, exercise)
%and lean tissue
%k_rate = k_type*k_tiss*k_flow
%by default k_tissue = k_flow = 1.0 % JW: not k_type
%RANGES: k_type: 3 subgroups
%
k_tissue: greater for people with excess body fat
%
k_flow: greater for decreased flow
%
%
%
%
%
%
%

if itype(1,:) > 0
k_type = 0.2;
elseif itype(2,:) > 0
k_type = 0.5;
elseif itype(3,:) > 0
k_type = 0.8;
end

% if ratMUSC >= 1.0
%
k_tissue = 0.2;
% elseif ratMUSC < 1.0
%
k_tissue = 0.8;
% end
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%WILL HAVE TO PUT AFTER EXERCISE INPUT
% if u3 > 0
%
k_flow = 0.2;
% elseif u4 > 0
%
k_flow = 0.5;
% else
%
k_flow = 1.5;
% end

% Input 3: Energy over time (power) consumed during Exercise (in Kcal/Hr)
% Notes: - Steady: WorkWatts/WorkEff, e.g., if max is 256 W = 220 Kcal/Hr, 220/.22 = 1000 Kcal/hr
%
- HRdiff in beats/min, e.g., if HRdiff = (HRmax-HRrest) = 170-70 = 100, then 10 Kcal/hr-HRdiff
%
- RRdiff in beaths/min, e.g., RRdiff = (RRdiff-RRrest) = ...
%
- PVO2Max: percent VO2max (can with resting being ~8% of this)
%
- If at <25% of VO2max: kcal/hr*0.6 (but at some stage higher), 25-50%: *0.7; 50-60%: *0.8 (or
lower); >60%: *0.95
WorkEff = 0.22;
% Efficiency in performing physical work (typically 20-25%, higher for
skilled tasks)
AerCap = 1100;
% Max capacity, in Kcal/hr, can map to "aerobic/mitochondrial" metrics (each
with scaling capability):
uptime = 1; downtime = 1; % exercise up-time & down-time, without using metric such as HR - hour is 100
units
intens =0; slopeu = intens/uptime; sloped = intens/downtime; % steady aerobic intensity, in Kcal/Hr
u(3,350:(350+uptime-1)) = [slopeu*([1:uptime].*ones(1,uptime))];
% aerobic ramp up, for now
u(3,(350+uptime):450) = intens;
% USER: Add exercise with intensity = kcal/hr (glucose) burned
u(3,451:(451+downtime-1)) = [sloped*((downtime-[1:downtime]).*ones(1,downtime))];
%CHAPTER 4 EXERCISE INPUTS
HRrest = 60;
HRmax = 200;
%NEW HOROMONAL INPUT--Grow array to multiple levels--time dependent.
uHM = ones(1,2401);
uHM(700:800) = stressrat*uHM(700:800);
% Input 4: DAILY ACTIVITY (using randomization) for u(4,:), in Kcal/Hr
nactive = 3;
% "moving/fidgeting activity" time periods of the day where muscles consume glucose
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abeg(1) = 200;
aend(1) = 250;
actave(1) = 100.0;
alow(1) = 0.7; ahi(1) = 1.3;
abeg(2) = 1100; aend(2) = 1200;
actave(2) = 80.0;
alow(2) = 0.6; ahi(2) = 1.4;
abeg(3) = 1600; aend(3) = 1700;
actave(3) = 60.0;
alow(3) = 0.7; ahi(3) = 1.3;
u4max = 50;
% assumed max Anaerobic in Kcal/hr before switch to mitochondrial/aerobic
for i = 1 : nactive
u(4,abeg(i):aend(i)) = actave(i)*(alow(i) + ((ahi(i)-alow(i)).*rand(1,(aend(i)-abeg(i)+1))));
end
% nsens = 19; salo = 0.9; saloM1 = 1/salo; sahi = 1.1; sahiM1 = 1/sahi; sadiff = sahi - salo;
% bt1 = 1250; bt2 = 1325; bt3 = 1375; % times for state magnitude behaviors
% btlo = 1250; bthi = 1500; % time window for examining behaviors (bt1, bt2 should be within this range)
% bx_min = zeros(2*nsens+1,9); bx_tmin = zeros(2*nsens+1,9);
% initializing behaviors for min
% bx_max = zeros(2*nsens+1,9); bx_tmax = zeros(2*nsens+1,9);
% init behaviors for max
% bx_t1 = zeros(2*nsens+1,9); bx_t2 = zeros(2*nsens+1,9); bx_t3 = zeros(2*nsens+1,9);
% init behaviors
for magn at strategic times
% for isens = 1 : (2*nsens)+1
% % bm, Cia, Cib, Cga, Kgt, Kugs, Grefi, Grefg, Greft, Gbt, wratm, wratt,Gratm
%
switch (isens-1)
%
case 1;
Ki
= salo*Ki;
case 2;
Ki
= sahi*Ki;
%
case 3;
Cia
= salo*Cia;
case 4;
Cia
= sahi*Cia;
%
case 5;
Cib
= salo*Cib;
case 6;
Cib
= sahi*Cib;
%
case 7;
Cga
= salo*Cga;
case 8;
Cga
= sahi*Cga;
%
case 9;
Kgt
= salo*Kgt;
case 10; Kgt
= sahi*Kgt;
%
case 11; Kugs
= salo*Kugs;
case 12; Kugs
= sahi*Kugs;
%
case 13; Grefi = salo*Grefi;
case 14; Grefi = sahi*Grefi;
%
case 15; Grefg = salo*Grefg;
case 16; Grefg = sahi*Grefg;
%
case 17; Greft = salo*Greft;
case 18; Greft = sahi*Greft;
%
case 19; Gbt
= salo*Gbt;
case 20; Gbt
= sahi*Gbt;
%
case 21; wratm = salo*wratm;
case 22; wratm = sahi*wratm;
%
case 23; wratt = salo*wratt;
case 24; wratt = sahi*wratt;
%
case 25; Kg2Max = salo*Kg2Max;
case 26; Kg2Max = sahi*Kg2Max;
%
case 27; kmxex = salo*kmxex;
case 28; kmxex = sahi*kmxex; %new pars
%
case 29; kse
= salo*kse;
case 30; kse
= sahi*kse; %new pars
%
case 31; ksds
= salo*ksds;
case 32; ksds
= sahi*ksds; %new pars
%
case 33; Kmintol= salo*Kmintol;
case 34; Kmintol= sahi*Kmintol; %new pars
%
case 35; insulindel= salo*insulindel; case 36; insulindel = sahi*insulindel; %new pars
%
case 37; Kid= salo*Kid;
case 38; Kid = sahi*Kid;
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%
otherwise ; % no change, e.g., last run
%
end
%
% SETTING INITIAL CONDITIONS:
x(1,1) = 100.;
% Glucose, Blood, x1=xG0
x(2,1) = (150*ratNONM)/wnm; % Glucose, Non-Musc, AMOUNT, in g/Kg_non-m, e.g., 140 g/ 35 Kg = 4, & max ~20
(~3-8% liver, ~1% adipose)
x(3,1) = (300*ratMUSC)/wmu; % Glucose, Musc, AMOUNT, in g/Kg_musc, e.g., 300 g/ 30 Kg = 10, & max ~600/30
= 20 (2%)
x(4,1)= 0.0;
% Glucose Mass Flow, Stomach, fast meal path, in grams/hr glucose
x(5,1) = 0.;
% Glucose Mass Flow, Stomach, slow meal path, in grams/hr glucose
x(6,1) = 1.0*ratType1i;
% Insulin, Blood, x6=xS0; default 1.0 mU/dL (7 mMol/L); for Type I, set to 0
JW CHANGE
x6(1:idel) = x(6,1);
% priming for delay
x(7,1) = 0.0;
% Insulin, Tissue, forward path state, monomeric
x(8,1) = 0.45*ratType1g ;
% Glucagon, blood; ~70 in pg/mL or 0.7 in micro-g/dL or ; for Type I, lower
than 0.35 JW CHANGE
x1d = 0.0;
x(9,1) = 0.0;
% Insulin, Tissue, forward path state, monomeric
x(10,1) = 0.0;
% Mitochondrial consumption
%
%PART OF SENSITIVITY ANALYSIS
% bxmin(1:9) = x(1:9,1); tbxmin(1:9) = btlo; % seting up auto-behaviors
% bxmax(1:9) = x(1:9,1); tbxmax(1:9) = btlo;
% LOOP FOR SIMULATION:
GG = [zeros(14,length(t))];
u1sum = 0; u1slowsum = 0;
x4sum = 0; x5sum = 0;
for i = 1 : length(t)-1
% NONLINEAR HILL Functionals:
% For Controllers:
% NEW NOTES: Basal (non-meal) insulin level is about 1 mU/dL (70 pMol/L), and max is about 10 mU/dL
GCi = ratType1i*fhillp1(x(1,i),6,Grefi,4);
% New control action: ratio, with k_1/2 higher
GCi2 = u(2,i)*(ka1+kd);
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GCi_hs_mag = fhill(u(2,i),hs_max,hs_ks,1); GG(10,i) = GCi_hs_mag; %Rate of exogenous infusion rate
(pmol/kg/min)
GCi_hs_rate = fhill(x(9,i),hs_rate, kd, 1); GG(11,i) = GCi_hs_rate;
if (x1d > 0)
GCiD = Kid*x1d*ratType1i; % rising, represents residual storage in pancreas, and "lead"
else
GCiD = 0.0;
% dropping, currently assumed 0
end
GCg = ratType1g*fhillrp1((x(1,i)),4,Grefg,4);
GG(2,i) = GCg;
% glucagon drive, sensing x1,
strong if low
% For Digestive:
%Gfast = 0.5 + fhill(x(4,i),0.5,10,2); % rate at which fast stomach glucose enters blood, either x4 or u1
(max overall is ~70 g/hr)
%Gslow = fhill(x(5,i),75,20,2);
%Gslow = 0.5 + fhill(x(5,i),0.3,4,2); % rate for slow path
Gabs = (fhill(x(4,i),(Kugd/2),ksds,4) + fhillr((x(4,i)),(Kugf/2),ksd2,4))*u1carb(1,i); GG(8,i) = Gabs; %
Kugd is max, in mid-range
Gslow = (Kugs + fhillr(x(5,i),Kugs,ksds2,4))*u1carb(1,i); GG(9,i) = Gslow; % Kugs is min, mid-range max
nearly double August Fit
% For Non-Muscle
NEW
Gnm_glut2 = fhill((x(1,i)),Kg2Max,Greft,2) - (Kg2Max/2);
liver, also pancreas, intestines, ...)

% bi-dir rate for non-musc, GLUT2 (mostly to

% For Intolerance (or could be used for glucose-to-fat conversion):
Gtintol = fhillr(x(2,i),kmxnm,Ktintol,8)+0.0;
GG(4,i) = Gtintol; % NL Hill - tissue intolerance, mult,
1.0=none, <0.1,1>
Gmintol = fhillr(x(3,i),kmxm,Kmintol,8)+0.0;
GG(7,i) = Gmintol; % NL Hill - muscle intolerance, mult,
1.0=none, <0.5,1>
% For Muscle (and exercise):
%NEW HR U5
%Take u3 and put through LPF with time constant of 6 min
%Perfect u3 and anticipated u3 informed by u5; as a function of u3
%Derivative of u5; sum the two
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%

%U5 INPUT

%Case Study Anaerobic Threshold (AT) = 170 bpm = 80% of HRmax, or (170-48)/(191-48) = 0.85
normalized
%Case Study AEROBIC ZONES:
Active Recovery = 0.7*AT = 111-126 bpm
%
Easy Aerobic = 0.8*AT = 128-145 bpm
%
Moderate Aerobic = 0.9*AT = 146-169 bpm
%
Threshold = 1.02*AT = 170-180 bpm
% Maximal = 1.06*AT = 180-191 (max HR)
%normalize HR
%for j = 1:1:length(t)
%
%
%
%
%
%
%
%
%
%

if u(5,j) >= 128 && u(5,j) <= 145
u(3,j) = 0.8*AerCap;
elseif u(5,j) > 145 && u(5,j) <= 169
u(3,j) = 0.9*AerCap;
elseif u(5,j) > 169 && u(5,j) <= 180
u(3,j) = 1.02*AerCap;
elseif u(5,j) > 180
u(3,j) = 1.06*AerCap;
elseif u(5,j) == 0
u(3,j) = u(3,j);
%NEW STEPS
%1. Take steps zones and create a hill functional to map u3 ref to HR
%ref; use delta hr to get delta u3 that adds or subtracts
%normalize HR
urelHR(i) = (u(5,i)-HRrest)/(HRmax-HRrest);
upredex(i) =(u(3,i)/AerCap);
urelHR = upredex; %IF NO HR DATA AVAILABLE delt will be 0
kscale = 500; %scaling
if urelHR(i) == 0
u3new(i) = u(3,i);
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%

else
deltu3(i) = kscale*(upredex(i) - urelHR(i));
u3new(i) = u(3,i) + deltu3(i);
end
end
if u(5,i) >= 1.25*HRrest && u(5,i) < 130
u(4,i) = 100; %200 would be 50 W
end

%end

%BAND PASS Filter for fluctuation?
%if (u3 is very high) & (u5 is very high) then (Gu35 is high)
Gsh2_u35 = u(3,i)*(fhill(u(3,i),1,500,2)) * fhill(u(5,i),1,0.85,4); GG(12,i) = Gsh2_u35;
% "aerobic
effort"-related high stress hormone to f2
%if (u4 is very high) & (u4 is fluctuating) & (u5 is high) then (Gu45 is high)
Gsh2_u45 = (u(3,i)+ u(4,i))*(fhill(u(3,i) + u(4,i),1,100,2)) * fhill(u(5,i),1,0.5,2);
GG(13,i) =
Gsh2_u45;
% "anaerobic effort"-related high stress hormone to f2
%if (u5 is not low) & [(u3 is low) & (u4 is low) & (x4 is low)] then (Gu5 is higher)
Gsh_ant = fhill(u(5,i),1, 0.8, 4)*[fhillr(u(3,i),1,100,2) * fhillr(u(4,i),1,10,2) * fhillr(u(4,i),1,10,2) *
fhill(x(4,i),1,0.5,2)]; GG(14,i) = Gsh_ant; %HR is high and not exercising

if Gsh2_u35 > 0
GfatAer = fhill(((u3new(i)/AerCap)), 0.4*AerCap, 0.2, 2);
else
GfatAer = fhill(((u3new(i)/AerCap)), 0.3*AerCap, 0.3, 2);
end
%GexerAer = 0.1*u(3,i) + fhill(u(3,i),10.0,500,1); GG(5,i) = GexerAer;
% NL Hill - exercise
consumption rate (muscle),
% GfatAer = fhill((u(3,i)/(AerCap)),0.3*AerCap,0.3,2); % proportion of fuel mix that is fats, normalized
GexerAer = (u3new(i)) - GfatAer; GG(5,i) = GexerAer;
% assumed energy of glucose within fuel mix
%if (u(3,i)) > 0 # JW COMMENTED OUT 7/24
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%
GexerAna = u4max;
% max out non-aerobic "activity" energy, to transition to need for aerobic
%else
GexerAna = 0;
%end
% Anaerobic max before aerobic, direct, assumed all glucose fuel, continues? Drops with slopeu?
GexerTot = (GexerAer + GexerAna);
% total glucose energy (not yet in grams-equivalent)
%Gmgrad = fhill(u(3,i),0.6,100,1) + fhill((x(1,i)-x(6,i)),0.04,100,1);
GG(6,i) = Gmgrad; % NL Hill blood glucose loss, with muscle demand gradient
Kgrad = .0;
Gmgrad = fhill(u(3,i)/4.0,kmxex*ratType1i,kse,1) - 0.1*fhillr(x(1,i), kmxex*ratType1i,kse,1); % +
Kgrad*(x(1,i)-(x(3,i)/gratm));
GG(6,i) = Gmgrad; % NL Hill - blood glucose loss, with muscle demand
gradient
% State Equation Functionals (dx/dt=):
f(1) = drat*x(4,i)- Kbr/wnm - ((Cia*Gtintol)+(Cib*Gmintol))*x(1,i)*x6(idel) - uHM(1,i)*Gnm_glut2*x(1,i) Gmgrad*(x(1,i)-(x(3,i)/gratm)) + (Cga+Cgb)*Kgt*x(8,i)*x(1,i); %- Gsh2_u45; % +uHRAer +uHRAna; %*G4;
%x(2,i)-; %+Gb %Gluc Bl
f(2) = wratt*(uHM(1,i)*Gnm_glut2 + Cia*x6(idel)*Gtintol)*x(1,i) - wratt*Cga*Kgt*x(8,i)*x(1,i) - (Gbt +
(Kcarb*x(5)))/wnm ; % - uHRAer - uHRAna; %.2*x(4,i)*x(5,i); %+.6*x(4,i); %*G4; % non-muscle tissue
f(3) = wratm*Cib*x(1,i)*x6(idel)*Gmintol - Gbm/wmu - wratm*Cgb*Kgt*x(8,i)*x(1,i) + wratm*(Gmgrad*(x(1,i)(x(3,i)/gratm))) + ratmito*x(10,i); %g/kgmusc %+uHRAna +uHRAer %+kFAT*x(10,i); %+.4*x(4,i)*0.2*x(8,i)*G5;
% musc tissue
f(4) = Gabs * ((u1fast(1,i)/4) + x(5,i) - Gugf*x(4,i)); % + x(5,ii); % Final common digestive rate
f(5) = Gslow* ((u1slow(1,i)/4) - Gugs*x(5,i));
% Slow low-GI path
f(6) = (ka2)*x(7,i) + (ka1)*x(9,i) - (Ki)*x(6,i) + GCi + GCiD ; %+ Kid*x6(idel)+ (ka1)*x(9,i); %
insulin in blood plasma, up via controller; fast monomeric path
f(9) = (ka1*x(9,i)) - GCi_hs_rate + GCi_hs_mag;
% new insulin tissue state
f(7) = (kd*(x(9,i)) - (ka2)*(x(7,i)));%GCi_hs; %*GCi_hs;
f(8) = Kgc*(GCg - x(8,i));
% glucagon in blood plasma (compare to f6)
f(10) = (Kmusc*((GexerTot + kprop*u(4,i))/4 - x(3,i) - x(10,i)))/wmito; % kcpt*(GexerAna+u(4,i)) kFAT*(x(10,i)); %MITOCHONDRIAL CONSUMPTION STATE, GIVEN DEMAND
%Generate Simulation Iteration of States
for j = 1 : 10
if x(j,i) < 0
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x(j,i) = 0.0;
end
x(j,i+1) = x(j,i) + f(j)*delt;
% Euler integration
if j == 4
x4sum = x4sum + x(4,i)*delt; % integrating x4 to get total grams
u1sum = u1sum + (u1fast(1,i)/4)*delt;
end
if j == 5
x5sum = x5sum + x(5,i)*delt; % integrating x5 to get total grams
u1slowsum = u1slowsum + (u1slow(1,i)/4)*delt;
end
%PART OF SENSITIVITY
%
if ((x(j,i+1) < bxmin(j)) & (i >= btlo) & (i <= bthi));
% behavior: finding low of state
%
bxmin(j) = x(j,i+1); tbxmin(j) = i+1 - btlo;
%
end
%
if ((x(j,i+1) > bxmax(j)) & (i >= btlo) & (i <= bthi)); % behavior: finding high of state
%
bxmax(j) = x(j,i+1); tbxmax(j) = i+1 - btlo;
%
end
%
if (i == bt1)
% behavior at t1
%
bxt1(j) = x(j,i+1);
%
end
%
if (i == bt2)
% behavior at t2
%
bxt2(j) = x(j,i+1);
%
end
%
if (i == bt3)
% behavior at t3
%
bxt3(j) = x(j,i+1);
%
end
end
x1d = (x(1,i+1) - x(1,i))/delt;
for ii = 1 : idel-1
x6(idel-ii+1) = x6(idel-ii);
% shifting for time delay
end
x6(1) = x(6,i+1);
end
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u1 = u1fast + u1slow;
%FIGURE 1: 1) INPUT CURVES 2) X1 (BLOOD GLUCOSE)WITH THRESHOLD LINES
%
3) TISSUE GLUCOSE, MUSCLE AND NON-MUSCLE (X2, X3) AND
%
4) GLUCAGON AND INSULIN CONTROLLERS
% 24 HOUR SIMULATION
figure(1); set(2,'Color',[1 1 1]);
hold on;
%tp = t(250:550);
up = u(:,250:550);
xp = x(:,250:550);
% ONE APPROACH: NEW VECTORS FOR PLOTTING
tpbeg = 0; tpend = 24;
% USE AXIS()
TO PLOT PART OF T VECTOR (EASIEST?)
subplot(5,1,1)
% Meal input, stomach state x4:
plot(t,u1(1,:),'k',t,x(4,:)*4,'r',t,u(3,:),'-.',t,u(4,:),'-',t,GG(5,:),':','LineWidth',1.5); hold on;
plot(t,x(5,:)*4,'g',t,x(10,:)*4,'b')
ylabel('G-Flow (Kcal/hr)','FontWeight','bold')
axis([tpbeg tpend 0 1200])
subplot(5,1,2)
% Glucose states:
winl = [70*ones(1,length(t))];
% low glucose line
winh = [150*ones(1,length(t))];
% somewhat high glucose line
winhh = [200*ones(1,length(t))];
% very high glucose line, intol and/or to fat
plot(t,x(1,:),'r','LineWidth',1.5); hold on;
plot(t,winl,':',t,winh,':',t,winhh,':'); hold on;
ylabel('Gluc Bl (mg/dl)','FontWeight','bold')
axis([tpbeg tpend 40 280])
subplot(5,1,3)
% Insulin input, states:
[hAx,hLine1,hLine2] = plotyy(t,x(6,:),t,x(8,:)); hold on;
% ,t,u(2,:),':',t,x(7,:),':'
set(hLine1,'LineStyle','-','LineWidth',1.5)
set(hLine2,'LineStyle','--','LineWidth',1.5)
ylabel(hAx(1),'Insulin (mU/dl)','FontWeight','bold') % left y-axis
axis(hAx(1),[tpbeg tpend 0 5]) % NEW, CAN COMMENT OUT
ylabel(hAx(2),'Glucagon (pg/dL)','FontWeight','bold') % right y-axis
axis(hAx(2),[tpbeg tpend 0 1.2]) % NEW, CAN COMMENT OUT
hold on;
subplot(5,1,5)
plot(t,u(2,:),'r',t,x(9,:),'g',t,x(7,:)),'m'; hold on;
ylabel('Exogenous Insulin')
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xlabel('Time (hours)','FontWeight','bold')
axis([tpbeg tpend 0 20])
subplot(5,1,4)
% Meal input, stomach state x4:
plot(t,x(2,:),':',t,x(3,:));
ylabel('Tissue','FontWeight','bold') %ADD MITOCHONDRIAL STATE HERE? SAME UNITS G/KG
axis([0 tmax 0 50])

%
%
%
%
%
%
%
%
%
%
%
%

%plot GG HILL FUNCTIONALS
figure(2)
subplot(3,2,1)
plot(u(2,:), GG(10,:)) %RATE OF EXOGENOUS INFUSION
subplot(3,2,3)
plot(u(2,:), GG(11,:)) %MAGNITUDE OF EXOGENOUS INFUSION
subplot(3,2,4)
plot(t,GG(8,:), t,GG(9,:)) %FINAL DIGESTIVE AND SLOW DIGESTIVE
axis([tpbeg tpend 0 10])
subplot(3,2,5)
plot(x(4,:),GG(8,:),'+') %FINAL DIGESTIVE AND INPUT
subplot(3,2,6)
plot(x(5,:),GG(9,:),'+') %SLOW DIGESTIVE AND INPUT

%INSULIN STATES
%figure(3);
%subplot (2,1,1)
%plot(t,x(6,:))
%ylabel('Plasma Insulin')
%subplot (2,1,2)
%plot(t,x(7,:))
%ylabel('Exogenous Insulin')
%xlabel('Time (hours)')
%PLOT MITOCHONDRIAL STATE
% figure(4)
% plot(t,x(10,:));
% ylabel('Mitochondrial State (g/kgmito/hr)')
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%DEMONSTRATE HR CODE AND INFORMING U3
% figure(6)
% subplot(4,1,1)
% plot(t, u(5,:))
% title('Heart Rate')
% axis([5 10 0 200])
% subplot(4,1,2)
% plot((t),deltu3)
% title('Delt U3')
% axis([5 10 -200 200])
% subplot(4,1,3)
% plot(t,u(3,:),'g')
% plot(t,u(4,:),'r')
% title('U3 and U4')
% axis([5 10 0 800])
% subplot(4,1,4)
% plot(t,x(1,:),'k', t, x(2,:),'r', t, x(3,:),'b')
% title('BG and Tissue')
% axis([5 10 0 800])
%~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
%END OF SENSITIVITY ANALYSIS
%
bx_min(isens,1:8) = bxmin(1:8); bx_tmin(isens,1:8) = tbxmin(1:8); % getting min behaviors
%
bx_max(isens,1:8) = bxmax(1:8); bx_tmax(isens,1:8) = tbxmax(1:8); % getting max behaviors
%
bx_t1(isens,1:8) = bxt1(1:8);
bx_t2(isens,1:8) = bxt2(1:8); bx_t3(isens,1:8) = bxt3(1:8);
getting magn at times behaviors
%
%
switch (isens-1)
% switch back, after run
%
case 1;
Ki
= saloM1*Ki;
case 2;
Ki
= sahiM1*Ki;
%
case 3;
Cia
= saloM1*Cia;
case 4;
Cia
= sahiM1*Cia;
%
case 5;
Cib
= saloM1*Cib;
case 6;
Cib
= sahiM1*Cib;
%
case 7;
Cga
= saloM1*Cga;
case 8;
Cga
= sahiM1*Cga;
%
case 9;
Kgt
= saloM1*Kgt;
case 10; Kgt
= sahiM1*Kgt;
%
case 11; Kugs
= saloM1*Kugs;
case 12; Kugs
= sahiM1*Kugs;
%
case 13; Grefi = saloM1*Grefi;
case 14; Grefi = sahiM1*Grefi;

%
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%
%
%
%
%
%
%
%
%
%
%
%
%
%
%
%
%
%
%
%
%
%
%
%
%
%
%
%

case
case
case
case
case
case
case
case
case
case
case
case

15;
17;
19;
21;
23;
25;
27;
29;
31;
33;
35;
37;

Grefg = saloM1*Grefg;
case 16; Grefg = sahiM1*Grefg;
Greft = saloM1*Greft;
case 18; Greft = sahiM1*Greft;
Gbt
= saloM1*Gbt;
case 20; Gbt
= sahiM1*Gbt;
wratm = saloM1*wratm;
case 22; wratm = sahiM1*wratm;
wratt = saloM1*wratt;
case 24; wratt = sahiM1*wratt;
Kg2Max = saloM1*Kg2Max;
case 26; Kg2Max = sahiM1*Kg2Max;
kmxex = saloM1*kmxex;
case 28; kmxex = sahiM1*kmxex; %new pars
kse
= saloM1*kse;
case 30; kse
= sahiM1*kse; %new pars
ksds
= saloM1*ksds;
case 32; ksds
= sahiM1*ksds; %new pars
Kmintol= saloM1*Kmintol;
case 34; Kmintol= sahiM1*Kmintol; %new pars
insulindel= saloM1*insulindel; case 36; insulindel = sahiM1*insulindel;
Kid= saloM1*Kid; case 38; Kid = sahiM1*Kid; %new pars

%new pars

end
end
% Param Sens Anal Loop (isens)
sens_xmin = zeros(nsens,8); sens_txmin = zeros(nsens,8);
sens_xmax = zeros(nsens,8); sens_txmax = zeros(nsens,8);
sens_xt1 = zeros(nsens,8); sens_xt2
= zeros(nsens,8); sens_xt3
= zeros(nsens,8);
for i = 1 : nsens
sens_xmin(i,:) = ((bx_min((2*i)+1,:)-bx_min(2*i,:))./bx_min(1,:))/sadiff;
sens_xmax(i,:) = ((bx_max((2*i)+1,:)-bx_max(2*i,:))./bx_max(1,:))/sadiff;
sens_txmin(i,:) = ((bx_tmin((2*i)+1,:)-bx_tmin(2*i,:))./bx_tmin(1,:))/sadiff;
sens_txmax(i,:) = ((bx_tmax((2*i)+1,:)-bx_tmax(2*i,:))./bx_tmax(1,:))/sadiff;
sens_xt1(i,:)
= ((bx_t1((2*i)+1,:)-bx_t1(2*i,:))./bx_t1(1,:))/sadiff;
sens_xt2(i,:)
= ((bx_t2((2*i)+1,:)-bx_t2(2*i,:))./bx_t2(1,:))/sadiff;
sens_xt3(i,:)
= ((bx_t3((2*i)+1,:)-bx_t3(2*i,:))./bx_t3(1,:))/sadiff;
end
sens_all = [ sens_xmin' ; sens_txmin' ; sens_xmax' ; sens_txmax' ; sens_xt1' ; sens_xt2'; sens_xt3' ];

%~~~~~~HILL FUNCTION CODE~~~~~
%
function [dfh] = fhill(df,kmax,ks,nh)
%
dfh = (kmax.*(df^nh))./((ks^nh) +(df^nh));
%
end
%
%
function [dfh] = fhillp1(df,kmax,ksp1,nh)
%
ks = (9*(ksp1.^(nh))).^(1/nh);
% mapping 10% to 50% for any nh
%
dfh = (kmax.*(df^nh))./((ks^nh) +(df^nh));
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%
end
%
%
function [dfh] = fhillr(df,kmax,ks,nh)
%
dfh = (kmax.*(ks^nh))./((ks^nh) +(df^nh));
%
end
%
% function [dfh] = fhillrp1(df,kmax,ksp1,nh)
%
ks = ((1/9)*(ksp1.^(nh))).^(1/nh);
% mapping 10% to 50% for any nh
%
dfh = (kmax.*(ks^nh))./((ks^nh) +(df^nh));
%
end
%~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
%LITERATURE PLOTTING CODE%
%u(3,:) = u3new;
%Import Literature Data
%t_moh = xlsread('Ins_clindata.xlsx', 'GI_avg', 'A3:A11');
%moh_gluc_potato = xlsread('Ins_clindata.xlsx', 'GI_avg','M3:M11'); %GI 41
%moh_gluc_bread = xlsread('Ins_clindata.xlsx', 'GI_avg','N3:N11'); % GI 25
%moh_gluc_spag = xlsread('Ins_clindata.xlsx', 'GI_avg','P3:P11');% GI 46
%moh_gluc_bar = xlsread('Ins_clindata.xlsx', 'GI_avg','Q3:Q11'); %GI71
%moh_gluc_juice = xlsread('Ins_clindata.xlsx', 'GI_avg','O3:O11');%GI 83
%figure(1)
%% %Mohammed et. al. GI
%plot(t_moh,moh_gluc_potato); hold on;
%plot(t_moh,moh_gluc_bread); hold on;
%plot(t_moh,moh_gluc_spag); hold on;
%plot(t_moh,moh_gluc_bar); hold on;
%plot(t_moh,moh_gluc_juice); hold on;
%~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
%%Aronoff, Blood Glucose, Insulin, and Glucagon, for normal and T1D 1)
%%before injection and 2) after
% aro_time_norm = xlsread('Ins_clindata.xlsx', 'Aronoff','A5:A17');
% aro_norm_BG = xlsread('Ins_clindata.xlsx', 'Aronoff','B5:B17'); %mg/dL
% aro_norm_ins = xlsread('Ins_clindata.xlsx', 'Aronoff','C5:C17'); %microU/mL
% aro_norm_gluc = xlsread('Ins_clindata.xlsx', 'Aronoff','D5:D17'); %pg/mL
%
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%
%
%
%
%
%
%
%
%
%
%
%
%
%
%
%
%
%
%
%
%
%
%
%
%
%
%
%
%
%
%
%
%
%
%
%
%
%

aro_time_T1D = xlsread('Ins_clindata.xlsx', 'Aronoff','F5:F16');
aro_T1Dinj_BG = xlsread('Ins_clindata.xlsx', 'Aronoff','G5:G16'); %mg/dL
aro_T1Dinj_ins = xlsread('Ins_clindata.xlsx', 'Aronoff','H5:H16'); %microU/mL
aro_T1Dinj_gluc = xlsread('Ins_clindata.xlsx', 'Aronoff','I5:I16'); %pg/mL
aro_time_T1D2 = xlsread('Ins_clindata.xlsx', 'Aronoff','O5:O14');
aro_T1Dninj_BG = xlsread('Ins_clindata.xlsx', 'Aronoff','K5:K16'); %mg/dL
aro_T1Dninj_ins = xlsread('Ins_clindata.xlsx', 'Aronoff','L5:L16'); %microU/mL
aro_T1Dninj_gluc = xlsread('Ins_clindata.xlsx', 'Aronoff','P5:P14'); %pg/mL
subplot(3,3,1)
plot(aro_time_norm, aro_norm_BG)
title('Aronoff Normal BG')
ylabel('mg/dL')
subplot(3,3,2)
plot(aro_time_norm, aro_norm_ins)
title('Aronoff Normal Ins')
ylabel('microU/mL')
subplot(3,3,3)
plot(aro_time_norm, aro_norm_gluc)
title('Aronoff Normal Glucagon')
ylabel('pg/mL')
subplot(3,3,4)
plot(aro_time_T1D,
title('Aronoff T1D
subplot(3,3,5)
plot(aro_time_T1D,
title('Aronoff T1D
subplot(3,3,6)
plot(aro_time_T1D,
title('Aronoff T1D

aro_T1Dinj_BG)
BG after Inj')
aro_T1Dinj_ins)
Ins after Inj')
aro_T1Dinj_gluc)
Gluc after Inj')

subplot(3,3,7)
plot(aro_time_T1D, aro_T1Dninj_BG)
title('Aronoff T1D BG before Inj')
subplot(3,3,8)
plot(aro_time_T1D, aro_T1Dninj_ins)
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% title('Aronoff T1D Ins before Inj')
% subplot(3,3,9)
% plot(aro_time_T1D2, aro_T1Dninj_gluc)
% title('Aronoff T1D Gluc before Inj')
%~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
%%Yamamoto Subcutaneous vs. Intravenous (from Sekigami) Insulin Effect--Not sure how I feel about this
data;
%the source does not match what is presented and for children only
% t_yam_sub = xlsread('Ins_clindata.xlsx', 'Yamamoto_ins','A4:A16');
% t_yam_iv = xlsread('Ins_clindata.xlsx', 'Yamamoto_ins','C4:C11');
% sub_ins_eff = xlsread('Ins_clindata.xlsx', 'Yamamoto_ins','B4:B16');
% iv_ins_eff = xlsread('Ins_clindata.xlsx', 'Yamamoto_ins','D4:D11');
% plot(t_yam_sub, sub_ins_eff);hold on;
% plot(t_yam_iv, iv_ins_eff);
% ylabel('Subcutaneous vs. Intravenous Ins Effect (/min)');
%
%
%
%
%
%

%~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
%Shimoda Peripheral Venous Insulin at 0.1 U/kg and Plasma Insulin Response
t_pvi = xlsread('Ins_clindata.xlsx', 'Shimoda1','A4:A12');
ins_conc = xlsread('Ins_clindata.xlsx', 'Shimoda1','B4:B12');
plot(t_pvi, ins_conc)
title('Insulin Concentration (pmol/l)')
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